

CURRICULUM VITAE: Dr. David A. Hanley

I. BIOGRAPHICAL DATA

Name: David Arthur Hanley
Position: Professor Emeritus, Department of Medicine (primary appointment)
Division of Endocrinology and Metabolism
Joint Appointment: Department of Oncology
Joint Appointment: Department of Community Health Sciences
Cumming School of Medicine, The University of Calgary

Address: McCaig Institute for Bone and Joint Health
HRIC Room 3AC58
3280 Hospital Drive NW
Calgary, Alberta T2N4Z6
Fax: 403-210-9573
email: dahanley@ucalgary.ca

Citizenship: Canadian

II. ACADEMIC RECORD

Final Degree: M.D.
Date Completed: 1970
Institution: University of Toronto
Toronto, Ontario, Canada

i. Undergraduate:
1966 B.A. (Psychology and Sociology)
University of Alberta at Calgary

ii. Special Professional:
1970-71 Rotating Internship, Foothills Hospital, Calgary, Alberta
1971-74 Residency in Internal Medicine, Foothills Hospital
1974-75 Chief Resident (Medicine), Foothills Hospital

Point of interest: I was the first person to complete the full four years of University of Calgary's Internal Medicine residency program from start to finish.

iii. Graduate and Post-Doctoral:

1975-78 Endocrinology Research Fellow, Michael Reese Medical Center (then affiliated with the Pritzker School of Medicine, University of Chicago). Supervisor: Louis M. Sherwood, M.D., Physician-in-Chief and Professor, Dept. of Medicine, Michael Reese Medical Center, University of Chicago, Chicago, Illinois. Supported by a Medical Research Council of Canada Fellowship

iv. Licensure and Boards:

1971 Licentiate of the Medical Council of Canada, Licence 31085.
1975 Fellow of the Royal College of Physicians and Surgeons of Canada (Internal Medicine).
1978 Minnesota State Board of Medical Examiners, Licence 24219.
(Resigned 2013)
1980 College of Physicians and Surgeons of Alberta, Licence 7556.
1995 College of Physicians and Surgeons of Alberta, Specialist Certificate: Endocrinology and Metabolism

III. AWARDS AND DISTINCTIONS

1965 University of Alberta First Class Standing Prize
1965 Queen Elizabeth Scholarship (Province of Alberta)
1975-78 Medical Research Council of Canada Fellowship
1981-86 Scholar, Alberta Heritage Foundation for Medical Research
1990 Antoni Nalecz Prize for the best abstract in Endocrinology and Metabolism submitted to the Annual Meeting of the Royal College of Physicians and Surgeons and the Canadian Society for Clinical Investigation (Hanley, D.A., Tanguay, K.E., Wood, P.H. and Mortimer, S.T.: Phorbol ester suppresses low calcium stimulated secretion of intact parathyroid hormone by bovine parathyroid cells).
2003 First recipient of the "Volunteer of Distinction Award" from the Osteoporosis Society of Canada. The award is for my involvement with the Society since 1983: Member of the Scientific Advisory Council (Chair from 1991-1995), Chair of three consensus conferences, Co-Chair of 1996 Clinical Practice Guidelines, and on Executive Writing Panel for 2002 Guidelines, Co-Founder of Alberta Chapter of the Osteoporosis Society of Canada.
2005 Robert Volpé Distinguished Service Award from the Canadian Society of Endocrinology and Metabolism. This is the Society's highest honour, and it recognizes a combination of contributions to Canadian Endocrinology in the areas of research, education and service to the profession.

2006 President-Elect of the Canadian Society of Endocrinology and Metabolism (CSEM).

2006 Received Osteoporosis Canada's 2006 Lindy Fraser Memorial Award. This award recognizes Canadians who have made outstanding contributions in osteoporosis research and education.

2007-09 President, Canadian Society of Endocrinology and Metabolism

2004-12 Chair, Canadian Panel, International Society for Clinical Densitometry

2012 Awarded Queen Elizabeth II Diamond Jubilee Medal for contributions to osteoporosis research, education and patient care

IV. ACADEMIC APPOINTMENTS

1. University of Minnesota 1978-1980:
 - Assistant Professor, Department of Medicine
 - Associate Director of Clinical Research Center
 - Attending Staff, Department of Medicine, University of Minnesota Hospitals

2. The University of Calgary:
 - Clinical Assistant Professor, Department of Medicine 1980
 - Assistant Professor, Department of Medicine 1981
 - Associate Professor, Department of Medicine 1984
 - Professor, Department of Medicine 1991
 - Professor Emeritus of Medicine, Oncology and Community Health Sciences, 2015 -

3. Other local appointments:
 - Head, Division of Endocrinology and Metabolism, 1993 - 2004
 - Chairperson, Endocrine Research Group, 1983 - 1984, 1998 - 1999
 - Adjunct Professor, Department of Biological Sciences, 1990 (approximate) - 2002
 - Professor, Department of Oncology. 1994 - present
 - Professor, Department of Community Health Sciences, 2009 - present
 - Active Medical Staff, Foothills Hospital, 1980 - present
 - Medical Staff, Tom Baker Cancer Centre 1990 - present
 - Tumour Group Leader, Endocrinology 1990 - 1997
 - Consultant Staff, Calgary General Hospital, 1980 - its destruction.
 - Associate Member, Joint Injury and Arthritis Research Group, 1989 - present
 - Member, Executive Committee Julia McFarlane Diabetes Research Centre, 1995 –

- 2004 Residency Program Director, Division of Endocrinology and Metabolism, 2002 –
- 2003

4. Medical Director, Calgary Osteoporosis and Metabolic Bone Disease Centre for the Calgary Health Zone, 1997(approximate) – June 2015 (the Osteoporosis Clinic opened in 2000)

5. Member of the Core Committee of the Bone and Joint Strategic Clinical Network for Alberta Health Services, 2012 – present
6. Visiting Scientist, Garvan Medical Research Institute, Bone Research Group, University of New South Wales, Sydney, Australia. January 1 to June 30, 2005.

V. EDUCATIONAL ACTIVITIES

i. Undergraduate Education:

1. Calcium Metabolism Unit manager, Endocrinology-Metabolism Course, Faculty of Medicine, University of Calgary, 1980- present.
2. Chairman, Endocrinology-Metabolism Course Subcommittee, Faculty of Medicine, University of Calgary, 1985 - 1989.
3. Member, Planning Group II (as Chairman of the Endocrine Course 1985 - 1989), for the setting of the exam in Endocrinology-Metabolism.
4. Preceptor, Clinical Skills, Endocrinology and Metabolism, 1980 - present.
5. Lectures, leading of seminar groups, etc. in Endocrinology-Metabolism Course, Musculoskeletal Course, Aging and Elderly Course, Reproduction Course, Renal Course, Clinical Clerkship Seminars.
6. Examiner, Clinical Skills Courses, Final M.D. oral exams.

ii. Graduate Education:

1. Courses:
 - MDSC 627 (Human Endocrinology): Have been on the planning committee for three of the terms in which this course was offered, and have lectured in the calcium metabolism section each year it has been offered.
 - MDSC 755.02: Molecular Basis of Clinical Endocrinology (Endocrine Research Group Graduate Course) Committee Member/Instructor.
2. M.Sc. Student Supervisor:
 - Brad Hamilton, 1988 (in Dr. Roncari's absence)
 - Shane Mortimer, 1989-1992 (MSc)
 - Farzana Shivji. 1993-1996 (MSc)
 - Brett McGuinness, 1998
 - Diana Rucker 1999-2002 (MSc)
3. PhD Students:
 - Shelly Vik 2003-2007 (Co-supervised with Dr. Scott Patten)
 - Tanis Fenton 2004-2007 (Co-supervised with Dr. Suzanne Tough)
4. M.Sc. Student Supervisory Committee:
 - Stephen C. Cooper (Dr. D.A.K. Roncari)
 - James Williams (Dr. O.P.Rorstad)
 - Brad Hamilton (Dr. D.A.K. Roncari)

Janet Petrillo (Dr. O.P. Rorstad)
Xue-Bin Li (Dr. J.-W. Yoon)
Andy Fischer (Dr. W. K. Stell)
Fatima E. Varzaneh (Dr. D.C.W. Lau)
Brett McGuinness (Dr. Zernicke and Dr. Nigg)
Pavan Ahluwalia (Dr. L. Metz)
Linda Starnes (Dr. F. Jirik)
John Schipilow (Dr. S.K. Boyd)
Erin Hildebrandt (Dr. S.K. Boyd)

5. Ph.D. Student Supervisory Committee and/or examiner:
 - Martin Scanlon (Dr. G. Moore) - examiner
 - Irene Wanke (Dr. O.P. Rorstad)
 - Michael Gaunt (Dr. D.A.K. Roncari) - examiner
 - Millina Lee, In-Young Ko (Dr. J.-W. Yoon)
 - Delia Roberts (Dr. David Smith and Dr. Henry Mandin)
 - Young-Hwa Chung (Dr. Ji-Won Yoon)
 - Stefan Judex (Dr. R. Zernicke) - examiner
 - Michael Doschak (Dr. R Zernicke)
 - Oana Smaranda Donescu, University of Alberta
 - Jeremy Lamothe (Dr. R. Zernicke)
 - Nguyen D. Nguyen, University of New South Wales, Australia
 - Christopher MacKay (Dr. R. Zernicke)
 - Kenneth Alexis Myers (Dr. D. Hart)
 - Kyle Nishiyama (Dr. S.K. Boyd)
 - Michelle Mann (Dr. S Ahmed)
6. External Examiner/Co-Mentor: McGill University:
 - Andrew Moulant - Ph.D. awarded October, 1993
 - Rana Samadfam – PhD, 2004
7. Academic Mentor to junior faculty 2004-2008:
 - Sumit R. Majumdar, MD, FRCPC, MPH
 - University of Alberta Department of Medicine
 - Anna M. Sawka, MD, FRCPC (also a PhD student)
 - McMaster University Department of Medicine, now University of Toronto

iii. Postgraduate Education:

(a) Internal Medicine and Endocrinology Residency Programs:

1. Medical Teaching Unit Director (Red Team), Department of Medicine, Foothills Hospital, 1989 - 1992).
2. Member, Department of Medicine Graduate Clinical Education Committee, 1989 - 1992).
3. Member, Department of Medicine Clinical Clerkship Advisory Committee, 1989 - 1992).
4. Member, Division of Endocrinology and Metabolism Graduate Training Committee, 1980 - present.
5. Member, Nuclear Medicine Residency Program Committee

(b) Post-Doctoral Research Fellows:

1. Susan K. Grimston, Ph.D., 1988-91, supported by a grant from the Dairy Bureau of Canada
2. Janice L. Pasioka, M.D., F.R.C.S.C., (Dept. of Surgery), one year research Fellowship in my laboratory, 1989-90.
3. Patricia H. (Wood) Watson, Ph.D., Alberta Heritage Foundation For Medical Research Fellowship, 1990 -1992.
4. Heather MacDonald, PhD, Alberta Heritage Foundation For Medical Research Fellowship, 2008 -2010. (Co-supervised with Dr. SK Boyd, Faculty of Engineering)
5. Lauren Burt, PhD, 2011- (Co-supervised with Dr. SK Boyd, Faculty of Engineering)

iv. Continuing Medical Education:

1. Member, Faculty of Medicine Postgraduate Education Committee 1989- 95.
2. Member of Planning Committees and lecturer in the Diabetes Update Symposia held at the Calgary General Hospital, 1981, 1984; Member of planning committee for the Julia MacFarlane Diabetes Symposium at University of Calgary, 1987.
3. Chairman of Planning Committee for University of Calgary Symposia on Endocrinology and Metabolism for Family Physicians, 1987, 1989, 1992.
4. Presentations on Osteoporosis or Metabolic Bone Disease at University of Calgary Continuing Medical Education Symposia: (a) Annual Therapeutics Course, 1991, 1989, 1988, 1987; (b) Geriatrics Symposium 1986 (Calgary General Hospital), 1988; (c) Evening Program for Family Physicians, 1987; Teleconference, 1989,1991.
5. Planning Committee and one of four keynote speakers, Faculty of Continuing Education Symposium "Living With Osteoporosis", 1987.
6. Endocrinology Update for Family Physicians, October 23, 1992, "Case Discussions of Calcium Metabolism" and "Hormone Replacement Therapy".

7. Continuing Medical Education program, "Osteoporosis", Lethbridge, Alberta, May 20, 1992.
8. Co-chairman and member of Planning Committee "Hypercalcemia, Tumor Osteolysis and the Role of the Bisphosphonates", a symposium for specialists in Internal Medicine co-sponsored by the University of Montreal and Rhone-Poulenc Rorer, November 14, 1992, Montreal, Quebec.
9. Chaired and organized a Consensus Conference on Issues in the Diagnosis and Management of Osteoporosis, for the Osteoporosis Society of Canada, Vancouver, B.C., Sept. 9, 1993.
10. Co-Chair Current Controversies in Clinical Endocrinology Annual Meeting of the Royal College of Physicians and Surgeons of Canada, Vancouver, B.C., September 11, 1993.
11. Chair, International Symposium on "Calcium: Current Controversies and Future Directions", Toronto, Ontario, May 8, 1995.
12. Chair, National Program on Osteoporosis for Specialists in Internal Medicine "Options in Osteoporosis", Toronto, Ontario, May 27, 1995.
13. Co-Chair and Speaker: Workshop on Osteoporosis - Society of Obstetrics and Gynecology of Canada (SOGC) Annual Meeting, Calgary, Alberta, June 24, 1995.
14. Speaker, SOGC International Symposium on Osteoporosis, Calgary, Alberta, June 27, 1995.
15. Planning Committee and Speaker: (i) "Hormone Replacement Therapy and Osteoporosis", (ii) Asymptomatic Primary Hyperparathyroidism, American College of Physicians program "Advances in Internal Medicine", Banff, Alberta, June 1995.
16. Keynote speaker in the Osteoporosis Society of Canada's Program on Osteoporosis for specialist physicians, Toronto, November 1, 1996.
17. Co-Chaired and Organized the Canadian consensus conference on "The Use of Technologies for Assessment of Bone" for the Scientific Advisory Board of the Osteoporosis Society of Canada, November 21-23, 1997.
18. Keynote speaker on osteoporosis at the annual meeting of the Atlantic Endocrine Society, Halifax, Nova Scotia, May 29-June 3, 1997.
19. Organized the scientific symposium for the Canadian Multicentre Osteoporosis Study (CaMOS) Steering Committee Meeting, Montreal, April 17-19, 1998
20. Invited Presentation on osteoporosis therapies to the Alberta Health and Wellness Expert Committee on drug evaluation and therapies for the management of osteoporosis, September 15, 1999.
21. Course Director and Organizer. 1st Biennial Foothills Osteoporosis Update and International Society for Clinical Densitometry (ISCD) Certification Course, Westin Hotel, Calgary, September 8-10, 2000.
22. Planning Committee and Major Presentations. Western Osteoporosis Alliance Meeting with Hong Kong University, Hong Kong, November 8-12, 2000.

23. Organizing Committee Member and Co-Chair. Western Osteoporosis Alliance 5th Annual Meeting held in conjunction with the International Association of Gerontology 17th World Congress, Vancouver, British Columbia, July 1-2, 2001.
24. Chairperson: Clinical Oral Abstract Session- Diabetes Research. Canadian Society of Endocrinology and Metabolism/Canadian Diabetes Association (CDA/CSEM), Edmonton, Alberta, October 17-20, 2001.
25. Symposium Speaker. "Subclinical Endocrine Disorders" at the annual meeting of the Canadian Society of Endocrinology and Metabolism, October 2-5, 2002.
26. Moderator and Speaker. Western Regional Women's Health and Osteoporosis Conference, Emerald Lake, Alberta, April 25-27, 2003.
27. Chair and Speaker, Standards in Bone Densitometry: An Alberta Initiative, Calgary, Alberta, January 11, 2003.
28. Co-chair, Canadian Course, International Society for Clinical Densitometry, September 10-12, 2004.
29. Chair and committee organizer for the International Bone and Joint Decade annual Meeting, Ottawa, 2005.

VI. ADMINISTRATIVE RESPONSIBILITIES

i. Departmental:

1. Member, Diabetes Service Committee, Calgary General Hospital, 1980-1995.
2. Member, Audit Committee, Department of Medicine, Foothills Hospital, 1987- present; Chairman, 1990-1992
3. Medical Teaching Unit Director (Red Team), Department of Medicine, Foothills Hospital, 1989 - 1992.
4. Member, Department of Medicine Graduate Clinical Education Committee, 1989 - 1992.
5. Member, Department of Medicine Clinical Clerkship Advisory Committee, 1989- 1992.
6. Member, Rheumatology Search and Selection Committee, Foothills Hospital, 1998
7. Member, Bone and Joint Health Clinical Services Committee, Calgary Health Region, 2003.
8. Chair, AD HOC Departmental Residency Appeals Committee, Department of Medicine, 2006.
9. Member, Executive Committee, McCaig Institute for Bone & Joint Health, 2007-2010.

ii. Faculty:

1. Chair, Endocrine Research Group, 1983-1985 and 1997-1998.
2. Member, University of Calgary AHFMR Visiting Lecturer and Travel Awards Committee 1986 - 1990; Chairman, 1989 -1990.

3. Member, University of Calgary Medical Library Committee, 1987 - 1988.
4. Member, Faculty of Medicine Budget Committee, 1989 - 1991
5. Member, Faculty of Medicine Postgraduate Education Committee 1989-present.
6. Member, Faculty of Medicine Continuing Education Advisory Committee Until September, 1995.

iii. University:

1. Member, General Faculties Council, 1991-94
2. Medical Director, Endocrinology and Metabolism Outpatient Programs, C.R.H.A. 1992-2004.

iv. Hospital, Alberta Health Services:

1. Member, Foothills Hospital Radiation Safety and Radioisotope Committee, 1986 - 2010.
2. Member, Foothills Hospital Health Education Advisory Committee, 1989 - 1993.
3. Member, Patient Care Committee, 1990 - 1992.
4. Member, Sub-committee on Tissue and Death, 1990 - 1992.
5. Medical Director, Calgary Health Zone Osteoporosis and Metabolic Bone Disease Centre (formerly Grace Osteoporosis Centre), 2000-present.
6. Member, Alberta Health Services Hip Fracture Care Pathway and Order Set Committee 2011-2014
7. Member, Alberta Strategic Clinical Network for Bone and Joint Health, Core Committee, 2012- present.
8. Member, Alberta Strategic Clinical Network for Bone and Joint Health, Fragility and Stability Subcommittee, 2013-present

VII. PROFESSIONAL ACTIVITIES

i. Membership in professional and learned societies:

1. Endocrine Society
2. American Society for Bone and Mineral Research
 3. Canadian Society for Clinical Investigation
 4. Royal College of Physicians and Surgeons of Canada
 5. Canadian Society of Endocrinology and Metabolism
 6. Canadian Diabetes Association, Clinical and Scientific Section
 7. Canadian Hypertension Society
 8. International Society for Clinical Densitometry (Chair of Canadian Panel 2004-2013)
 9. Executive Scientific Advisory Committee of the Dairy Farmers of Canada
10. Scientific Advisory Council, Osteoporosis Society of Canada, 1983 - present (Chairperson 1991-1995)

ii. Professional Service:

(a) Grant panels:

1. Alberta Heritage Foundation for Medical Research, Clinical Applications Advisory Committee 1986 - 1987.
2. Dairy Farmers of Canada Executive Scientific Advisory Committee, 1990 - present.
3. Osteoporosis Society of Canada Scientific Advisory Committee for Research Grant Review, 1986 - 1990
4. Lilly Fellowship in Pediatric Endocrinology, member of Selection Committee, 1991-1992.
5. Medical Research Council of Canada/Canadian Institutes of Health Research
 - (a) University - Industry Committee 1998-2006 (Oct)
 - (b) Experimental Medicine (occasional internal reviewer for 1-2 proposals - not part of whole committee review process)
6. Eli Lilly Mature Women's Health Fellowship Committee 1998-2003
7. National Institutes of Health (USA)
 - (a) Data Safety and Monitoring Board Member PaTH Study (Comparison of Parathyroid Hormone and Alendronate or Combination) 2000-2004
 - (b) Safety Officer Once a Week PTH Study 2005-2007
 - (c) Committee Reviewer: Disease Registries for Musculoskeletal Disorders 2000
 - (d) Committee Reviewer: Combination Therapies 1999

(b) Grant reviewer for the following agencies:

Alberta Heritage Foundation for Medical Research, Canadian Institutes of Health Research, Canadian Foundation for Ileitis and Colitis, Dairy Bureau of Canada, Fonds de la Recherche en Santé du Québec, Kidney Foundation of Canada, Manitoba Health Research Council, Manitoba Health Sciences Centre Foundation, Medical Research Council of Canada, National Science and Engineering Research Council, Osteoporosis Society of Canada, P.S.I. Foundation of Ontario, Arthritis Society (Canada), The Hospital for Sick Children Foundation, Crohn's and Colitis Foundation of Canada, PPP Healthcare Medical Trust, and the Canadian Cystic Fibrosis Foundation.

(c) Journal reviews:

Archives of Internal Medicine, Bone, Canadian Journal of Physiology and Pharmacology, Canadian Journal on Aging, Clinical Investigative Medicine, Endocrinology, European Journal of Pharmacology, International Journal for Vitamin and Nutrition Research, Journal of Bone and Mineral Research, Journal of Clinical Densitometry, CMAJ, Osteoporosis International, Journal of Rheumatology, Endocrine, Hormone and Metabolic Research, International Journal of Tuberculosis and Lung Disease.

(d) Editorships, Editorial Boards:

1. Co-editor with Dr. M. A. Andersen of an annual section in Current Opinion in Orthopedics, on the topic of Metabolic Bone Disease. (1991-1993)
2. Editor of the Canadian Society of Endocrinology and Metabolism Newsletter, 1988 - 1992.
3. Member, Editorial Committee, Osteoporosis Society of Canada Osteoporosis Bulletin for Physicians, 1990 - present.
4. Member, Editorial Committee, Journal of Clinical Densitometry. (1998-2001)
5. Guest co-editor (with Dr. Chris Triggler) of a special issue of Drug Development Research on the topic of Osteoporosis Research in Canada. (2000)
6. Editor for Spring/Summer Osteoporosis Update (a practical guide for Canadian physicians) edition for Osteoporosis Canada 2006. Vol. 10 No.2.
7. Member, Writing Committee, Canadian Guidelines on Bisphosphonate-Associated Osteonecrosis of the Jaw. (Chair: Dr. A. Khan, McMaster University).
8. Member, Editorial Board, Osteoporosis International. 2012-

(e) National and International Committees:

1. Member, Scientific Advisory Council, Osteoporosis Canada, 1983 - present. Chairman 1991-1995.
2. Council Member, Canadian Society of Endocrinology and Metabolism, 1986-1992.
3. Chairman, Education Committee, Canadian Society of Endocrinology and Metabolism, 1988 - 1992.
4. Dairy Farmers of Canada Executive Scientific Advisory Committee, 1990 - 2004.
5. Member, Nucleus Committee in Endocrinology and Metabolism, Royal College of Physicians and Surgeons of Canada, 1991-1996.
6. Chair, Canadian Panel, International Society of Clinical Densitometry 2005-present.
7. Member, Vitamin D Guideline Committee, Endocrine Society.
8. Member of the CDA/CSEM Annual Meeting Program Committee – as President Elect of CSEM, I am the co-chair of the annual meeting program committee 2006-present.

(f) Other:

1. Site visit (with Dr. Francis Glorieux) University of Toronto Bone and Mineral Group, September, 1992.
2. Examiner, Medical Council of Canada, Qualifying Examination Part II, 1992- present.

VIII. EDUCATIONAL AND RESEARCH CONFERENCES

1. Co-chairman: Hypercalcemia, tumour osteolysis, and the role of bisphosphonates. November 14, 1992. sponsors: University of Montreal and Rhone-Poulenc Rorer.
2. Chairman: Consensus conference on selected aspects of osteoporosis. A consensus conference of the Medical Advisory Board of the Osteoporosis Society of Canada. September 9, 1993, Vancouver, British Columbia
3. Participant: Round table on bone disorders. October 8, 1993, Toronto, Ontario.
4. Chairman: Consensus conference on endpoints for clinical trials in osteoporosis. November 6, 1993, Montreal, Quebec.
5. Chair: Consensus Conference on Osteoporosis Therapy: Osteoporosis Society of Canada 1995
6. Co Chair with Dr. Rick Adachi of 1995 Conference to Establish the Osteoporosis Society of Canada Clinical Practice Guidelines published in CMAJ 1995
7. Chair: Osteoporosis Society of Canada Consensus Conference on Bone Measurement, Victoria, BC, November 1997
8. Co-Chair: Annual meeting program committee for Canadian Diabetes Association and Canadian Society of Endocrinology and Metabolism 2006.

IX. RESEARCH SUPPORT (not a complete list of Clinical Trial Support)

1. Alberta Heritage Foundation for Medical Research Scholarship 1981 - 1986.
2. Medical Research Council of Canada operating grant No. MA-8089, 1983 - 1986.
3. M.S.I. Foundation operating grant "PTH Secretion by Abnormal Parathyroid Tissue In Vitro, \$35,000/year, 1987 - 1989.
4. Dairy Bureau of Canada operating grant "Dietary history and absorption of calcium in the long distance female runner", \$84,650.00 Jan.1-Dec. 31,1989.
5. Medical Research Council of Canada operating grant #MA-10299, "Studies of PTH Secretion", \$47,170.00/yr. 1988-1991.
6. Upjohn Co. of Canada, "Effects of Flurbiprofen and Exercise on Oophorectomy-Induced Osteopenia in the Rat - a Pilot Study". \$11,500.00, 1991.
7. Dairy Bureau of Canada operating grant "Nutritional, Skeletal, Hormonal, and Developmental Profile of Children: A Longitudinal Study". \$121,500.00/yr., Jan.1990 - Dec.1992; continued support through June 1994.
8. Clinical Assay of Parathyroid Hormone. Foothills Hospital, \$14,000-\$16,000/yr.
9. Medical Research Council of Canada operating grant #MT-11591, "Studies of Parathyroid Hormone Secretion", \$63,725.00/yr. 1992-1995.
10. Merck & Co. Inc., "A randomized, parallel-group, international, multi-centre study to compare the effect on bone density of alendronate 10 mg or placebo in postmenopausal women with osteoporosis", \$156,000.00 (starting 1995).
11. Lilly Research Laboratories, Eli Lilly and Company, "Comparison of Raloxifene HCl, placebo, and Premarin in the prevention of osteoporosis in postmenopausal, hysterectomized women", \$71,865.00 (1995-1998).

12. Procter & Gamble Pharmaceuticals, "A randomized, double-blind, placebo-controlled, multi-centre, parallel group study to determine the efficacy and safety of risedronate in the treatment of postmenopausal women with established osteoporosis-related vertebral deformities", \$46,634.90 (1995-1998).
13. Allelix Pharmaceuticals. "Recombinant human parathyroid hormone in the treatment of Osteoporosis", \$14,213.84 (1996).
14. Boehringer Mannheim Corporation - Two studies of "Ibandronate in the Treatment of Osteoporosis", \$32,183.00 (1996-1999).
15. Lilly Research Laboratories, Eli Lilly and Company, "LY3334 in the treatment of osteoporosis", \$95,170.00/yr (1998-1999).
16. Johann Jacob Foundation, "Adaptive Bone Remodeling in Young Females", Co-Investigator with Dr. Benno Nigg (Principal Investigator). \$170,000.00 (1997-2000).
17. Merck USA Medical School Grant Programme, "Multinational Study of Alendronate for Renal Transplant Bone Disease", principal investigator for Calgary site. \$30,000.00/yr (1997-2000).
18. Merck Frosst Canada Inc. "Canadian Multicentre Osteoporosis Study (CaMos) Quality of Life Sub-Study", \$20,000.00 (1997).
19. Alberta Heritage Foundation for Medical Research. Health Research Award. "Serum 25-Hydroxy Vitamin D Levels and Bone Density", \$40,000.00/yr, (1998-2003).
20. Wyeth-Ayerst Canada Inc. Fracture incidence and reduction safety of TSE-424 (Bazedoxifene Acetate) compared to placebo and Raloxifene in osteoporotic postmenopausal women, \$80,000.00 (2005-2007).
21. Aventis Pharmaceuticals. A multicentre, double-blind randomized active-controlled parallel group non-inferiority study comparing 75 mg Risedronate dosed on 2 consecutive days monthly with 5 mg. Daily Risedronate in the treatment of postmenopausal osteoporosis as assessed over 24 months, \$131,358.00 (2005-2007).
22. Amgen Canada Inc.. A randomized double-blind study to evaluate AMG162 in prevention of postmenopausal osteoporosis, \$105,694.00 (2005-2007).
23. A phase III, multicentre double-blind, randomized, active controlled, parallel group, non-inferiority study comparing 150 mg Risedronate monthly with 5 mg Risedronate daily in the treatment of postmenopausal osteoporosis as assessed at 12 and 24 months, \$43,598.00 (2006-2007).
24. Amgen Canada Inc. A multicentre, randomized placebo controlled pilot microCT study to estimate the effect of treatment with Denosumab (AMG 162) and Alendronate sodium in postmenopausal women with low bone mineral density, \$288,689.00 (2006-2007).
25. Co-investigator: Canadian Foundation for Innovation 2000 grant award: "Nutrition, Genetics, and Human Performance". Dr. Ron Zernicke, Principal Investigator. \$3,200,000.00.
26. NHRDP and MRC, Canadian Multi-Centre Osteoporosis Study (CaMos) - Five year epidemiology study of osteoporosis (Dr. David Hanley, Principal Investigator

- Calgary site). Awarded to McGill University (Dr. Alan Tenenhouse, Principal Investigator), \$146,316.00/yr (1998-2003).
27. Co-investigator: Canadian Institutes of Health Research Operating Grant. Strategies Targeting Osteoporosis to Prevent Recurrent Fractures (STOP Study). Principal Investigator: Dr. S.R. Majumdar. \$340,000.00/total. (Apr 1, 2003-Dec 31, 2005).
 28. Co-investigator: Canadian Institutes of Health Research Operating Grant. Canadian Longitudinal Study on Aging: Developmental Activities Phase. Principal Investigators: Christina Wolfson, Susan Kirkland, Parminder Raina. \$1,744,000.00/total. (Apr 1, 2004-Dec 31, 2005).
 29. Canadian Institutes of Health Research Operating Grant (MOP 67187). Canadian Multicentre Osteoporosis Study (CaMos). (Dr. David Hanley, Principal Investigator-Calgary site). Awarded to McGill University (Dr. Alan Tenenhouse, Principal Investigator), \$4,225,469.00/total (Apr 1, 2004-Mar 31, 2010).
 30. Co-Investigator. Creating Bone and Joint Health from the Bedside to the Bench and Back Again: Reducing the Burden of Osteoarthritis (OA) - from Mechanisms to Prevention. Principal Investigator: Dr. Cy Frank; \$250,000 (2008-2013)
 31. Co-Investigator. Breast Cancer to Bone Metastases (B2B) Program: Core Research Project 1: Vitamin D, inflammation and bone metastasis in breast cancer survivors. Principal Investigator: Nigel Brockton. Alberta Cancer Research Institute 1,390,888 (2009)
 32. Co-investigator. Canadian Institutes of Health Research Operating Grant. Bone Quality in Osteoporosis study. Principal Investigator: Dr. Steven K. Boyd. \$285,955/total (2006-2009). Renewed 2010 for 5 years (2010-2015)
 33. Co-Investigator and Director of the Calgary Centre. Canadian Institutes of Health Research Operating Grant. "Canadian Multicentre Osteoporosis Study" \$684,410/year Approved 5 years (2011-2016) Principal Investigator, Dr. David Goltzman McGill University.
 34. Co-Investigator. Canadian Institutes of Health Research Operating Grant. "On the development of bone quality parameters for assessing osteoporosis using peripheral quantitative computed tomography" P.I. Dr. J. D. Adachi. funds still being negotiated (2012-2016)
 35. Co- Principal Investigator. Pure North S'Energy Foundation operating grant. "Randomized double-blind study investigating dose-dependent longitudinal effects of vitamin D supplementation on bone health." A 3-year clinical trial that commenced recruiting November 2013, expected completion 2017. \$2,500,000 (approximate total). Dr. Steven K. Boyd is the other Co-Principal Investigator.

X. INVITED ADDRESSES (not a complete list)

1. Medical Grand Rounds, Abbott-Northwestern Hospital, Minneapolis, Minnesota, February, 1980, "Hyperparathyroidism"
2. Endocrine Surgery Review at University of Minnesota, Minneapolis, June, 1980, "Clinical Physiology of Parathyroid Hormone and Vitamin D"

3. Special Endocrine Research Conference, Michael Reese Medical Center, Chicago, Illinois, January 28, 1983, "Recent Studies of Parathyroid Hormone Physiology"
4. Cranbrook District Medical Society, Oct. 1, 1986 "Treatment of Osteoporosis"
5. Garry Van Petten Memorial Lecture (University of Alberta Faculty of Pharmacy annual Continuing Education Program), June 16, 1988. Seminar on Osteoporosis Management.
6. Co-chairman (with Dr. R. A. L. Sutton) of a Royal College of Physicians and Surgeons of Canada Symposium on Nephrolithiasis, at the RCPSC annual Meeting, Sept. 1988.
7. American College of Physicians and University of Calgary Therapeutics Course Workshop on Osteoporosis Therapy, March 9, 1990.
8. 23rd International Dairy Congress, Montreal, October 9, 1990. Invited Lecture: "Bone: The Role of Dietary Calcium and Exercise in the Maintenance of the Skeleton".
9. Calcium and Peak Bone Density Workshop, Utrecht, Netherlands, November 6, 1990. Invited Lecture: "Dietary History and the Absorption of Calcium in the Long Distance Female Runner".
10. University of Saskatchewan Osteoporosis Update, Saskatoon, December 7, 1990. Three presentations (lectures/workshops on diagnosis, pathophysiology, establishment of Osteoporosis clinics, and clinical case discussions).
11. Continuing Medical Education Seminar, Holy Cross Hospital, Calgary. "Common Dilemmas in Internal Medicine", Feb. 8, 1991. Topic: Osteoporosis: Cost-effective Investigation and Treatment.
12. College of Family Physicians of Canada, Annual Scientific Assembly, Toronto, May 7, 1991. Invited Lecture: "Osteoporosis: Prevention and Treatment".
13. American College of Physicians and Universities of Alberta and Calgary "Advances in Internal Medicine", Banff, Alberta, June 1991. Invited lecture/workshop: "Management of Osteoporosis in the Post-Fluoride, Didronel Era".
14. University of Alberta Symposium on Osteoporosis, October 25, 1991. Invited lecture: "Osteoporosis: How, Why, What and When"
15. Canadian Society of Laboratory Technologists 1992 National Congress. Invited speaker: "Clinical Usefulness of Endocrine Testing" June 15, 1992.
16. Member of Planning Committee, presented two seminars in Endocrinology Update for Family Physicians, October 23, 1992.
17. University of British Columbia Bone Interest Group seminar speaker: Calcium Regulation of PTH Synthesis and Secretion", Vancouver General Hospital, December 16, 1992.
18. University of Calgary Therapeutics Course. Workshop: "Osteoporosis: Prevention, Management and Patient Compliance". April 15-16, 1993.
19. American College of Physicians 12th Biennial Conference: Advances in Internal Medicine. Workshop: "Update on Osteoporosis". June 21-25, 1993, Banff, Alberta.

20. Royal College of Physicians and Surgeons of Canada/CSCI Annual Meeting: Co-chairman of CSEM Symposium on Osteoporosis (Controversies in Endocrinology and Metabolism) Saturday, September 11, 1993.
21. Osteoporosis: Prevention and Management” presentation at Family Medicine Review 1993, 39th Annual Meeting of the College of Family Physicians of Canada Saskatchewan Chapter September 23, 1993.
22. University of Calgary Family Practice Update and Review. Workshop on Osteoporosis November 22, 1993
23. 1996 Prairie Provinces Chapter Meeting, Society of Nuclear Medicine held in Banff, Friday April 12, 1996, "Overview of Osteoporosis" presented.
24. Tom Baker Cancer Centre Endocrine Surgical Symposium, "Asymptomatic Hyperparathyroidism", June 9, 1994.
25. Visiting Professor: Memorial University, St. John's, Newfoundland: Medical Grand Rounds: "New Developments in Osteoporosis", Research Seminar: "Regulation of Parathyroid Hormone Secretion", June, 1994.
26. Visiting Professor: University of Saskatchewan, Department of Medicine Grand Rounds: "Lessons Learned From Unusual Causes of Hypercalcemia", "Calcium and Metabolic Bone Disease Problems", August 24, 1994.
27. Medical Grand Rounds, The University of Illinois College of Medicine, Chicago, Illinois, March 2, 1995, "New Therapies For Osteoporosis".
28. Visiting Professor: University of Saskatchewan, Regina General Hospital, Department of Medicine Grand Rounds, Friday, April 21, 1995.
29. Visiting Professor - University of Western Ontario. Two presentations on April 20, 1996; 1) City-wide Endocrine Rounds 8-10 a.m., "The parathyroid calcium receptor and the regulation of PTH secretion", followed by clinical case discussions on metabolic bone disease' 2) Skeletal Biology Group, Department of Physiology, "Regulation of secretion of parathyroid hormone (PTH) and its relationship to intracellular degradation and secretion of PTH fragments".
30. Atlantic Endocrine Society Conference, Topics: "Overview of Bisphosphonates for Treatment of Osteoporosis", "Hypophosphatemic Bone Disease – a Calgarian Approach", Halifax, May 29-June 3, 1997.
31. Annual Meeting of the American Society for Bone & Mineral Research, Speaker – "Meet the Professor Session", Topic: "Bone Complications of Malignancy and Their Treatment", Poster Presentation: Abstract – Etidronate Therapy in Patients on High Dose Corticosteroids: Differences in Bone Resorption Marker Responses, Cincinnati Ohio, September 10-14, 1997.
32. Consensus Conference – Diagnosis of Osteoporosis, Osteoporosis Society of Canada, Speaker and Chair of Conference, Victoria, BC, November 20-24, 1997.
33. Foothills Hospital, Department of Medicine, Medical Grand Rounds. Topic: Glucocorticoid-Induced Osteoporosis, Calgary, January 22, 1998.
34. Procter & Gamble Pharmaceuticals – Symposium on Osteoporosis Therapies. Topic: Current and Future Therapies in the Prevention and Treatment of Osteoporosis, Toronto, Ontario, February 6, 1998.
35. Speaker and Chair - Merck Frosst Regional Osteoporosis Consultative Symposium (CME program for Medical Specialists). "The Burden of Illness of

- Osteoporosis and its Effective Management with Alendronate”. Topic: FOSIT and Guidelines for Identifying Patients with Osteoporosis, Calgary, February 21, 1998.
36. University of Manitoba, invited by the Section of Endocrinology and Metabolism, Department of Medicine - Grand Rounds, Topic: “Glucocorticoid Induced Osteoporosis”, Winnipeg, Manitoba, March 17, 1998.
 37. Health Research Group. Debate: Osteoporosis Management is Helped by Bone Density Measurements. Pro: D. Hanley – Con: D. Hailey. AHFMR Technology Assessment, Health Sciences Centre, University of Calgary, March 20, 1998.
 38. The Society of Obstetricians and Gynaecologists (SOGC), West/Central Canadian Continuing Medical Education Program, 2 Lectures: “Osteoporosis Prevention and Treatment” and “Selective Estrogen Receptor Modulators”, Speaker/Facilitator, Banff, Alberta, March 26, 1998.
 39. Dalhousie University Division of Endocrinology and Metabolism, Special Seminar on Osteoporosis. Topic: Bisphosphonate Therapy. Invited guest speaker with Dr. J. Cauley (U of Pittsburgh), New Halifax Infirmary, Halifax, Nova Scotia, April 3, 1998.
 40. 39th Annual Alberta Health Record Association Convention. Topic: Osteoporosis, Banff, Alberta, April 16, 1998.
 41. Western Osteoporosis Alliance Second Annual Meeting. Organizing Committee Member/Speaker. Topic: Recent Guidelines for Osteoporosis Care: European, American, Canadian Consensus on Diagnostic Technology, Saskatoon, Saskatchewan, May 9, 1998.
 42. The Canadian Society of Clinical Investigation (CSCI), Theme Symposium for the Annual Meeting of the CSCI and the Royal College of Physicians and Surgeons of Canada. Symposium Title: “The Adverse Effects of Selected Efficacious Medical Therapies” Topic: Steroids and Osteoporosis, Toronto, Ontario, September 24, 1998.
 43. An Update on Osteoporosis and Diabetes. Topic: Treatment of Osteoporosis – New Therapeutic Options, Banff, Alberta, October 16-18, 1998.
 44. Advance Healthcare Strategies – Osteoporosis Symposium. Topic: FOSIT Study, Toronto, Ontario, October 23, 1998.
 45. Division of Gastroenterology Journal Club Presentation. Topic: Steroid Induced Osteoporosis, University of Alberta, Edmonton, Alberta, December 8, 1998.
 46. Knights of the Round Table. Topic: Osteoporosis and You, Calgary, Alberta, December 15, 1998.
 47. Tenth Annual GI Retreat – Division of Gastroenterology. Topic: Treatment of Steroid-Induced Osteopenia, Buffalo Mountain Lodge, Banff, Alberta, January 30, 1999.
 48. Department of Medicine – Medical Grand Rounds. Topic: Diagnosis and Treatment of Osteoporosis, Foothills Hospital, February 11, 1999.
 49. The Medicine Group – Postmenopausal Health. Topic: Raloxifene: A New Option for Postmenopausal Health, Westin Hotel, Edmonton, Alberta, February 18, 1999.
 50. Department of Medicine – Medical Grand Rounds. Topic: Diagnosis and Treatment of Osteoporosis, Peter Lougheed Hospital, February 28, 1999.

51. Faculty of Continuing Education Health Seminar with the Chinese Cultural Service Association of Calgary, Public Forum. Topic: Osteoporosis, Chinese Cultural Centre, Calgary, Alberta, March 13, 1999.
52. Calgary Therapeutics Course - 300 Family Physicians and Pharmacists. Topic: New Developments in Osteoporosis Management, Libin Lecture Theatre, University of Calgary, Calgary, Alberta, March 18, 1999.
53. Continuing Medical Education – Teleconference Program. Approximately 32 Hospitals; 70 Physicians and 40 Health Professionals. Topic: Osteoporosis/Menopause and Bone Densitometry, Health Sciences Centre, University of Calgary, Calgary, Alberta, March 30, 1999.
54. Merck Frosst Canada Inc – Scientific Exchange Programme entitled: Update on Treatment and Diagnosis of Osteoporosis. Topic: Update on the Guidelines for the Diagnosis of Osteoporosis, Toronto, Ontario, April 10, 1999.
55. Osteoporosis Research Centre – Osteoporosis: New Indications and New Managements. Topic: Raloxifene: What is its role in the Management of Osteoporosis? St. Vincent’s Hospital, Vancouver, British Columbia, April 23, 1999.
56. Osteoporosis: Debating the Issues, Topic: “Conventional Medical Management of Osteoporosis, Debate: A 65 Year Old Caucasian Woman with a DXA Spine T-Score of –3.0 Requires Pharmacotherapy for her Osteoporosis”, BC Women’s Health Centre and St. Vincent Hospital, Vancouver, April 24, 1999.
57. Crossroads Regional Health Authority Public Forum – Building Better Bones! Topic: Osteoporosis Diagnosis, Research and Prognosis, Wetaskiwin, Alberta, May 27, 1999.
58. Osteoporosis Society – Alberta Chapter Retreat. Topic: Osteoporosis, Calgary, Alberta, May 28, 1999.
59. Procter & Gamble – Chair and Speaker for the Western Regional Osteoporosis Meeting – Focus on Risedronate. Whistler, British Columbia, June 5, 1999.
60. University of Calgary, Canadian Society of Internal Medicine, American College of Physicians/American Society of Internal Medicine – 15th Biennial Advances in Internal Medicine. Topic: Osteoporosis: Who to Screen, Who to Treat and How, Banff, Alberta, June 8, 1999.
61. Evening Program for Specialists and Family Physicians. Topic: SERM’s: Their Effective Use in the Management of Post-Menopausal Health, Lethbridge, Alberta, June 17, 1999.
62. The Leading Edge – Obstetrics and Gynecology in 1999. Topic: Osteoporosis, Canada Olympic Park, Calgary, Alberta, June 18, 1999.
63. Evening Program for Specialists and Family Physicians. Topic: SERM’s: Their Effective Use in the Management of Post-Menopausal Health, Medicine Hat, Alberta, June 22, 1999. Annual Meeting of The Society of Obstetricians and Gynaecologists of Canada. International Symposium: How to Identify and Manage Women at Risk of Osteoporosis. Topic: “Current Techniques for the Diagnosis of Osteoporosis”, Ottawa, Ontario, June 27, 1999.

64. 4th Annual Stampede Sport Medicine Conference for Family Physicians. Topic: Skeletal Aging and Exercise, Physical Education Building, University of Calgary, Calgary, Alberta, July 10, 1999.
65. University of Manitoba, Department of Continuing Medical Education – Rehabilitation Challenges for the New Millennium, CME - Health Care Professionals and Students, Topic: Comprehensive Approach to the Treatment of Osteoporosis, Winnipeg, Manitoba, September 16-19, 1999.
66. Canadian Society of Endocrinology and Metabolism Annual Meeting – Current Trends and Future Directions in Osteoporosis. Topic: Current Trends in Osteoporosis in Canada: Review of Current Therapies, Ottawa Congress Centre, Ottawa, Ontario, October 14, 1999.
67. Calgary Regional Health Authority, Division of Continuing Care Rounds. Topic: Osteoporosis – An Informal Review, Bethany Care Centre, Calgary, November 3, 1999.
68. Canadian Osteoporosis Symposium: A joint Presentation of the Osteoporosis Society of Canada, International Society for Clinical Densitometry, Canadian Association of Radiologists, Society of Obstetricians and Gynaecologists of Canada, Canadian Association of Gerontology. Topics: Laboratory Diagnosis of Osteoporosis: Biochemical Markers of Bone Turnover, What is Osteoporosis, Physiology, Pathophysiology, Epidemiology. Workshop: Other Therapies – Case Presentations (PTH, Sodium Fluoride, Calcitonin). Toronto, Ontario, November 3-6, 1999.
69. Osteoporosis and Paget’s Disease in the New Millennium Symposium. Chair and Program Organizer. Topic: Recent Advances in Histology and Bone Metabolism: Update on the Mode of Action of Bisphosphonate Therapy. Vancouver, British Columbia, November 27, 1999.
70. Continuing Care Physicians – Rounds Presentation. Topic: Osteoporosis Management, Calgary, December 1, 1999.
71. University of British Columbia, Division of Endocrinology and Metabolism Basic Science Seminar. Topic: Mechanism of Action of Bisphosphonates. Vancouver, British Columbia, January 10, 2000.
72. Journal Club and Grand Rounds Presentation, Royal University Hospital, University of Saskatchewan, Department of obstetrics and Gynecology. Topic: Current Concepts in Diagnosis and Management of Osteoporosis. Saskatoon, Saskatchewan, February 3-4, 2000.
73. Ontario Provincial Specialist Event – Aventis Pharma Seminar – “Facing a New Reality in Metabolic Bone Disease Management: Focus on Osteoporosis and Paget’s Disease”. Topics: Learning from the Canadian Multicentre Osteoporosis Study: Current and Future Trends; Paget’s Disease: Review and Update; Workshop: Case Reviews – Examining the Treatment Options. Four Seasons Hotel, Toronto, Ontario, March 4, 2000.
74. Round Table Discussion – CME Program. Topic: New Treatments in Osteoporosis. Health Sciences Centre, University of Calgary, Calgary, Alberta, March 10, 2000.

75. University of Alberta Hospitals, Division of Geriatric Medicine – “Geriatric Challenges”. Topic: Osteoporosis Management and Investigation. Rimrock Resort, Banff, Alberta, June 9, 2000.
76. 1st Biennial Foothills Osteoporosis Update and International Society for Clinical Densitometry (ISCD) Certification Course. Course Chairperson/Speaker. Topics: Bone Densitometry in Clinical Management, Combination Therapies of Osteoporosis, Use of Biochemical Markers of Bone Turnover. Westin Hotel, Calgary, Alberta, September 8-10, 2000.
77. Prairie Provinces Family Physicians Program – “Managing Patients with High Sugars or Brittle Bones”. Topic: Prevention and Treatment of Osteoporosis. Delta Lodge, Kananaskis, Alberta, September 30, 2000.
78. Oncology Grand Rounds - Tom Baker Cancer Centre. Topic: Prevention of osteoporosis induced by glucocorticoid therapy of malignant and non-malignant disorders. Calgary, Alberta, October 4, 2000.
79. University of Calgary/Calgary Regional Health Authority – CME Conference on Women’s Health. Topic: What’s New In Osteoporosis... Rimrock Hotel, Banff, Alberta, October 27-29, 2000.
80. Department of Internal Medicine Grand Rounds, Peter Lougheed Centre. Topic: Lessons from the Canadian Multicentre Osteoporosis Study. Calgary, Alberta, October 31, 2000.
81. Western Osteoporosis Alliance Fourth Annual Meeting: Held in conjunction with the University of Hong Kong and International Society for Clinical Densitometry. International Conference and CME – Planning Committee Member Co-Chair of 2 Sessions5 oral presentations. Topics: Selective Estrogen Receptor Modulators: Their role in Postmenopausal Women’s Health, Canadian Multicentre osteoporosis study, Cyclic Etidronate and the role of Bisphosphonates in Combination Therapy of Osteoporosis, Clinical Applications of BMD – monitoring serial change, Bone Densitometry in Clinical Management. The Kowloon Hotel, Kowloon, Hong Kong, November 7-14, 2000.
82. Department of Internal Medicine Grand Rounds. Topic: New Therapy for Osteoporosis, Foothills Medical Centre, Calgary, Alberta, December 4, 2000.
83. Canadian Rheumatology Association Winter Workshop and Annual Meeting – Osteoporosis and Beyond – Role of Bisphosphonates, Calcitonin and SERMs. Topic: What’s New with Calcitonin and SERMs. Chateau Mont Tremblant, Mont Tremblant, Quebec, February 21-24, 2001.
84. Calgary Therapeutics Course. Topic: Osteoporosis: A Perspective for Primary Care. Libin Theatre, University of Calgary, Calgary, Alberta, March 16, 2001.
85. Western Hormone Alliance Meeting (WHAM). Topic: Bone Mineral Density: Role in Monitoring Therapy of Osteoporosis. Emerald Lake Lodge, British Columbia, May 10-13, 2001.
86. Western Osteoporosis Alliance Fifth Annual Meeting. Held in conjunction with the International Association of Gerontology 17th World Congress. Organizing Committee Member and Co-Chair of two sessions. Topics: Some Answers More Questions: Critical Issues in Osteoporosis Care for Western Canadians, Unsolved Issues with Bisphosphonates. Vancouver, British Columbia, July 1-2, 2001.

87. CASM/ACMS Annual Symposium and Stampede Sport Medicine Conference 2001. Topic: Disease-Specific Exercise Therapy: Osteoporosis and Exercise. Rozsa Centre, University of Calgary, Calgary, Alberta, July 4-7, 2001.
88. Department of Medicine, Grand Rounds, Department of Gynecology and Obstetrics. Topic: Diagnosis of Osteoporosis and the Role of Salmon Calcitonin NS (Miacalcin). Foothills Medical Centre, Calgary, Alberta, September 14, 2001.
89. Teleconference Program– Faculty of Medicine, Office of Continuing Medical Education. Topic: Osteoporosis in Men and Women. Health Sciences Centre, University of Calgary, Calgary, Alberta, September 18, 2001.
90. Physician Education Services - Long Term Care Conference. Topic: Osteoporosis Management in LTC, Optimal Assessment and Treatment. Best Western Hospitality Inn, Calgary, Alberta, November 3, 2001.
91. Canadian Osteoporosis Guidelines Symposium and ISCD Certification Course. Topics: Risk Factors (Osteoporosis), Clinical Applications of Bone Densitometry: Monitoring Serial Changes. Hilton, Toronto, Ontario, November 30 – December 2, 2001.
92. Alberta Chapter, College of Family Physicians of Canada - 47th Annual Scientific Assembly – Fun, Fitness and Facts. Topics: Bones Through the Ages: An Overview of Osteoporosis, Osteoporosis: Before the Break. February 27-March 2, 2002.
93. 2nd Biannual Conference – Geriatrics. Topic: The Importance of Vertebral Fractures and Their Management. Rimrock Resort, Banff, Alberta, April 25, 2002.
94. Alberta Annual Rheumatology Update - Expert Forum in Rheumatology. Topic: Issues in Osteoporosis Management. Delta Lodge, Kananaskis, Alberta, September 6-8, 2002.
95. Geriatric Grand Rounds - Glenrose Rehabilitation Hospital. Topic: Osteoporosis. Edmonton, Alberta, October 22, 2002.
96. Canadian Society of Endocrinology and Metabolism/Canadian Diabetes Association (CDA/CSEM) Professional - Conference and Annual Meeting. Symposium on “Subclinical Endocrine Disorders. Vancouver, British Columbia, October 2-5, 2002.
97. Oncology Grand Rounds - Tom Baker Cancer Centre. Topic: The Women’s Health Initiative. Calgary, Alberta, October 30, 2002.
98. Current Issues in Menopause Program - Kelowna General Hospital. Topic: Osteoporosis Prevention Strategies. Kelowna, British Columbia, November 1, 2002.
99. Western Canada Obstetrics and Gynecology Conference – “Science and Beyond.” Topic: Osteoporosis Update. Rimrock Hotel, Banff, Alberta, November 8-10, 2002.
100. Canadian Osteoporosis Guidelines Symposium and ISCD Certification Course. Topics: Risk factors and Management, Bone Densitometry for the Diagnosis of Osteoporosis (ISCD Course). Hotel Vancouver, Vancouver, British Columbia, November 21-24, 2002.

101. Regional Conference Program (Rounds) - Rural Physicians CME Program. Topic: Parathyroid Disorders. Red Deer General Hospital, Red Deer, Alberta, November 28, 2002.
102. Standards in Bone Densitometry: An Alberta Initiative. CME-Alberta Specialists. Topics: Reporting of Bone Density, Quality Assurance, and Recommendations Regarding Use of Follow-up BD Measurements. Chair/Co-Presenter. Fairmont Palliser Hotel, Calgary, Alberta, January 11, 2003.
103. Department of Internal Medicine Grand Rounds. Topic: Vitamin D and Bone Health: Supplements for Everyone? Foothills Hospital, Calgary, Alberta, March 18, 2003.
104. Western Regional Women's Health and Osteoporosis Conference. Moderator/Presenter. Topic: An Introduction to Parathyroid Hormone; New Treatment Option for Severe Osteoporosis. Emerald Lake Lodge, Alberta, April 25-27, 2003.
105. Seventh Annual Glen Edwards Day (Orthopedic Surgery) – Bad to the Bones-Holes in Bone. Department of Surgery, Division of Orthopedic Surgery, and Bone and Joint Health Education. Topic: Metabolic Bone Disease – Osteoporosis, Paget's Disease, Osteomalacia. Health Sciences Centre, University of Calgary, Calgary, Alberta, May 23, 2003.
106. Evening Program for Medical Specialists. Topic: Assessment of Bone Quality. Edmonton, Alberta, June 26, 2003.
107. The College of Family Physicians of Canada – Family Medicine Forum. Topic: Osteoporosis Diagnosis. Telus Convention Centre, Calgary, Alberta, October 25, 2003.
108. Rocky Mountain/ACP Internal Medicine Conference – CME Workshop. Topic: Approach to Osteopenia. Banff, Alberta, November 15, 2003.
109. Canadian Rheumatology Association Annual Meeting, Basic Science Symposium on Osteoporosis: "Biochemical Markers of Bone Turnover" Feb 26, 2004 Lake Louise Alberta.
110. University of Manitoba Department of Medicine, Medical Grand Rounds: "Recent Advances in Osteoporosis" University of Manitoba Health Sciences Centre, Winnipeg, Manitoba, March 2, 2004.
111. American Society for Nutritional Sciences 2004 Symposium - Vitamin D Insufficiency: A Significant Risk Factor in Chronic Diseases and Potential Disease-Specific Biomarkers of Vitamin D Sufficiency. Dr. Hanley's Topic: "Prevalence of Vitamin D Insufficiency in North America". Presented at the annual meeting of the Federation of American Societies for Experimental Biology (FASEB). Washington, DC, April 18, 2004.
112. University of Manitoba Division of Rheumatology Rounds: Parathyroid Hormone in the Treatment of Osteoporosis", University of Manitoba Health Sciences Centre, Winnipeg, Manitoba, September 16, 2004.
113. Orthopedic Research Society of North America. Symposium on Hip Fracture: "Treatment of Osteoporosis" Banff, Alberta, October 13, 2004.
114. Canadian Society of Endocrinology and Metabolism Annual Meeting. Debate: SERMs for Postmenopausal Osteoporosis" Quebec City, October 30, 2004

115. Osteoporosis Society of Canada – Saskatchewan Chapter. Keynote speaker: Treatment of Osteoporosis: Latest Advances in Therapy. Regina, Saskatchewan, November 14, 2004.
116. Canadian Association of Radiologists conference “Radiology for Family Physicians”, “Osteoporosis” November 19, 2004, Lake Louise Alberta.
117. National Osteoporosis Foundation Sixth International Symposium on Osteoporosis: Current Status and Future Directions, Washington, DC April 6-10, 2005. Dr. Hanley’s topic: “Approved Treatment Options: Parathyroid Hormone”.
118. Canadian Diabetes Association/Canadian Society of Endocrinology, Edmonton, Program Co-Chair. Meet the Professor. October 2005.
119. Preventative Nutrition: The Impact on the Future Health of Canadians. Symposium sponsored by Wyeth Consumer Healthcare. Topic: “Osteoporosis: Nutrition Effects on Bone”. Toronto, Ontario, October 2005.
120. Department of Medicine Grand Rounds. University of Montreal (CHUM). Topic: “Vitamin D Inadequacy: An Epidemic?” November 2005.
121. UBC Nuclear Medicine Rounds and Presentation to the BC Bone Interest Group. Rounds and Presentation “Osteoporosis, BMD, Parathyroid Disease”. University of British Columbia, November 2005.
122. Canadian Cancer Society/National Institute of Canada North American Conference on UV, Vitamin D and Health. Presented lecture on relationship between Vitamin D and bone health. Toronto, Ontario, March 2006.
123. International Osteoporosis Foundation symposium on Osteoporosis. Presented lecture on Patient compliance Osteoporosis. Toronto, Ontario, June 2006.
124. University of Western Ontario, Division of Endocrinology and Metabolism. Presented two seminars and examiner for Endocrine Residency Program. London, Ontario, January 2007.
125. CSEM/AACE/AMEQ Clinical Endocrinology Winter Update Meeting. Presented lecture on “Other Roles for Vitamin D”, meet the professor session, and regulator for bone symposium. Also a member of planning committee for this meeting. Mont Tremblant, Quebec, February 2007.
126. Albert College of Family Physicians Annual Meeting. Presented lecture on “Those Aging Bones”. February 2007.
127. St. Michaels Hospital Outreach Program on Metabolic Bone Disease. Presented lecture on “PTH and Combination Therapies: Where are We Now?” University of Toronto, March 2007.
128. Northwest Rheumatism Society (B.C., Washington, Oregon) “Osteoporosis Therapy: New Drugs, Old Drugs and Choices”. April 2007.
129. SEIOMM (Spanish Society for Bone and Mineral Research) annual meeting opening symposium “Treatment of Osteoporosis with Recombinant Human Parathyroid Hormone: The TOP Study” Valencia, Spain, October 2007.
130. University of Saskatchewan CME Program. Presented lecture on “Controversies in the Diagnosis and Management of Osteoporosis”. November 2007.
131. Symposium on Parathyroid Hormone Therapy of Osteoporosis. Presented lecture on “Efficacy of Parathyroid Hormone in the Treatment of Osteoporosis: The TOP Study”. Lisbon, Portugal, February 2008.

132. ISCD Annual Meeting. Symposium on Osteoporosis Care Around the Globe: Canada". San Francisco, California, March 2008.
133. International Symposium on Asymptomatic Primary Hyperparathyroidism - an ancillary symposium at the annual meeting of the American Association of Clinical Endocrinologists May 13, 2008. Presentation: "Clinical implications of vitamin D insufficiency". Orlando, Florida
134. 6th St Michael's Hospital Osteoporosis and Metabolic Bone Disease Symposium. Invited presentation "Vitamin D: New Roles, New Guidelines". March 26, 2010, Toronto, ON.
135. McMaster/University of Western Ontario, Clinical Endocrine Update. Invited Presentation: "Emerging Therapies of Osteoporosis". April 9, 2010.
136. Fraser Health (British Columbia)/CIHR symposium: Development and Implementation of a Vitamin D Protocol for Long-term Care Facilities. Invited Keynote Presentation: "Current State of Knowledge on Vitamin D". February 15, 2011, Surrey, British Columbia.
137. Wood Osteoporosis Forum for the public (McCaig Centre and Joint Injury and Arthritis Research Group). Invited presentation "Osteoporosis Fracture Risk and Mortality, Diagnostic and Treatment Strategies". November 1, 2012
138. McMaster/ Western University Canadian Endocrine Update. Invited Presentation: "Vitamin D and Calcium Supplements - Current Evidence for Benefit and Harm 2014". April 11, 2014, Hamilton Ontario
139. 2008-2014 Multiple CME Presentations for University of Calgary Continuing Medical Education programs: Family Practice Update, Therapeutics Course, Evening Family Practice programs.

XI. PUBLICATIONS

i. Peer-reviewed manuscripts:

1. Franken RE, Jones CEB, Hanley DA: Strychnine facilitation of latent learning. *Psychological Reports*, 21:140, 1967
2. Franken RE, Jones, CEB, Hanley DA: Adaptation, intertrial interval and interval, and response to preferred and non-preferred change. *Can. J. Psychol.*, 22: 45-51, 1968.
3. Birnbaumer ME, Schneider AB, Palmer D, Hanley DA, Sherwood LM. Secretion of parathyroid hormone by abnormal parathyroid glands *in vitro* *J Clin Endocrinol Metab* 45:105-113, 1977.
4. Hanley DA. Takatsuki K, Sultan JM, Schneider AB, Sherwood LM. Direct release of parathyroid hormone fragments from functioning bovine parathyroid glands *in vitro*. *J. Clin. Invest.* 62: 1247-1254, 1978.
5. Guenter CA, Hanley DA, Sproule BJ, Coalson JJ. Rapid onset of emphysema associated with diffuse parenchymal disease. *Am. J. Med.* 67: 335-338, 1979.
6. Hanley D A. Parathyroid Hormone and Age. Letter to the editor: *New Engl J Med* 301: 841-2, 1979.

7. Hanley DA, Takatsuki K, Birnbaumer ME, Schneider AB, Sherwood LM. In vitro perfusion system for the study of parathyroid hormone secretion: Effects of extracellular calcium concentration and beta-adrenergic regulation on bovine parathyroid hormone secretion in vitro. *Calcified Tissue International* 32: 19-27, 1980.
8. Takatsuki K, Hanley DA, Sherwood LM. The effects of magnesium ion on parathyroid hormone secretion in vitro. *Calcified Tissue International* 32: 201-206, 1980.
9. Corenblum B, Hanley DA. Bromocriptine reduction of prolactinoma size. *Fertility and Sterility* 36: 716-719, 1981.
- 9a. This article was summarized and published with editorial comment in *Yearbook of Obstetrics & Gynecology* 1983, edited by R.M. Pitkin and F.J. Zlotnik, Yearbook Medical Publishers, Chicago, 1983, P. 369.
10. Huang M, Hanley DA, Rorstad OP. Parathyroid hormone stimulates adenylate cyclase in rat cerebral microvessels. *Life Sciences* 32: 1009-1014, 1983.
11. Hanley DA, Wellings PG. A carboxyl terminal radioimmunoassay for parathyroid hormone with apparent recognition preference for the intact hormone. *J. Immunoassay* 6: 245-260, 1985.
12. Hanley DA, Wellings PG. Dopamine-stimulated parathyroid hormone release in vitro: Further evidence for two-pool model of parathyroid hormone secretion. *Can J Physiol Pharmacol* 63: 1139-1144, 1985.
13. Hanley D.A., Ayer LM. Calcium-dependent release of carboxyl terminal fragments of PTH by hyperplastic human parathyroid tissue in vitro. *J. Clin. Endocrinol. Metab.* 63: 1075-1079, 1986.
14. Duggan MA, Forestell CF, Hanley DA. Adrenal metastases of renal-cell carcinoma 19 years after nephrectomy. Fine needle aspiration cytology of a case. *Acta Cytologica* 31: 512-516, 1987.
15. Cole DEC, Gundberg CM, Stirk, LJ, Atkinson, SA, Hanley DA, Ayer LM, Baldwin LS. Changing osteocalcin concentrations during pregnancy and lactation: Implications for maternal mineral metabolism. *J. Clin. Endocrinol. Metab.* 65: 290-294, 1987.
16. Sheldon R, Becker W, Hanley DA, Culver, R. Hypoparathyroidism and pseudotumour cerebri: An infrequent clinical association. *Can. J. Neurol. Sci.* 15: 622: 625, 1987.
17. McLeod DR, Hanley DA, McArthur RG. Autosomal dominant hypoparathyroidism with intracranial calcification outside the basal ganglia. *Am. J. Med. Genetics* 32: 32-35, 1989.
18. Ayer LM, Szarka RJ, Mortimer ST, Alexander FJ, Martin JME, Andersen MA Hanley DA. Analysis of parathyroid hormone in bovine parathyroid cysts. *J. Bone Min. Res.* 3: 335-340, 1989.
19. Akai PS, Wong T, Chang-Poon V, Green FHY, Whitelaw WA, Hanley DA. Resectable bronchogenic carcinoma presenting with hypercalcemia: tumor - associated granulomatous reaction and probable production of 1,25-Dihydroxyvitamin D. *Clinical and Investigative Medicine* 12: 212-216, 1989.

20. Russell JA, Hanley DA. Full-term pregnancy after allogeneic transplantation for leukemia in a patient with oligomenorrhea. *Bone Marrow Transplant* 4: 579-580, 1989.
21. Mortimer ST, Hanley DA, Stell WK: Immunohistochemical identification of calcitonin gene-related peptide and substance P in nerves of the bovine parathyroid gland. *Cell Tissue Res* 261: 339-345, 1990.
22. Pasiaka JL, Andersen MA, and Hanley DA: Familial Benign Hypercalcemia: hypercalciuria and hypocalciuria in affected members of a small kindred. *Clin. Endocrinol.* 33: 429-433, 1990.
23. Grimston, SK, Engsberg JR, Kloiber RH, Hanley DA. Menstrual, calcium, and training history: relationship to bone health in female runners. *Clinical Sports Medicine* 2: 119-128, 1990.
24. Tanguay KE, Mortimer ST, Wood PH, Hanley DA. The effects of phorbol myristate acetate on the intracellular degradation of parathyroid hormone, *Endocrinology* 128: 1863-1868, 1991.
25. Hanley DA, Ayer LM, Gundberg CM, Minuk GY. Parameters of calcium metabolism during a pilot study of cyclosporin A in patients with primary biliary cirrhosis. *Clin. Invest. Med.* 14: 282-287, 1991.
26. Grimston SK, Engsberg JR, Hanley DA. Bone mass, external loads, and stress fractures in female runners. *International J. Sport Biomechanics* 7: 293-302, 1991.
27. Watson PH, Mortimer ST, Tanguay KE, Hanley DA. Activation and inhibition of protein kinase C in cultured bovine parathyroid cells: effect on the release of C-terminal fragments of parathyroid hormone. *J. Bone Min. Res.* 7: 667-674, 1992.
28. Grimston SK, Morrison K, Harder JA, Hanley DA. Bone mineral density during puberty in western Canadian children. *Bone and Mineral* 19: 85-96, 1992.
29. Grimston SK, Nigg BM, Hanley DA, Engsberg JR. Differences in ankle joint complex range of motion as a function of age. *Foot and Ankle* 14: 215-222, 1993.
30. Grimston SK, Tanguay KE, Gundberg CM, Hanley DA. The calciotropic hormone response to changes in serum calcium during exercise in female long-distance runners. *J. Clin. Endocrinol. Metab.* 76: 867-872, 1993.
31. Watson PH, Hanley DA. Parathyroid Hormone: regulation of synthesis and secretion. *Clin. Invest. Med.* 16: 58-77, 1993.
32. Grimston SK, Willows ND, Hanley DA. Mechanical loading regime and its relationship to bone mineral density in children. *Med. Sci. Sports Ex.* 25 (11): 1203-1210, 1993.
33. Donovan L, Hanley DA, Rorstad OP. Factitious thyroid cancer: A case report. *The Endocrinologist* 3: 398-399, 1993.
34. Willows ND, Grimston SK, Roberts D, Smith DJ, Hanley DA. Iron and hematologic status in young athletes relative to puberty: a cross-sectional study. *Pediatric Exercise Science* 5:367-376, 1993.
35. Willows ND, Grimston SK, Smith DJ, Hanley DA. Iron and hematological status among athletes tracked through puberty. *Pediatric Exercise Science*, 7: 253-262, 1995.

36. Watson PH, Mortimer ST, Wang KKW, Croall DE, Hanley DA: Calcium activated proteases in the parathyroid gland: Potential role in degradation of parathyroid hormone to peptide fragments. *J. Mol. Endocrinol.*, 15: 61-71, 1995.
37. Shivji F, Cheng H, Zwieters H, Hollenberg MD, Hanley, DA: Identification of classical, novel and atypical protein kinase C isoenzymes in the bovine parathyroid. *Endocrinology* 137:3777-83, 1996.
38. Hanley, DA: New (and old) drugs for the treatment of osteoporosis. *J. Soc. Obstet. Gynecol Canada (Supplement on Osteoporosis):7-14,1996. Supplement:pp 1-33.*
39. Adachi JD, Bensen WG, Brown J, Hanley DA, et al: Intermittent Cyclical Etidronate Therapy in the Prevention of Corticosteroid - Induced Osteoporosis. *New England Med.*, 1997; 337:382-7.
40. Lockyer J, Hanley DA, Fidler H, Toews J, Lysholm-Andrews B. Physician Educational Needs in Osteoporosis: An Approach to Needs Assessment. *The Journal of Continuing Education in the Health Professions*, Vol. 18; No.3: pp. 185-189, 1998.
41. Pols, HAP, Felsenberg, D, Hanley, DA, Stephan, J, Munoz-Torres, M, Wilkin, TJ, Quin-Sheng, G, Galich, A, Vandormael, K, Yates, J, Stych, B, for the FOSIT study group: Multinational, Placebo controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study, H. Pols, et al. *Osteoporosis International*, 1999;9:461-8.
42. Hargrove GM, Pasiaka JL, Hanley DA, Murphy MB. Short- and Long-Term Outcome of Total Parathyroidectomy with Immediate Autografting versus Subtotal Parathyroidectomy in Patients with End-Stage Renal Disease. *Am J Nephrol* 1999;19:559-564.
43. Hanley DA, Ioannidis G, and Adachi JD. Etidronate Therapy in the Treatment and Prevention of Osteoporosis. *Journal of Clinical Densitometry*, 2000;3:79-95.
44. Adachi JD, Olszynski WP, Hanley DA, Hodsman AB, Kendler DL, Siminoski KG, Brown J, Cowden EA, Goltzman D, Ioannidis G, Josse RG, Ste-Marie L-G, Tenenhouse AM, Davison KS, Blocka KLN, Pollock AP, Sibley J: Management of corticosteroid-induced osteoporosis. *Seminars in Arthritis and Rheumatism*, Vol 29, No 4 (February), 2000: pp 228-251.
45. Jackson SA, Tenenhouse A, Robertson L, and CaMos Study Group: Vertebral Fracture Definition from Population-Based Data: Preliminary Results from the Canadian Multicentre Osteoporosis Study (CaMos). *Osteoporosis International* 2000;11(8):680-687.
46. Hopman WM, Towheed T, Anastassiades T, Tenenhouse A, Poliquin S, Berger C, Joseph L, Brown J, Murray T, Adachi JD, Hanley D, Papadimitropoulos M, and the CaMos Research Group: Canadian Normative Data for the SF-36 Health Survey. *Can Med Assoc J* 2000;163(3):265-71.
47. Rittmaster RS, Bolognese M, Ettinger MP, Hanley DA, Hodsman AB, Kendler DL and Rosen CJ. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. *J Clin Endocrinol Metab* 2000;85:2129-34.

Selected as the “article of the day” for July, 10, 2000, by AMEDEO, a “guide to the medical literature” medical education group.

48. Crilly RG, Sebaldt RJ, Hodsman AB, Adachi JD, Brown JP, Goldsmith CH, Hanley DA, Olszynski WO, Ste-Marie LG, Stephenson GF. Predicting subsequent bone density response to intermittent cyclical therapy with etidronate from initial density response in patients with osteoporosis. *Osteoporos Int.* 2000;11(7):607-14.
49. Ungar W.J., Josse R., Lee S., Ryan N., Adachi R., Hanley D., Brown J., Breton M-C.: The Canadian SCORE questionnaire - optimizing the use of technology for low bone density assessment. *J. Clin. Densitometry*, Vol. 3, No. 3, Fall 2000:269-280.
50. Tenenhouse A, Joseph L, Kreiger N, Poliquin S, Murray TM, Blondeau L, Berger C, Hanley DA, Prior JC. Estimation of the prevalence of low bone density in Canadian women and men using a population-specific DXA reference standard: the Canadian Multicentre Osteoporosis Study (CaMos). *Osteoporos Int.* 2000;11(10):897-904.
51. T.L. Yanagawa, M.E. Maitland, K. Burgess, L. Young, and D. Hanley. The Assessment of Thoracic Kyphosis Using the Flexicurve for Individuals with Osteoporosis. *The Hong Kong Physiotherapy Journal.* 2000;18(2):53-57.
52. Mather KJ, Meddings JB, Beck PL, Scott RB, Hanley DA. Prevalence of IgA-antiendomysial antibody in asymptomatic low bone mineral density. *Am J Gastroenterol.* 2001;96(1):120-125.
53. Prior JC, Kirkland SA, Joseph L, Kreiger N, Murray TM, Hanley DA, Adachi JD, Vigna YM, Berger C, Blondeau L, Jackson, SA, Tenenhouse A. Oral contraceptive use and bone mineral density in premenopausal women: cross-sectional, population-based data from the Canadian Multicentre Osteoporosis Study. *CMAJ.* 2001 Oct 16;165(8):1023-9.
54. Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB, Licata A, Benhamou L, Geusens P, Flowers K, Stracke H, Seeman E. Risk of new vertebral fracture in the year following a fracture. *JAMA.* 2001;285:320-323.
55. Adachi JD, Ioannidis G, Berger C, Joseph L, Papaioannou A, Pickard L, Papadimitropoulos EA, Hopman W, Poliquin S, Prior JC, Hanley DA, Olszynski WP, Anastassiades T, Brown JP, Murray T, Jackson SA, Tenenhouse A, and the Canadian Multicentre Osteoporosis Study (CaMos) Research Group: The Influence of Osteoporotic Fractures on Health-Related Quality of Life in Community-Dwelling Men and Women across Canada. *Osteoporos Int* 12 (2001) 11, 903-908.
56. Brown JP, Olszynski WP, Hodsman A, Bensen WG, Tenenhouse A, Anastassiades TP, Ste-Marie LG, Kendler DL, Hanley DA, Josse R, Hanly JG, Lentle B, Jovaisas A, Ioannidis G, Stephenson GF, Barton I, Pack S, Chines A, Dias R, Adachi. Positive effect of etidronate therapy is maintained after drug is terminated in patients using corticosteroids. *J Clin Densitom* 2001 Winter;4(4):363-71.
57. D'Souza-Li L, Yang B, Canaff L, Bai M, Hanley DA, Bastepe M, Salisbury SR, Brown EM, Cole DE, Hendy GN. Identification and functional characterization of novel calcium-sensing receptor mutations in familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia. *J Clin Endocrinol Metab.* 2002 Mar;87(3):1309-18.

58. Adachi J.D., Ioannidis G, Olszynski W.P., Brown J.P., Hanley D.A., Sebaldt R.J., Petrie A., Tenenhouse A., Stephenson G.F., Papaioannou A., Guyatt G.H., Goldsmith C.H.: The impact of incident vertebral and non-vertebral fractures on health related quality of life in postmenopausal women. *BMC Musculoskelet Disord.* 2002 Apr 22;3(1):11.
59. Hodsman A.B, Hanley D.A., Josse R.: Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date. *CMAJ* 2002 May 28; 166(11):1426-30.
60. Rucker D, Allan JA, Fick GH, Hanley DA. Vitamin D insufficiency in a population of healthy western Canadians. *CMAJ* 2002 Jun 11;166(12):1517-24. Comment in: *CMAJ.* 2002 Jun 11;166(12):1541-2.
61. Hopman W.M., Berger C., Joseph L., Towhead T., Anastassiades T., Tenenhouse A., Poliquin S., Brown J.P., Murray T.M., Adachi J.D., Hanley D.A., Papadimitropoulos E.A., and the CaMos Research Group. Is there Regional Variation in the SF-36 Scores of Canadian Adults? *Canadian J Public Health* 2002;93(3):229-32.
62. Olszynski WP, Ioannidis G, Sebaldt RJ, Hanley DA, Petrie A, Brown JP, Josse RG, Murray TM, Goldsmith CH, Stephenson GF, Papaioannou A, Adachi JD. The association between iliocostal distance and the number of vertebral and non-vertebral fractures in women and men registered in the Canadian Database For Osteoporosis and Osteopenia (CANDOO). *BMC Musculoskeletal Disorders* 2002, 3:22 (3 October 2002).
63. Hanley DA. Puzzling vitamin D results. (letter to editor) *CMAJ* 2002 Oct 15;167(8):849-850.
64. Jacques P. Brown, Robert G. Josse and The Scientific Advisory Council of the Osteoporosis Society of Canada. 2002 Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. *CMAJ* 2002;167(10 suppl): S1-S34. (David A. Hanley was chair and author of the Risk Factor Section, co-author of the Definitions Section, contributor to the Bisphosphonates Section, and member of the executive council overseeing the final edited version).
65. Khan AA, Brown J, Faulkner K, Kendler D, Lentle B, Leslie W, Miller PD, Nicholson L, Olszynski WP, Watts NB, Hanley D, Hodsman A, Josse R, Murray TM, Yuen K; International Society for Clinical Densitometry. Standards and guidelines for performing central dual X-ray densitometry from the Canadian panel of International Society for Clinical Densitometry. *J Clin Densitom.* 2002 Fall;5(3):247-57. Corrected and republished in: *J Clin Densitom.* 2002 Winter;5(4):435-45.
66. Rucker D., Hanley D.A., Zernicke R.F.: Response of bone to exercise and aging. *Locomotor System-Advances in Research, Diagnostics and Therapy* 9:6-22, 2002.
67. Hanley, D.A., Brown J., Tenenhouse A., Olszynski W., Ioannidis G., Berger C., Prior J., Prickard L., Murray T., Anastassiades T., Kirkland S., Joyce C., Joseph L., Papaioannou A., Jackson S., Poliquin S., Adachi J., CaMOS Research Group. Associations Among Disease Conditions, Bone Mineral Density, and Prevalent Vertebral Deformities in Men and Women 50 Years of Age and Older: Cross-

Sectional Results from the Canadian Multicentre Osteoporosis Study. *J. Bone Miner. Res.* 2003 Apr;18(4):784-90.

68. Khan A., Hanley, D.A., O'Brien C., Pasieka J., Ste-Marie L., Rotstein L., Rosen I., Young J., Josse R., Bilezikian J.: Asymptomatic primary hyperparathyroidism: Standards and guidelines for diagnosis and management in Canada. *Endocr Pract.* 2003;9(No.5) 400-405.
69. Hodsman A.B., Hanley D.A., Ettinger M.P., Bolognese M.A., Fox J., Metcalfe A.J., Lindsay R.: Efficacy and Safety of Human Parathyroid Hormone (1-84) in Increasing Bone Mineral Density in Postmenopausal Osteoporosis. *J Clin Endocrinol Metab* 2003 Nov;88(11):5212-20.
70. Alagiakrishnan K., Juby A., Hanley D., Tymchak W., Sclater A.: Role of Vascular Factors in Osteoporosis. *J. Gerontol* 2003;58A: 362-6.
71. Adachi J.D., Ioannidis G., Pickard L, Berger C., Prior J.C., Joseph L., Hanley D.A., Olszynski W.P., Murray T.M., Anastassiades T., Hopman W., Brown J.P., Kirland S., Joyce C., Papaioannou A., Poliquin S., Tenenhouse A., Papadimitropoulos E.A.: The association between osteoporotic fractures and health related quality of life as measured by the Health Utilities Index in the Canadian Multicentre Osteoporosis Study (CaMOS). *Osteoporos Int.* 2003;14:895-904.
72. Papaioannou A., Ioannidis G., Adachi J.D., Sebaldt R.J., Ferko, N., Puglia M., Brown J., Tenenhouse A., Olszynski W.P., Boulos P., Hanley D.A., Josse R., Murray T., Petrie A., Stephenson G.F., Goldsmith C. H. Adherence to Bisphosphonates and Hormone Replacement Therapy in a Tertiary Care Setting of Patients in the CANDOO Database. *Osteoporos Int.* 2003 Oct;14(10):808-13.
73. Sawka A.M., Adachi J.D., Ioannidis G., Olszynski W., Brown J.P., Hanley D.A., Murray T., Josse R., Sebaldt R.J., Petrie A., Tenenhouse A., Papaioannou A., Goldsmith C.H. What Predicts Early Fracture or Bone Loss on Bisphosphonate Therapy? *J Clin Densitom.* 2003 Winter;6(4):315-22.
74. Olszynski WP, Shawn Davison K, Adachi JD, Brown JP, Cummings SR, Hanley DA, Harris SP, Hodsman AB, Kendler D, McClung MR, Miller PD, Yuen CK. Osteoporosis in men: epidemiology, diagnosis, prevention, and treatment. *Clin Ther.* 2004 Jan;26(1):15-28. Review.
75. Rucker D., Ezzat S., Diamandir A., Khosravi J., Fung T.S., Hanley D.A.: IGF-1 and testosterone levels as predictors of bone mineral density in healthy, community-dwelling men. *Clin Endocrinol (Oxf).* 2004 Apr;60(4):491-9.
76. Harris S.T., Watts N.B., Li Z., Chines A.A., Hanley D.A., Brown J.P.: Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis. *Curr Med Res Opin.* 2004 May;20(5):757-64.
77. Hodsman AB, Hanley DA, Ettinger MP, Bolognese MA, Fox J, Metcalfe AJ, Lindsay R. Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis. *Obstet Gynecol Surv.* 2004 May;59(5):356-8.
78. Khan AA, Bachrach L, Brown JP, Hanley DA, Josse RG, Kendler DL, Leib ES, Lentle BC, Leslie WD, Lewiecki EM, Miller PD, Nicholson RL, O'Brien C, Olszynski WP, Theriault MY, Watts NB; Canadian Panel of the International Society of

Clinical Densitometry. Standards and guidelines for performing central dual-energy x-ray absorptiometry in premenopausal women, men, and children. *J Clin Densitom.* 2004 Spring;7(1):51-64. Review.

79. L'Abbé M.R., Whiting S.J., Hanley D.A.: The Canadian health claim for calcium, vitamin D and osteoporosis. *J. Am. Coll. Nutr.* 2004 Aug;23(4):303-8.
80. Hopman WM, Berger C, Joseph L, Towheed T, vandenKerkhof E, Anastassiades T, Cranney A, Adachi JD, Ioannidis G, Poliquin S, Brown JP, Murray TM, Hanley DA, Papadimitropoulos EA, Tenenhouse A, and the CaMos Research Group. Stability of Normative Data for the SF-36: Results of a Three-Year Prospective Study in Middle-Aged Canadians. *Can J Public Health.* 2004 Sep-Oct;95(5):387-91.
81. Majumdar S.R., Rowe B.H., Folk D., Johnson J.A., Holroyd B.H., Morrish D.W., Maksymowych W.P., Steiner I.P., Harley C.H., Wirzba B., Hanley D.A., Blitz S., Russell A.S.: A controlled trial to increase detection and treatment of osteoporosis in older patients with a wrist fracture. *Ann Intern Med.* 2004 Sep 7;141(5):366-73.
82. Doschak M.R., Wohl G.R., Hanley D.A., Bray R.C., Zernicke R.F.: Antiresorptive therapy conserves some periarticular bone and ligament mechanical properties after anterior cruciate ligament disruption in the rabbit knee. *J Orthop Res.* 2004 Sep;22(5):942-8.
83. Sawka AM, Adachi JD, Papaioannou A, Thabane L, Ioannidis G, Davison KS, Olszynski WP, Brown JP, Hanley DA, Murray TM, Josse RG, Sebaldt RJ, Petrie A, Tenenhouse A, Goldsmith CH. Are there differences between men and women prescribed bisphosphonate therapy in canadian subspecialty osteoporosis practices? *J Rheumatol.* 2004 Oct;31(10):1993-5.
84. Papaioannou A., Joseph L., Ioannidis G., Berger C., Tassos Anastassiades T., Brown J.P., Hanley D.A., Hopman W., Josse R.G., Kirkland S., Murray T.M., Olszynski W.P., Pickard L., Prior J.C., Siminoski K., Adachi J.D. Risk Factors Associated with Incident Clinical Vertebral and Non-Vertebral Fractures in Postmenopausal Women: The Canadian Multicentre Osteoporosis Study (CaMos). *Osteoporos Int.* 2005 May;16(5):568-78. Epub 2004 Oct 27.
85. Hanley D.A. and Davison K.S. Vitamin D insufficiency in North America. *J Nutr.* 2005 Feb;135(2):332-7.
86. Vik SA, Maxwell CJ, Hanley DA. Treatment of osteoporosis in an older home care population. *BMC Musculoskelet Disord.* 2005 Feb 11;6(1):7.
87. Sawka AM, Boulos P, Beattie K, Thabane L, Papaioannou A, Gafni A, Cranney A, Zytaruk N, Hanley DA, Adachi JD. Do hip protectors decrease the risk of hip fracture in institutional- and community-dwelling elderly? A systematic review and meta-analysis of randomized controlled trials. *Osteoporos Int.* 2005 Dec;16(12):1461-74. Epub 2005 July 5.
88. Sawka AM, Thabane L, Papaioannou A, Gafni A, Hanley DA, Adachi JD. A Systematic Review of the Effect of Alendronate on Bone Mineral Density in Men. *J Clin Densitom.* 2005 Spring;8(1):7-13.
89. Sawka AM, Ioannidis G, Papaioannou A, Thabane L, Olszynski WP, Brown JP, Hanley DA, Murray TM, Josse RG, Sebaldt RJ, Petrie A, Tenenhouse A, Goldsmith CH, Boulos P, Kouroukis T, Adachi JD. Are oral bisphosphonates effective in

- improving lumbar bone mineral density in breast cancer survivors with osteopenia or osteoporosis? *J Obstet Gynaecol Can.* 2005 Aug;27(8):759-64.
90. Ettinger B., Hillier T.A., Pressman A., Che M., Hanley D.A.: Simple computer model for calculation and reporting 5-year osteoporotic fracture risk in postmenopausal women. *J Women's Health (Larchmt).* 2005 Mar;14(2):159-71.
 91. Siminoski K., Jiang G., Adachi J.D., Hanley D.A., Cline G., Ioannidis G., Hodsmann A., Josse R.G., Kendler D., Olszynski W.P., Ste Marie L.G., Eastell R. Accuracy of Height Loss During Prospective Monitoring for Detection of Incident Vertebral Fractures. *Osteoporosis Int.* 2005;16:403-410.
 92. Majumdar SR, Kim N, Colman I, Chahal AM, Raymond G, Jen H, Siminoski KG, Hanley DA, Rowe BH. "Incidental" vertebral fractures discovered by chest radiography in the emergency department: prevalence, recognition, and osteoporosis management in a cohort of elderly patients. *Arch Intern Med.* 2005 Apr 25;165(8):905-9.
 93. Sawka A.M., Papaioannou A., Adachi J.D., Gafni A., Hanley D.A., Thabane L.: Does Alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women. *BMC Musculoskeletal Disorders* 2005 Jul 11;6:39.
 94. Hodsmann A.B., Bauer D.C., Dempster D.W., Dian L., Hanley D.A., Harris S.T., Kendler D.L., McClung M.R., Miller P.D., Olszynski W.P., Orwoll E.S. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guideline for its use. *Endocr Rev.* 2005 Aug;26(5):688-703. Epub 2005 Mar 15. Review
 95. Doschak M., Zernicke R., Cooper D., Bray R.C., Hanley D., Lamothe J. Bisphosphonates reduce bone mineral loss at ligament entheses after joint injury. *Osteoarthritis Cartilage* 2005 Sept;13(9):790-7.
 96. Bensen R, Adachi JD, Papaioannou A, Ioannidis G, Olszynski WP, Sebaldt RJ, Murray TM, Josse RG, Brown JP, Hanley DA, Petrie A, Mark Puglia M, Goldsmith CH: Evaluation of easily measured risk factors in the prediction of osteoporotic fractures. *BMC Musculoskeletal Disorders* 2005, Sep 5;6:47.
 97. Olszynski W.P., Davison K.S., Ioannidis G., Brown J.P., Hanley D.A., Josse R.G., Murray T.M., Papaioannou A., Sebaldt R.J., Tenenhouse A.M., Petrie A., Goldsmith C.H., Adachi J.D.: Effectiveness of alendronate and etidronate in the treatment of osteoporosis in men: a prospective observational study. *Osteoporosis Int.* 2006 Feb;17(2):217-24. Epub 2005 Jul 5.
 98. Papaioannou A, Kennedy CC, Ioannidis G, J Brown JP, Pathak A, Hanley DA, Josse RG, Sebaldt RJ, Olszynski WP, Tenenhouse A, Murray TM, Petrie A, Goldsmith CH, Adachi JD. Determinants of health-related quality of life in women with vertebral fractures. *Osteoporosis Int.* 2006;17(3):355-63. Epub 2005 Dec 9.
 99. Fenton TR, Hanley DA. Calcium, Dairy Products, and Bone Health in Children and Young Adults: An Inaccurate Conclusion. *Pediatrics.* 2006 Jan;117(1):259-260; author reply 260-1.
 100. Rucker D, Rowe BH, Johnson JA, Steiner IP, Russell AS, Hanley DA, Maksymowych WP, Holroyd BR, Harley CH, Morrish DW, Wirzba BJ, Majumdar SR. Educational intervention to reduce falls and fear of falling in patients after

- fragility fracture: results of a controlled pilot study. *Prev Med.* 2006 Apr;42(4):316-9. Epub 2006 Feb 20.
101. Hopman WM, Berger C, Joseph L, Towheed T, Vandenberg E, Anastassiades T, Adachi JD, Ioannidis G, Brown JP, Hanley DA, Papadimitropoulos EA; CaMos Research Group. The Natural Progression of Health-Related Quality of Life: Results of a Five-Year Prospective Study of SF-36 Scores in a Normative Population. *Qual Life Res.* 2006 Apr;15(3):527-536.
 102. Khan AA, Hanley DA, Bilezikian JP, Binkley N, Brown JP, Hodsmann AB, Josse RG, Kendler DL, Lewiecki EM, Miller PD, Olszynski WP, Petak SM, Syed ZA, Theriault D, Watts NB; Canadian Panel of the International Society for Clinical Densitometry. Standards for performing DXA in individuals with secondary causes of osteoporosis. *J Clin Densitom.* 2006 Jan-Mar;9(1):47-57. Epub 2006 Apr 4.
 103. Cranney A, Papaioannou A, Zytaruk N, **Hanley D**, Adachi J, Goltzman D, Murray T, Hodsmann A; Parathyroid hormone for the treatment of osteoporosis: a systematic review. *CMAJ.* 2006 Jul 4;175(1):52-9.
 104. Hopman WM, Towheed TE, Gao Y, Berger C, Joseph L, Vik SA, **Hanley DA**, Carran J, Anastassiades T. Prevalence of and factors associated with glucosamine use in Canada. *Osteoarthritis Cartilage.* 2006 Dec;14(12):1288-93. Epub 2006 Jul 10.
 105. Davison KS, Siminoski K, Adachi JD, **Hanley DA**, Goltzman D, Hodsmann AB, Josse R, Kaiser S, Olszynski WP, Papaioannou A, Ste-Marie L, Kendler DL, Tenenhouse A, Brown JP. The effects of antifracture therapies on the components of bone strength: assessment of fracture risk today and in the future. *Semin Arthritis Rheum.* 2006 Aug;36(1):10-21. Epub 2006 Jul 3.
 106. Davison KS, Siminoski K, Adachi JD, **Hanley DA**, Goltzman D, Hodsmann AB, Josse R, Kaiser S, Olszynski WP, Papaioannou A, Ste-Marie L, Kendler DL, Tenenhouse A, Brown JP. Bone strength: the whole is greater than the sum of its parts. *Semin Arthritis Rheum.* 2006 Aug;36(1):22-31. Epub 2006 Jul 3. Review.
 107. Majumdar SR, Johnson JA, Lier DA, Russell AS, **Hanley DA**, Blitz S, Steiner IP, Maksymowych WP, Morrish DW, Holroyd BR, Rowe BH. Persistence, reproducibility, and cost-effectiveness of an intervention to improve the quality of osteoporosis care after a fracture of the wrist: results of a controlled trial. *Osteoporosis Int.* 2007 Mar;18(3):261-70. Epub 2006 Nov 4.
 108. Sawka AM, Papaioannou A, Josse RG, Murray TM, Ioannidis G, **Hanley DA**, Prior JC, Thabane L, Papadimitropoulos EA, Gafni A, Pickard L, Anastassiades T, Kirkland S, Adachi JD, The CaMOS Research Group. What is the number of older Canadians needed to screen by measurement of bone density to detect an undiagnosed case of osteoporosis? A population-based study from CaMOS. *J Clin Densitom.* 2006 Oct-Dec;9(4):413-8. Epub 2006 Sep 1.
 109. Kline GA, **Hanley DA**. Differences of vertebral area in serial bone density measurements: a common source of potential error in interpretation of BMD change. *J Clin Densitom.* 2006 Oct-Dec;9(4):419-24. Epub 2006 Sep 22.
 110. Richards JB, Leslie WD, Joseph L, Siminoski K, Hanley DA, Adachi JD, Brown JP, Morin S, Papaioannou A, Josse RG, Prior JC, Davison KS, Tenenhouse A,

- Goltzman D; CaMos Study Group. Changes to osteoporosis prevalence according to method of risk assessment. *J Bone Miner Res.* 2007 Feb;22(2):228-34.
111. Sawka AM, Boulos P, Beattie K, Papaioannou A, Gafni A, Cranney A, **Hanley DA**, Adachi JD, Papadimitropoulos EA, Thabane L. Hip protectors decrease hip fracture risk in elderly nursing home residents: a Bayesian meta-analysis. *J Clin Epidemiol.* 2007 Apr;60(4):336-44. Epub 2006 Oct 23. Review.
 112. Sawka AM, Gafni A, Boulos P, Beattie K, Papaioannou A, Cranney A, **Hanley DA**, Adachi JD, Cheung A, Papadimitropoulos EA, Thabane L. Could a policy of provision of hip protectors to elderly nursing home residents result in cost savings in acute hip fracture care? The case of Ontario, Canada. *Osteoporosis Int.* 2007 Jun;18(6):819-27. Epub 2007 Jan 13.
 113. Greenspan SL, Bone HG, Ettinger MP, **Hanley DA**, Lindsay R, Zanchetta JR, Blosch CM, Mathisen AL, Morris SA, Marriott TB; Treatment of Osteoporosis with Parathyroid Hormone Study Group. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. *Ann Intern Med.* 2007 Mar 6;146(5):326-39. Summary for patients in: *Ann Intern Med.* 2007 Mar 6;146(5):120.
 114. Josse RG, **Hanley DA**, Kendler D, Ste Marie LG, Adachi JD, Brown J; Canadian Society of Endocrinology and Metabolism. Diagnosis and treatment of Paget's disease of bone. *Clin Invest Med.* 2007;30(5):E210-23.
 115. Khan AA, Colquhoun A, **Hanley DA**, Jankowski LG, Josse RG, Kendler DL, Lentle B, Leslie WD, Lewiecki EM, O'Neill E, Robertson S, Syed ZA, Tanner SB, Webster D. Standards and guidelines for technologists performing central dual-energy X-ray absorptiometry. *J Clin Densitom.* 2007 Apr-Jun;10(2):189-95. Epub 2007 Feb 28. No abstract available. PMID: 17485038 [PubMed – in process].
 116. **Hanley DA**, Zhang Q, Meilleur M-C, Mavros P, S. Sen SS. Prescriptions for vitamin D among patients taking antiresorptive agents in Canada. *Current Medical Research and Opinion.* 2007 Jun;23(6):1473-80. Epub 2007 May 18.
 117. Vik SA, Jantzi M, Poss J, Hirdes J, **Hanley DA**, Hogan DB, Maxwell CJ. Factors associated with the pharmacologic treatment of osteoporosis in an older home care population. *J. Gerontol. A Biol. Sci. Med. Sci.* 2007 Aug;62(8):872-8.
 118. Cranney A, Horsley T, O'Donnell S, Weiler HA, Puil L, Ooi DS, Atkinson SA, Ward LM, Moher D, **Hanley DA**, Fang M, Yazdi F, Garritty C, Sampson M, Barrowman N, Tsertsvadze A, Mamaladze V. Effectiveness and safety of vitamin D in relation to bone health. *Evid Rep Technol Assess (Full Report).* 2007 Aug;(158):1-235. Review.
 119. Adachi JD, **Hanley DA**, Lorraine JK, Yu M. Assessing compliance, acceptance, and tolerability of Teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: An 18-month, multicenter, open-label, prospective study. *Clinical Therapeutics* 2007 Sep;29(9):2055-67.
 120. Majumdar SR, Beaupre LA, Harley CH, **Hanley DA**, Lier DA, Juby AG, Maksymowych WP, Cinats JG, Bell NR, Morrish DW. Using a case-manager to improve

- osteoporosis treatment after hip fracture: results of a randomized controlled trial. *Arch Intern Med.* 2007 Oct 22;167(19):2110-5.
121. Majumdar SR, Johnson JA, McAlister FA, Bellerose D, Russell AS, **Hanley DA**, Morrish DW, Maksymowych WP, Rowe BH. Multifaceted intervention to improve osteoporosis diagnosis and treatment in patients with recent wrist fracture: a randomized controlled trial. *CMAJ.* 2008 Feb 26;178(5):569-75.
 122. Papaioannou A, Kennedy CC, Ioannidis G, Gao Y, Sawaka AM, Goltzman D, Tenenhouse A, Pickard L, Olszynski WP, Davidson S, Kaiser S, Josse RG, Kreiger N, **Hanley DA**, Prior JC, Brown JP, Anastassiades T, Adachi JD, and the CaMos Research Group. The osteoporosis care gap in men with fragility fractures: The Canadian Multicentre Osteoporosis Study. *Osteoporosis Int.* 2008 Apr;19(4):581-7. Epub 2007 Oct 9.
 123. Khan AA, Sándor GKB, Dore E, Morrison AD, Alsahli M, Amin F, Peters E, **Hanley DA**, Chaudhry SR, Dempster D, Glorieux FH, Neville A, Talwar RM, Clokie CM, Al Mardini M, Paul T, Khosla S, Josse RG, Sutherland S, Lam DK, Carmichael RP, Blanas N, Kendler D, Petak S, St. Marie LG, J. Brown, A. W. Evans, L. Rios, Compston JE. Canadian Consensus Practice Guidelines for Bisphosphonate-Associated Osteonecrosis of the Jaw. *J Rheumatol.* 2008 Jul;35(7):1391-7. Epub 2008 Jun 1. Erratum in: *J Rheumatol.* 2008 Aug;35(8):1688. *J Rheumatol.* 2008 Oct;35(10):2084..
 124. Barnabe C, **Hanley DA**. Effect of Tumor Necrosis Factor Alpha (TNF α) Inhibition on Bone Density and Turnover Markers in Patients with Rheumatoid Arthritis and Spondyloarthropathy. *Semin Arthritis Rheum* 2008 Jun 26. [Epub ahead of print].
 125. O'Donnell S, Cranney A, Horsley T, Weiler HA, Atkinson SA, **Hanley DA**, Ooi DS, Ward L, Barrowman N, Fang M, Sampson M, Tsertsvadze A, Yazdi F. Efficacy of food fortification on serum 25-hydroxyvitamin D concentrations: systematic review. *Am J Clin Nutr.* 2008 Dec;88(6):1528-34.
 126. O'Donnell S, Moher D, Thomas K, **Hanley DA**, Cranney A. Systematic review of the benefits and harms of calcitriol and alfacalcidol for fractures and falls. *J Bone Miner Metab.* 2008;26(6):531-42. Epub 2008 Nov 1. Review.
 127. Berger C, Langsetmo L, Joseph L, **Hanley DA**, Davison S, Josse RG, Prior JC, Kreiger N, Tenenhouse A, Goltzman D; the CaMos Research Group. Association Between Change in Bone Mineral Density (BMD) and Fragility Fracture in Women and Men. *J Bone Miner Res.* 2009 Feb;24(2):361-70.
 128. Fenton TR, Eliasziw M, Lyon AW, Tough SC, **Hanley DA**. Meta-analysis of the quantity of calcium excretion associated with the net acid excretion of the modern diet under the acid-ash diet hypothesis. *Am J Clin Nutr.* 2008 Oct;88(4):1159-66.
 129. ~~Jamal SA, Goltzman D, **Hanley DA**, Papaioannou A, Prior JC, Josse RG. Nitrate use and changes in bone mineral density: the Canadian Multicentre Osteoporosis Study. *Osteoporos Int.* 2009 May;20(5):737-44. Epub 2008 Sep 18. **RETRACTED:**~~
Jamal, S.A., Goltzman, D., Hanley, D.A. et al. *Osteoporos Int* 2017 Jan;28(1):421
 130. Langsetmo L, **Hanley DA**, Kreiger N, Jamal SA, Prior J, Adachi JD, Davison KS, Kovacs C, Anastassiades T, Tenenhouse A, Goltzman D; CaMos Research Group. Geographic variation of bone mineral density and selected risk factors for

- prediction of incident fracture among Canadians 50 and older. *Bone*. 2008 Oct;43(4):672-8. Epub 2008 Jul 1.
131. Berger C, Langsetmo L, Joseph L, **Hanley DA**, Davison KS, Josse R, Kreiger N, Tenenhouse A, Goltzman D; Canadian Multicentre Osteoporosis Study Research Group. Change in bone mineral density as a function of age in women and men and association with the use of antiresorptive agents. *CMAJ*. 2008 Jun 17;178(13):1660-8.
 132. Majumdar SR, Lier DA, Beaupre LA, **Hanley DA**, Maksymowych WP, Juby AG, Bell NR, Morrish DW. Osteoporosis case manager for patients with hip fractures: results of a cost-effectiveness analysis conducted alongside a randomized trial. *Arch Intern Med*. 2009 Jan 12;169(1):25-31.
 133. Morrish DW, Beaupre LA, Bell NR, Cinats JG, **Hanley DA**, Harley CH, Juby AG, Lier DA, Maksymowych WP, Majumdar SR. Facilitated bone mineral density testing versus hospital-based case management to improve osteoporosis treatment for hip fracture patients: Additional results from a randomized trial. *Arthritis Rheum*. 2009 Jan 29;61(2):209-215. [Epub ahead of print]
 134. Eastell R, Arnold A, Brandi ML, Brown EM, D'Amour P, **Hanley DA**, Rao DS, Rubin MR, Goltzman D, Silverberg SJ, Marx SJ, Peacock M, Mosekilde L, Bouillon R, Lewiecki EM. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. *J Clin Endocrinol Metab*. 2009;94(2):340-50.
 135. Bilezikian JP, Khan AA, Potts JT Jr; Third International Workshop on the Management of Asymptomatic Primary Hyperthyroidism. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. *J Clin Endocrinol Metab*. 2009 Feb;94(2):335-9. (**I was a conference speaker and participant in the preparation of this summary** - the three listed authors indicate that all participants should be considered co-authors [listed on page 335])
 136. Khan AA, Sándor GK, Dore E, Morrison AD, Alsahli M, Amin F, Peters E, **Hanley DA**, Chaudry SR, Lentle B, Dempster DW, Glorieux FH, Neville AJ, Talwar RM, Clokie CM, Mardini MA, Paul T, Khosla S, Josse RG, Sutherland S, Lam DK, Carmichael RP, Blanas N, Kendler D, Petak S, Ste-Marie LG, Brown J, Evans AW, Rios L, Compston JE. Bisphosphonate associated osteonecrosis of the jaw. *J Rheumatol*. 2009 Mar;36(3):478-90.
 137. Chen P, Krege JH, Adachi JD, Prior JC, Tenenhouse A, Brown JP, Papadimitropoulos E, Kreiger N, Olszynski WP, Josse RG, Goltzman D; **CaMOS Research Group**. Vertebral fracture status and the world health organization risk factors for predicting osteoporotic fracture risk. *J Bone Miner Res*. 2009 Mar;24(3):495-502. (I am one of the CaMOS Research Group members)
 138. Langsetmo L, Goltzman D, Kovacs CS, Adachi JD, **Hanley DA**, Kreiger N, Josse R, Papaioannou A, Olszynski WP, Jamal SA; the CaMos Research Group. Repeat Low-Trauma Fractures Occur Frequently Among Men and Women who have Osteopenic Bone Mineral Density. *J Bone Miner Res*. 2009 Sep;24(9):1515-22. Apr 1. [Epub ahead of print]

139. Brown JP, Albert C, Nassar BA, Adachi JD, Cole D, Davison KS, Dooley KC, Don-Wauchope A, Douville P, **Hanley DA**, Jamal SA, Josse R, Kaiser S, Krahn J, Krause R, Kremer R, Lepage R, Letendre E, Morin S, Ooi DS, Papaioannou A, Ste-Marie LG. Bone turnover markers in the management of postmenopausal osteoporosis. *Clin Biochem*. 2009 Jul;42(10-11):929-42. Epub 2009 Apr 10.
- ~~Jamal SA, Swan VJ, Brown JP, **Hanley DA**, Prior JC, Papaioannou A, Langsetmo L, Josse RG; Canadian Multicentre Osteoporosis Study Research Group. Kidney Function and Rate of Bone Loss at the Hip and Spine: The Canadian Multicentre Osteoporosis Study. *Am J Kidney Dis*. 2010 Feb;55(2):291-9. Epub 2009 Dec 28.~~
- RETRACTED**
140. Davison KS, Kendler DL, Ammann P, Bauer DC, Dempster DW, Dian L, **Hanley DA**, Harris ST, McClung MR, Olszynski WP, Yuen CK. Assessing fracture risk and effects of osteoporosis drugs: bone mineral density and beyond. *Am J Med*. 2009 Nov;122(11):992-7. Review.
141. Nishiyama KK, Macdonald HM, Buie HR, **Hanley DA**, Boyd SK. Postmenopausal Women With Osteopenia Have Higher Cortical Porosity and Thinner Cortices at the Distal Radius and Tibia Than Women With Normal aBMD: An In Vivo HR-pQCT Study. *J Bone Miner Res*. 2010 Apr;25(4):882-90. Epub 2009 Oct 19
142. Fenton TR, Lyon AW, Eliasziw M, Tough SC, **Hanley DA**. Phosphate decreases urine calcium and increases calcium balance: a meta-analysis of the osteoporosis acid-ash diet hypothesis. *Nutr J*. 2009 Sep 15;8:41. Review.
143. Leslie WD, O'Donnell S, Jean S, Lagacé C, Walsh P, Bancej C, Morin S, Hanley DA, Papaioannou A; Osteoporosis Surveillance Expert Working Group. Trends in hip fracture rates in Canada. *JAMA*. 2009 Aug 26;302(8):883-9.
144. Ioannidis G, Papaioannou A, Hopman WM, Akhtar-Danesh N, Anastassiades T, Pickard L, Kennedy CC, Prior JC, Olszynski WP, Davison KS, Goltzman D, Thabane L, Gafni A, Papadimitropoulos EA, Brown JP, Josse RG, **Hanley DA**, Adachi JD. Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study. *CMAJ*. 2009 Sep 1;181(5):265-71. Epub 2009 Aug 4.
145. Fenton TR, Eliasziw M, Lyon AW, Tough SC, Brown JP, **Hanley DA**. Low 5-year stability of within-patient ion excretion and urine pH in fasting-morning-urine specimens. *Nutr Res*. 2009 May;29(5):320-6.
146. Fenton TR, Eliasziw M, Lyon AW, Tough SC, Brown JP, **Hanley DA**. Meta-analysis of the effect of the acid-ash hypothesis of osteoporosis on calcium balance. *J Bone Miner Res*. 2009 Nov;24(11):1835-40.
147. Langsetmo L, Poliquin S, **Hanley DA**, Prior JC, Barr S, Anastassiades T, Towheed T, Goltzman D, Kreiger N; CaMos Research Group. Dietary patterns in Canadian men and women ages 25 and older: relationship to demographics, body mass index, and bone mineral density. *BMC Musculoskelet Disord*. 2010 Jan 28;11:20.
148. Hopman WM, Berger C, Joseph L, Towheed T, Prior JC, Anastassiades T, Poliquin S, Zhou W, Adachi JD, **Hanley DA**, Papadimitropoulos EA, Tenenhouse A; CaMos Research Group. *Can J Public Health*. 2009 Nov-Dec;100(6):449-52.

149. Seeman E, Delmas PD, **Hanley DA**, Sellmeyer D, Cheung AM, Shane E, Kearns A, Thomas T, Boyd SK, Boutroy S, Bogado C, Majumdar S, Fan M, Libanati C, Zanchetta J. Microarchitectural deterioration of cortical and trabecular bone: Differing effects of denosumab and alendronate. *J Bone Miner Res.* . 2010 Aug;25(8):1886-94. [Epub 2010 Mar 10]
150. Berger C, Goltzman D, Langsetmo L, Joseph L, Kreiger N, Tenenhouse A, Davison KS, Josse RG, Prior JC, **Hanley DA**; the CaMos Research Group. Peak bone mass from longitudinal data: implications for the prevalence, pathophysiology, and diagnosis of osteoporosis. *J Bone Miner Res.* 2010 Sep;25(9):1948-57. [Epub 2010 Mar 26.]
151. Majumdar SR, Johnson JA, Bellerose D, McAlister FA, Russell AS, **Hanley DA**, Garg S, Lier DA, Maksymowych WP, Morrish DW, Rowe BH. Nurse case-manager vs multifaceted intervention to improve quality of osteoporosis care after wrist fracture: randomized controlled pilot study. *Osteoporos Int.* 2011 Jan;22(1):223-30. [Epub 2010 Apr 1]
152. Macdonald HM, Nishiyama KK, **Hanley DA**, Boyd SK. Changes in trabecular and cortical bone microarchitecture at peripheral sites associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis. *Osteoporos Int.* 2011 Jan;22(1):357-62. [Epub 2010 May 11]
153. Zhou W, Langsetmo L, Berger C, Adachi JD, Papaioannou A, Ioannidis G, Webber C, Atkinson SA, Olszynski WP, Brown JP, **Hanley DA**, Josse R, Kreiger N, Prior J, Kaiser S, Kirkland S, Goltzman D, Davison KS and the CaMos Research Group. Normative Bone Mineral Density Z-scores for Canadians aged 16-24 years: The Canadian Multicentre Osteoporosis Study. *J Clin Densitom* 2010 July - September;13(3):267-276. Epub 2010 May 31.
154. Genant HK, Engelke K, **Hanley DA**, Brown JP, Omizo M, Bone HG, Kivitz AJ, Fuerst T, Wang H, Austin M, Libanati C. Denosumab Improves Density and Strength Parameters as Measured by QCT of the Radius in Postmenopausal Women With Low Bone Mineral Density. *Bone.* 2010 Jul;47(1):131-9. Epub 2010 Apr 22.
155. Nishiyama KK, Macdonald HM, Buie HR, **Hanley DA**, Boyd SK. Postmenopausal women with osteopenia have higher cortical porosity and thinner cortices at the distal radius and tibia than women with normal aBMD: an in vivo HR-pQCT study. *J Bone Miner Res.* 2010 Apr;25(4):882-90.
156. Langsetmo L, Leslie WD, Zhou W, Goltzman D, Kovacs CS, Prior J, Josse R, Olszynski WP, Davison KS, Anastassiades T, Towheed T, **Hanley DA**, Kaiser S, Kreiger N; for the CaMos Research Group. Using the same bone density reference database for men and women provides a simpler estimation of fracture risk. *J Bone Miner Res.* 2010 Oct;25(10):2108-14. [Epub 2010 Apr 30]
157. Fenton TR, Eliasziw M, Tough SC, Lyon AW, Brown JP, **Hanley DA**. Low urine pH and acid excretion do not predict bone fractures or the loss of bone mineral density: a prospective cohort study. *BMC Musculoskelet Disord.* 2010 May 10;11:88.
158. Langsetmo L, Morin S, Kovacs CS, Kreiger N, Josse R, Adachi JD, Papaioannou A, Goltzman D, **Hanley DA**, Olszynski WP, Prior J, Jamal SA; the CaMos Research Group. Determining whether women with osteopenic bone mineral density have

- low, moderate, or high clinical fracture risk. *Menopause*. 2010; Sep-Oct;17(5):1010-6. [Epub Jun 15, 2010.]
159. Macdonald HM, Nishiyama KK, Kang J, **Hanley DA**, Boyd SK. Age-related patterns of trabecular and cortical bone loss differ between sexes and skeletal sites: A population-based HR-pQCT study. *J Bone Miner Res*. 2011; 26(1): 50-62. [Epub 2010 Jun 30.]
160. **Hanley DA**, Cranney A, Jones G, Whiting S, Leslie WD, for the Guidelines Committee of the Scientific Advisory Council of Osteoporosis Canada. Vitamin D in Adult Health and Disease: A Review and Guideline Statement from Osteoporosis Canada. *CMAJ*. 2010 Sep 7;182(12):1315-9. Epub 2010 Jul 12.
161. **Hanley DA**, Cranney A, Jones G, Whiting S, Leslie WD, David E. C. Cole, Stephanie A. Atkinson, Robert G. Josse, Sidney Feldman, Gregory A. Kline, and Cheryl Rosen for the Guidelines Committee of the Scientific Advisory Council of Osteoporosis Canada. Vitamin D in Adult Health and Disease: A Review and Guideline Statement from Osteoporosis Canada. *CMAJ*. 2010 Sep 7;182(12):E610-8. Epub 2010 Jul 12.
162. Fraser LA, Ioannidis G, Adachi JD, Pickard L, Kaiser SM, Prior J, Brown JP, **Hanley DA**, Olszynski WP, Anastassiades T, Jamal S, Josse R, Goltzman D, Papaioannou A; the CaMos Research Group. Fragility fractures and the osteoporosis care gap in women: the Canadian Multicentre Osteoporosis Study. *Osteoporos Int*. 2011 Mar;22(3):789-796. Epub 2010 Aug 4
163. Greene-Finestone LS, Berger C, de Groh M, Hanley DA, Hidioglou N, Sarafin K, Poliquin S, Krieger J, Richards JB, Goltzman D; CaMos Research Group. 25-Hydroxyvitamin D in Canadian adults: biological, environmental, and behavioral correlates. *Osteoporos Int*. 2011;22(5):1389-99. [Epub 2010 Aug 21]
164. Majumdar SR, Lier DA, Rowe BH, Russell AS, McAlister FA, Maksymowych WP, Hanley DA, Morrish DW, Johnson JA. Cost-effectiveness of a multifaceted intervention to improve quality of osteoporosis care after wrist fracture. *Osteoporos Int*. 2011; 22(6):1799-808. [Epub 2010 Sep 29.]
165. Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S, **Hanley DA**, Hodsmann A, Jamal SA, Kaiser SM, Kvern B, Siminoski K, Leslie WD; Scientific Advisory Council of Osteoporosis Canada. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. *CMAJ*. 2010 Nov 23;182(17):1864-73. Epub 2010 Oct 12.
166. Leslie WD, Berger C, Langsetmo L, Lix LM, Adachi JD, **Hanley DA**, Ioannidis G, Josse RG, Kovacs CS, Towheed T, Kaiser S, Olszynski WP, Prior JC, Jamal S, Kreiger N, Goltzman D; Canadian Multicentre Osteoporosis Study (CaMos) Research Group. Construction and validation of a simplified fracture risk assessment tool for Canadian women and men: results from the CaMos and Manitoba cohorts. *Osteoporos Int*. 2011; 22(6):1873-83. [Epub ahead of print 2010 Oct 22]
167. Beaupre LA, Morrish DW, **Hanley DA**, Maksymowych WP, Bell NR, Juby AG, Majumdar SR. Oral bisphosphonates are associated with reduced mortality after hip fracture. *Osteoporos Int*. 2011 Mar;22(3):983-91. Epub 2010 Nov 4.
168. Langsetmo L, Hanley DA, Prior JC, Barr SI, Anastassiades T, Towheed T, Goltzman D, Morin S, Poliquin S, Kreiger N; CaMos Research Group. Dietary patterns and

- incident low-trauma fractures in postmenopausal women and men aged ≥ 50 y: a population-based cohort study. *Am J Clin Nutr*. 2011 Jan;93(1):192-9. Epub 2010 Nov 10.
169. Fraser LA, Langsetmo L, Berger C, Ioannidis G, Goltzman D, Adachi JD, Papaioannou A, Josse R, Kovacs CS, Olszynski WP, Towheed T, Hanley DA, Kaiser SM, Prior J, Jamal S, Kreiger N, Brown JP, Johansson H, Oden A, McCloskey E, Kanis JA, Leslie WD; CaMos Research Group. Fracture prediction and calibration of a Canadian FRAX® tool: a population-based report from CaMos. *Osteoporos Int*. 2011 Mar;22(3):829-37. Epub 2010 Dec 16.
 170. Leslie WD, Lix LM, Langsetmo L, Berger C, Goltzman D, Hanley DA, Adachi JD, Johansson H, Oden A, McCloskey E, Kanis JA. Construction of a FRAX(®) model for the assessment of fracture probability in Canada and implications for treatment. *Osteoporos Int*. 2011 Mar;22(3):817-27. Epub 2010 Dec 16.
 171. Langsetmo L, Nguyen TV, Nguyen ND, Kovacs CS, Prior JC, Center JR, Morin S, Josse RG, Adachi JD, Hanley DA, Eisman JA; the Canadian Multicentre Osteoporosis Study Research Group. Independent external validation of nomograms for predicting risk of low-trauma fracture and hip fracture. *CMAJ*. 2011 Feb 8;183(2):E107-E114. Epub 2010 Dec 20.
 172. Karaplis AC, Chouha F, Djandji M, Sampalis JS, **Hanley DA**. Vitamin D Status and Response to Daily 400 IU Vitamin D3 and Weekly Alendronate 70 mg in Men and Women with Osteoporosis. *Ann Pharmacother*. 2011 May;45(5):561-8. Epub 2011 Apr 26.
 173. Fenton TR, Tough SC, Lyon AW, Eliasziw M, **Hanley DA**. Causal assessment of dietary acid load and bone disease: A systematic review and meta-analysis applying Hill's epidemiologic criteria for causality. *Nutr J*. 2011 Apr 30;10(1):41. [Epub ahead of print]
 174. Lentle B, Cheung AM, **Hanley DA**, Leslie WD, Lyons D, Papaioannou A, Atkinson S, Brown JP, Feldman S, Hodsman AB, Jamal AS, Josse RG, Kaiser SM, Kvern B, Morin S, Siminoski K; Scientific Advisory Council of Osteoporosis Canada. Osteoporosis Canada 2010 guidelines for the assessment of fracture risk. *Can Assoc Radiol J*. 2011 Nov;62(4):243-50.
 175. Cauley JA, El-Hajj Fuleihan G, Arabi A, Fujiwara S, Ragi-Eis S, Calderon A, Chionh SB, Chen Z, Curtis JR, Danielson ME, **Hanley DA**, Kroger H, Kung AW, Lesnyak O, Nieves J, Pluskiewicz W, El Rassi R, Silverman S, Schott AM, Rizzoli R, Luckey M; FRAX(®) Position Conference Members. Official Positions for FRAX® clinical regarding international differences from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®. *J Clin Densitom*. 2011 Jul-Sep;14(3):240-62.
 176. Papaioannou A, Kennedy CC, Giangregorio L, Ioannidis G, Pritchard J, **Hanley DA**, Farrauto L, DeBeer J, Adachi JD. A randomized controlled trial of vitamin D dosing strategies after acute hip fracture: no advantage of loading doses over daily supplementation. *BMC Musculoskelet Disord*. 2011 Jun 20;12:135.
 177. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, **Hanley DA**, Heaney RP, Murad MH, Weaver CM; Endocrine Society. Evaluation, treatment, and

- prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab.* 2011 Jul;96(7):1911-30. Epub 2011 Jun 6. Erratum in: *J Clin Endocrinol Metab.* 2011 Dec;96(12):3908.
178. Pauchard Y, Liphardt AM, Macdonald HM, **Hanley DA**, Boyd SK. Quality control for bone quality parameters affected by subject motion in high-resolution peripheral quantitative computed tomography. *Bone.* 2012 Jun;50(6):1304-10. Epub 2012 Mar 14
179. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, **Hanley DA**, Heaney RP, Murad MH, Weaver CM. Guidelines for preventing and treating vitamin D deficiency and insufficiency revisited. *J Clin Endocrinol Metab.* 2012 Apr;97(4):1153-8. Epub 2012 Mar 22.
180. Berger C, Greene-Finestone LS, Langsetmo L, Kreiger N, Joseph L, Kovacs CS, Richards JB, Hidiroglou N, Sarafin K, Davison KS, Adachi JD, Brown J, **Hanley DA**, Prior JC, Goltzman D; CaMos Research Group. Temporal trends and determinants of longitudinal change in 25-hydroxyvitamin D and parathyroid hormone levels. *J Bone Miner Res.* 2012 Jun;27(6):1381-9. doi: 10.1002/jbmr.1587.
181. Black DM, Bilezikian JP, Greenspan SL, Wüster C, Muñoz-Torres M, Bone HG, Rosen CJ, Andersen HS, **Hanley DA**. Improved adherence with PTH(1-84) in an extension trial for 24 months results in enhanced BMD gains in the treatment of postmenopausal women with osteoporosis. *Osteoporos Int.* 2013 Apr;24(4):1503-11. Epub 2012 Aug 29.
182. Zheng HF, Tobias JH, Duncan E, Evans DM, Eriksson J, Paternoster L, Yerges-Armstrong LM, Lehtimäki T, Bergström U, Kähönen M, Leo PJ, Raitakari O, Laaksonen M, Nicholson GC, Viikari J, Ladouceur M, Lyytikäinen LP, Medina-Gomez C, Rivadeneira F, Prince RL, Sievanen H, Leslie WD, Mellström D, Eisman JA, Movérare-Skrtic S, Goltzman D, **Hanley DA**, Jones G, St Pourcain B, Xiao Y, Timpson NJ, Smith GD, Reid IR, Ring SM, Sambrook PN, Karlsson M, Dennison EM, Kemp JP, Danoy P, Sayers A, Wilson SG, Nethander M, McCloskey E, Vandenput L, Eastell R, Liu J, Spector T, Mitchell BD, Streeten EA, Brommage R, Pettersson-Kymmer U, Brown MA, Ohlsson C, Richards JB, Lorentzon M. WNT16 Influences Bone Mineral Density, Cortical Bone Thickness, Bone Strength, and Osteoporotic Fracture Risk.. *PLoS Genet.* 2012 Jul;8(7):e1002745. Epub 2012 Jul 5.
183. Dempster DW, Zhou H, Recker RR, Brown JP, Bolognese MA, Recknor CP, Kendler DL, Lewiecki EM, **Hanley DA**, Rao DS, Miller PD, Woodson GC 3rd, Lindsay R, Binkley N, Wan X, Ruff VA, Janos B, Taylor KA. Skeletal Histomorphometry in Subjects on Teriparatide or Zoledronic Acid Therapy (SHOTZ) Study: A Randomized Controlled Trial. *J Clin Endocrinol Metab.* 2012 Aug;97(8):2799-808. Epub 2012 Jun 14.
184. Majumdar SR, McAlister FA, Johnson JA, Bellerose D, Siminoski K, **Hanley DA**, Qazi I, Lier DA, Lambert RG, Russell AS, Rowe BH. Interventions to increase osteoporosis treatment in patients with "incidentally" detected vertebral fractures. *Am J Med.* 2012 Sep;125(9): 929-936.
185. Nishiyama KK, Macdonald HM, **Hanley DA**, Boyd SK. Women with previous fragility fractures can be classified based on bone microarchitecture and finite element

- analysis measured with HR-pQCT. *Osteoporos Int.* 2013; 24(5):1733-40 [Epub ahead of print 2012 Nov 20]
186. McClung M, Harris ST, Miller PD, Bauer DC, Davison KS, Dian L, **Hanley DA**, Kendler DL, Yuen CK, Lewiecki EM. Bisphosphonate Therapy for Osteoporosis: Benefits, Risks, and Drug Holiday. *Am J Med.* 2013 Jan;126(1):13-20. [Epub ahead of print 2012 Nov 20.]
 187. **Hanley DA**, Adachi JD, Bell A, Brown V. Denosumab: mechanism of action and clinical outcomes. *Int J Clin Pract.* 2012 Dec;66(12):1139-46.
 188. Majumdar SR, Lier DA, McAlister FA, Rowe BH, Siminoski K, **Hanley DA**, Russell AS, Johnson JA. Cost-effectiveness of interventions to increase osteoporosis treatment for "incidental" vertebral fractures. *Am J Med.* 2013 Feb;126(2):169.e9-17.
 189. Khan A, Weinstein Z, **Hanley DA**, Casey R, McNeil C, Ramage B, Boyd S. In vivo bone architecture in pompe disease using high-resolution peripheral computed tomography. *JIMD Rep.* 2013;7:81-8. Epub 2012 Jun 6.
 190. Olszynski WP, Brown JP, Adachi JD, **Hanley DA**, Ioannidis G, Davison KS; the CaMos Research Group. Multisite quantitative ultrasound for the prediction of fractures over five years of follow-up: The Canadian Multicentre Osteoporosis Study. *J Bone Miner Res.* 2013 Sep;28(9):2027-34. Epub 2013 Mar 20.
 191. Cheung AM, Adachi JD, **Hanley DA**, Kendler DL, Davison KS, Josse R, Brown JP, Ste-Marie LG, Kremer R, Erlandson MC, Dian L, Burghardt AJ, Boyd SK. High-Resolution Peripheral Quantitative Computed Tomography for the Assessment of Bone Strength and Structure: A Review by the Canadian Bone Strength Working Group. *Curr Osteoporos Rep.* 2013 Jun;11(2):136-46. Epub 2013 Mar 24.
 192. Zheng HF, Duncan E, Yerges-Armstrong LM, Eriksson J, Bergström U, Leo PJ, Leslie WD, Goltzman D, Blangero J, **Hanley DA**, Carless MA, Streeten EA, Lorentzon, Brown MA, Spector TD, Pettersson-Kymmer U, Ohlsson C, Mitchell BD, Richards JB. Meta-Analysis of Genome-Wide Studies Identifies *MEF2C* SNPs Associated with Bone Mineral Density at Forearm. *J Med Genet.* 2013 Jul;50(7):473-8. Epub 2013 Apr 9
 193. Langsetmo L, Berger C, Kreiger N, Kovacs CS, **Hanley DA**, Jamal SA, Whiting SJ, Genest J, Morin SNHodsman A, Prior JC, Lentle B, Patel MS, Brown JP, Anastasiades T, Towheed T, Josse RG, Papaioannou A, Adachi JD, Leslie WD, Davison KS, Goltzman D; CaMos Group. Calcium and Vitamin D Intake and Mortality: Results from the Canadian Multicentre Osteoporosis Study (CaMos). *J Clin Endocrinol Metab.* 2013 Jul;98(7):3010-8. Epub 2013 May 23.
 194. Armstrong L, Jett K, Birch P, Kendler DL, McKay H, Tsang E, Stevenson DA, **Hanley DA**, Egeli D, Burrows M, Friedman JM. The generalized bone phenotype in children with neurofibromatosis 1: A sibling matched case-control study. *Am J Med Genet A.* 2013 Jul;161(7):1654-61. Epub 2013 May 25
 195. **Hanley DA**, Whiting SJ. Does a high dietary acid content cause bone loss, and can bone loss be prevented with an alkaline diet? *J Clin Densitom.* 2013 Oct-Dec;16(4):420-5. Epub 2013 Oct 2.
 196. Olszynski WP, Brown JP, Adachi JD, **Hanley DA**, Ioannidis G, Davison KS; The CaMos Research Group. Normative Data for Multisite Quantitative Ultrasound: The

- Canadian Multicenter Osteoporosis Study. *J Clin Densitom.* 2013 Oct 26. [Epub ahead of print]
197. Lewiecki EM, Miller PD, Harris ST, Bauer DC, Davison KS, Dian L, **Hanley DA**, McClung MR, Yuen CK, Kendler DL. Understanding and Communicating the Benefits and Risks of Denosumab, Raoxifene, and Teriparatide for the Treatment of Osteoporosis. *J Clin Densitom.* 2013 Oct 24. pii: S1094-6950(13)00180-7. [Epub ahead of print]
 198. Zebaze RM, Libanati C, Austin M, Ghasem-Zadeh A, **Hanley DA**, Zanchetta JR, Thomas T, Boutroy S, Bogado CE, Bilezikian JP, Seeman E. Differing effects of denosumab and alendronate on cortical and trabecular bone. *JBone.* 2014 Feb;59:173-9. Epub 2013 Nov 22.
 199. Zhou W, Langsetmo L, Berger C, Poliquin S, Kreiger N, Barr SI, Kaiser SM, Josse RG, Prior JC, Towheed TE, Anastassiades T, Davison KS, Kovacs CS, **Hanley DA**, Papadimitropoulos EA, Goltzman D; CaMos Research Group. Longitudinal changes in calcium and vitamin D intakes and relationship to bone mineral density in a prospective population-based study: the Canadian Multicentre Osteoporosis Study (CaMos). *J Musculoskelet Neuronal Interact.* 2013 Dec;13(4):470-9.
 200. Siminoski K, O'Keefe M, Brown JP, Burrell S, Coupland D, Dumont M, Ganguli SN, **Hanley DA**, Law-Dillabough A, Lévesque J; Canadian Association of Radiologists. Canadian Association of Radiologists Technical Standards for Bone Mineral Densitometry Reporting. *Can Assoc Radiol J.* 2013 Nov;64(4):281-94.
 201. Burt LA, Macdonald HM, **Hanley DA**, Boyd SK. Bone microarchitecture and strength of the radius and tibia in a reference population of young adults: an HR-pQCT study. *Arch Osteoporos.* 2014 Dec;9(1):183. doi: 10.1007/s11657-014-0183-2. Epub 2014 May 27
 202. Majumdar SR, McAlister FA, Johnson JA, Weir DL, Bellerose D, **Hanley DA**, Russell AS, Rowe BH. Critical impact of patient knowledge and bone density testing on starting osteoporosis treatment after fragility fracture: secondary analyses from two controlled trials. *Osteoporos Int.* 2014 Sep;25(9):2173-9. [Epub ahead of print May 7.]
 203. Seida JC, Mitri J, Colmers I, Majumdar SR, Davidson MB, Edwards AL, **Hanley DA**, Pittas AG, Tjosvold L, Johnson JA. Effect of Vitamin D Supplementation on Improving Glucose Homeostasis and Preventing Diabetes: A Systematic Review and Meta-Analysis. *J Clin Endocrinol Metabol.* 2014 Oct;99(10):3551-60. [Epub ahead of print, Jul 25, 2014].
 204. Zheng HF, Duncan EL, Yerges-Armstrong LM, Eriksson J, Bergström U, Leo PJ, Leslie WD, Goltzman D, Blangero J, **Hanley DA**, Carless MA, Streeten EA, Lorentzon M, Brown MA, Spector TD, Pettersson-Kymmer U, Ohlsson C, Mitchell BD, Richards JB. Meta-analysis of genome-wide studies identifies MEF2C SNPs associated with bone mineral density at forearm. *J Med Genet.* 2013 Jul;50(7):473-8.
 205. Brown JP, Morin S, Leslie W, Papaioannou A, Cheung AM, Davison KS, Goltzman D, **Hanley DA**, Hodsmann A, Josse R, Jovaisas A, Jubly A, Kaiser S, Karaplis A, Kendler D, Khan A, Ngui D, Olszynski W, Ste-Marie LG, Adachi J.

- Bisphosphonates for treatment of osteoporosis: Expected benefits, potential harms, and drug holidays. *Can Fam Physician*. 2014 Apr;60(4):324-33.
206. Leslie WD, Langsetmo L, Zhou W, Goltzman D, Kovacs CS, Prior J, Josse R, Olszynski WP, Davison KS, Anastassiades T, Towheed T, **Hanley DA**, Kaiser SM, Lentle B, Kreiger N; CaMos Research Group. Choice of lumbar spine bone density reference database for fracture prediction in men and women: a population-based analysis. *J Clin Densitom*. 2014 Apr-Jun;17(2):295-300.
207. Dasgupta D, Wee MJ, Reyes M, Li Y, Simm PJ, Sharma A, Schlingmann KP, Janner M, Biggin A, Lazier J, Gessner M, Chrysis D, Tuchman S, Baluarte HJ, Levine MA, Tiosano D, Insogna K, **Hanley DA**, Carpenter TO, Ichikawa S, Hoppe B, Konrad M, Sävendahl L, Munns CF, Lee H, Jüppner H, Bergwitz C. Mutations in SLC34A3/NPT2c Are Associated with Kidney Stones and Nephrocalcinosis. *J Am Soc Nephrol*. 2014 Oct;25(10):2366-75. [Epub ahead of print Apr 3.]
208. Berger C, Almohareb O, Langsetmo L, **Hanley D**, Kovacs C, Josse R, Adachi J, Prior J, Towheed T, Davison K, Kaiser S, Brown J, Goltzman D; The CaMos Research Group. Characteristics of hyperparathyroid states in the Canadian multicentre osteoporosis study (CaMos) and relationship to skeletal markers. *Clin Endocrinol (Oxf)*. 2014 Jul 25. doi: 10.1111/cen.12569. [Epub ahead of print]
209. Hopman WM, Berger C, Joseph L, Zhou W, Prior JC, Towheed T, Anastassiades T, Adachi JD, **Hanley DA**, Papadimitropoulos EA, Kirkland S, Kaiser SM, Josse RG, Goltzman D; and the CaMos Research Group. Prospectively measured 10-year changes in health-related quality of life and comparison with cross-sectional estimates in a population-based cohort of adult women and men. *Qual Life Res*. 2014 Dec;23(10):2707-21 [Epub ahead of print Jun 13.]
210. Mann MC, Exner DV, Hemmelgarn BR, **Hanley DA**, Turin TC, MacRae JM, Ahmed SB. The VITAH Trial Vitamin D supplementation and cardiac autonomic tone in hemodialysis: a blinded, randomized controlled trial. *BMC Nephrol*. 2014 Aug 6;15:129.
211. Campbell EJ, Campbell GM, **Hanley DA**. The effect of parathyroid hormone and teriparatide on fracture healing. *Expert Opin Biol Ther*. 2015 2015 Jan;15(1):119-29. [Epub ahead of print 2014 Nov 3]
212. Leong A, Rehman W, Dastani Z, Greenwood C, Timpson N, Langsetmo L, Berger C; METASTROKE, Fu L, Wong BY, Malik S, Malik R, **Hanley DA**, Cole DE, Goltzman D, Richards JB. The Causal Effect of Vitamin D Binding Protein (DBP) Levels on Calcemic and Cardiometabolic Diseases: A Mendelian Randomization Study. *PLoS Med*. 2014 Oct 28;11(10):e1001751.
213. Khan AA, Morrison A, **Hanley DA**, Felsenberg D, McCauley LK, O’Ryan F, Reid IR, Ruggiero S, Taguchi A, Tetradis S, Watts NB, Brandi ML, Peters E, Guise T, Eastell R, Cheung AM, Morin SN, Masri B, Cooper C, Morgan S, Obermayer-Pietsch B, Langdahl BL, Al Dabagh R, Davison KS, Kendler D, Sándor GK, Josse, RG, Bhandari, M, El Rabbany, M, Pierroz, DD, Sulimani, R, Saunders, DP, Brown JP, Compston J, on behalf of the International Task Force on Osteonecrosis of the Jaw. Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus. *J Bone Miner Res*. 2015 Jan; 30(1):3-23.

214. Liphardt AM, Schipilow J, **Hanley DA**, Boyd SK. Bone quality in osteopenic postmenopausal women is not improved after 12 months of whole-body vibration training. *Osteoporos Int*. 2015 Mar;26(3):911-20. Epub 2015 Jan 8.
215. Khan A, **Hanley DA**, McNeil C, Boyd SK. Improvement in bone mineral density and architecture in a patient with Gaucher disease using teriparatide. *J Inherit Metab Dis*. 2015; 22:23-8. Epub 2015 Mar 3
216. Langsetmo L, Barr SI, Berger C, Kreiger N, Rahme E, Adachi JD, Papaioannou A, Kaiser SM, Prior JC, **Hanley DA**, Kovacs CS, Josse RG, Goltzman D. Associations of Protein Intake and Protein Source with Bone Mineral Density and Fracture Risk: A Population-Based Cohort Study. *J Nutr Health Aging*. 2015;19(8):861-8.
217. Mann MC, Hollenberg MD, **Hanley DA**, Ahmed SB. Vitamin D, the autonomic nervous system, and cardiovascular risk. *Physiol Rep*. 2015 Apr;3(4).
218. Mann MC, Hemmelgarn BR, Exner DV, **Hanley DA**, Turin TC, Wheeler DC, Sola DY, Ellis L, Ahmed SB. Vitamin D supplementation is associated with stabilization of cardiac autonomic tone in IgA nephropathy. *Hypertension*. 2015 Aug;66(2):e4-6. Epub 2015 Jun 8.
219. Olszynski WP, Adachi JD, **Hanley DA**, Davison KS, Brown JP. Comparison of Speed of Sound Measures Assessed by Multisite Quantitative Ultrasound to Bone Mineral Density Measures Assessed by Dual-Energy X-Ray Absorptiometry in a Large Canadian Cohort: the Canadian Multicentre Osteoporosis Study (CaMos). *J Clin Densitom*. 2015 Jun 5. pii: S1094-6950(15)00042-6. [Epub ahead of print]
220. Brockton NT, Gill SJ, Laberge SL, Paterson AH, Cook LS, Vogel HJ, Shemanko CS, **Hanley DA**, Magliocco AM, Friedenreich CM. The Breast Cancer to Bone (B2B) Metastases Research Program: a multi-disciplinary investigation of bone metastases from breast cancer. *BMC Cancer*. 2015 Jul 10;15:512.
221. Nour MA, Burt LA, Perry RJ, Stephure DK, **Hanley DA**, Boyd SK. Impact of Growth Hormone on Adult Bone Quality in Turner Syndrome: A HR-pQCT Study. *Calcif Tissue Int*. 2016 Jan;98(1):49-59. Epub 2015 Oct 6.
222. Hildebrandt EM, Manske SL, **Hanley DA**, Boyd SK. Bilateral Asymmetry of Radius and Tibia Bone Macroarchitecture and Microarchitecture: A High-Resolution Peripheral Quantitative Computed Tomography Study. *J Clin Densitom*. 2015 Apr 8. pii: S1094-6950(15)00015-3. [Epub ahead of print]
223. Boyd SK, Burt LA, Sevick LK, **Hanley DA**. The relationship between serum 25(OH)D and bone density and microarchitecture as measured by HR-pQCT. *Osteoporos Int*. 2015 Sep;26(9):2375-80. Epub 2015 Apr 8.
224. Kendler DL, Bauer DC, Davison KS, Dian L, **Hanley DA**, Harris ST, McClung MR, Miller PD, Schousboe JT, Yuen CK, Lewiecki EM. Vertebral Fractures: Clinical Importance and Management. *Am J Med*. 2016 Feb;129(2):221.e1-221.e10. Epub 2015 Oct 30.
225. Aghajafari F, Field CJ, Rabi D, Kaplan BJ, Maggiore JA, O'Beirne M, **Hanley DA**, Eliasziw M, Dewey D, Ross S; APrON Study Team. Plasma 3-Epi-25-Hydroxycholecalciferol Can Alter the Assessment of Vitamin D Status Using the Current Reference Ranges for Pregnant Women and Their Newborns. *J Nutr*. 2016 Jan;146(1):70-5. Epub 2015 Nov 25.2015

226. Langsetmo L, Barr SI, Dasgupta K, Berger C, Kovacs CS, Josse RG, Adachi JD, **Hanley DA**, Prior JC, Brown JP, Morin SN, Davison KS, Goltzman D, Kreiger N. Dietary patterns in men and women are simultaneously determinants of altered glucose metabolism and bone metabolism. *Nutr Res.* 2016 Apr;36(4):328-36. Epub 2015 Dec 23.
227. Dempster DW, Zhou H, Recker RR, Brown JP, Bolognese MA, Recknor CP, Kendler DL, Lewiecki EM, **Hanley DA**, Rao SD, Miller PD, Woodson GC 3rd, Lindsay R, Binkley N, Alam J, Ruff VA, Gallagher ER, Taylor KA. A Longitudinal Study of Skeletal Histomorphometry at 6 and 24 Months Across Four Bone Envelopes in Postmenopausal Women with Osteoporosis Receiving Teriparatide or Zoledronic Acid in the SHOTZ Trial. *J Bone Miner Res.* 2016 Jul;31(7):1429-39. Epub 2016 Mar 8.
228. Burt LA, Liang Z, Sajobi TT, **Hanley DA**, Boyd SK. Sex- and Site-Specific Normative Data Curves for HR-pQCT. *J Bone Miner Res.* 2016 May 18. doi: 10.1002/jbmr.2873. [Epub ahead of print]
229. Aghajafari F, Field CJ, Kaplan BJ, Rabi DM, Maggiore JA, O'Beirne M, **Hanley DA**, Eliasziw M, Dewey D, Weinberg A, Ross SJ; APrON Study Team. The Current Recommended Vitamin D Intake Guideline for Diet and Supplements During Pregnancy Is Not Adequate to Achieve Vitamin D Sufficiency for Most Pregnant Women. *PLoS One.* 2016 Jul 1;11(7):e0157262.
230. Retraction Notice to "Kidney Function and Rate of Bone Loss at the Hip and Spine: The Canadian Multicentre Osteoporosis Study" [*Am J Kidney Dis.* 55(2):291-299]. Jamal SA, Swan VJ, Brown JP, **Hanley DA**, Prior JC, Papaioannou A, Langsetmo L, Josse RG; Canadian Multicentre Osteoporosis Study Research Group. *Am J Kidney Dis.* 2016 Aug;68(2):333. doi: 10.1053/j.ajkd.2016.06.005. No abstract available.
231. Sulimani RA, Mohammed AG, Alfadda AA, Alshehri SN, Al-Othman AM, Al-Daghri NM, **Hanley DA**, Khan AA. Vitamin D deficiency and biochemical variations among urban Saudi adolescent girls according to season. *Saudi Med J.* 2016 Sep;37(9):1002-8.
232. Mann MC, Exner DV, Hemmelgarn BR, **Hanley DA**, Turin TC, MacRae JM, Wheeler DC, Sola DY, Ramesh S, Ahmed SB. The VITAH Trial-Vitamin D Supplementation and Cardiac Autonomic Tone in Patients with End-Stage Kidney Disease on Hemodialysis: A Blinded, Randomized Controlled Trial. *Nutrients.* 2016 Sep 28;8(10). pii: E608.
233. Khan AA, **Hanley DA**, Rizzoli R, Bollerslev J, Young JE, Rejnmark L, Thakker R, D'Amour P, Paul T, Van Uum S, Shrayyef MZ, Goltzman D, Kaiser S, Cusano NE, Bouillon R, Mosekilde L, Kung AW, Rao SD, Bhadada SK, Clarke BL, Liu J, Duh Q, Lewiecki EM, Bandeira F, Eastell R, Marcocci C, Silverberg SJ, Udelsman R, Davison KS, Potts JT Jr, Brandi ML, Bilezikian JP. Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. *Osteoporos Int.* 2017 Jan;28(1):1-19.
234. Khan AA, Morrison A, Kendler DL, Rizzoli R, **Hanley DA**, Felsenberg D, McCauley LK, O'Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S, Watts NB, Brandi

- ML, Peters E, Guise T, Eastell R, Cheung AM, Morin SN, Masri B, Cooper C, Morgan SL, Obermayer-Pietsch B, Langdahl BL, Dabagh RA, Davison KS, Sándor GK, Josse RG, Bhandari M, El Rabbany M, Pierroz DD, Sulimani R, Saunders DP, Brown JP, Compston J; International Task Force on Osteonecrosis of the Jaw. Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ. *J Clin Densitom.* 2017 Jan - Mar;20(1):8-24.
235. Mazzetti G, Berger C, Leslie WD, Hans D, Langsetmo L, **Hanley DA**, Kovacs CS, Prior JC, Kaiser SM, Davison KS, Josse R, Papaioannou A, Adachi JR, Goltzman D, Morin SN; CaMos Research Group. Densitometer-Specific Differences in the Correlation Between Body Mass Index and Lumbar Spine Trabecular Bone Score. *J Clin Densitom.* 2017; Apr - Jun;20(2):233-238. [Epub ahead of print 2016 Dec 26]
236. Burt LA, Bhatla JL, **Hanley DA**, Boyd SK. Cortical porosity exhibits accelerated rate of change in peri- compared with post-menopausal women. *Osteoporos Int.* 2017 Apr;28(4):1423-1431 [Epub ahead of print 2017 Jan 10.]
237. Tran T, Bliuc D, van Geel T, Adachi JD, Berger C, van den Bergh J, Eisman JA, Geusens P, Goltzman D, **Hanley DA**, Josse RG, Kaiser SM, Kovacs CS, Langsetmo L, Prior JC, Nguyen TV, Center JR. Population-wide Impact of Non-hip Non-vertebral Fractures on Mortality. *J Bone Miner Res.* 2017 Mar 3. [Epub ahead of print]
238. Majumdar SR, Lier DA, **Hanley DA**, Juby AG, Beaupre LA; STOP-PRIHS Team. Economic evaluation of a population-based osteoporosis intervention for outpatients with non-traumatic non-hip fractures: the "Catch a Break" li [type C] FLS. *Osteoporos Int.* 2017 Jun;28(6):1965-1977 [Epub ahead of print Mar 9.]
239. Burt LA, **Hanley DA**, Boyd SK. Cross-sectional Versus Longitudinal Change in a Prospective HR-pQCT Study. *J Bone Miner Res.* 2017 Mar 15. [Epub ahead of print]
240. Aghajafari F, Field CJ, Kaplan BJ, Maggiore JA, O'Beirne M, **Hanley DA**, Eliasziw M, Dewey D, Ross S, Rabi D; APrON Study Team. The High Prevalence of Vitamin D Insufficiency in Cord Blood in Calgary, Alberta (APrON-D Study). *J Obstet Gynaecol Can.* 2017 May;39(5):347-353.e1. Epub 2017 Mar 21.
241. **Hanley DA**, McClung MR, Davison KS, Dian L, Harris ST, Miller PD, Lewiecki EM, Kendler DL; Writing Group for the Western Osteoporosis Alliance. Western Osteoporosis Alliance Clinical Practice Series: Evaluating the Balance of Benefits and Risks of Long-Term Osteoporosis Therapies. *Am J Med.* 2017 Jul;130(7):862.e1-862.e7. Epub 2017 Mar 27.
- 242.

ii. **Non-peer reviewed manuscripts (not a complete list):**

1. Sherwood, L.M., Hanley, D.A., Takatsuki, K., Birnbaumer, M.E., Schneider, A.B. and Wells Jr., S.A.: Regulation of parathyroid hormone secretion, in *Endocrinology*

- of Calcium Metabolism: Proceedings of the 6th International Parathyroid Conference, June 1977, Excerpta-Medica, Amsterdam-Oxford: 301-307, 1978.
2. Hanley, D.A. and Sherwood, L.M.: Secondary hyperparathyroidism in chronic renal failure: Pathophysiology and treatment. *Medical Clinics of North America* 62: 1319-1339, 1978 (November).
 3. Hanley, D.A. and Brown, D.M.: Parathyroid disorders: Pathophysiology, diagnosis and treatment. *Minn. Med.* 63: 479-483, 1980.
 4. Hanley, D.A. and Andersen, M.A.: Disorders of Vitamin D metabolism. *Medicine North America*, 3rd Series, Volume 14 (October, 1987) pp 2752-2762.
 5. Hanley, D.A.: Treating osteoporosis: Calcium, estrogen and fluoride. *Can. J. Geriatrics* 3: 38-53, 1987.
 6. Hanley, D.A.: Investigating and managing primary hyperparathyroidism. *Can. J. Geriatrics* 4 (6): 41-55, 1988.
 7. Hanley, D.A.: Treating Osteoporosis. *Can. J. Continuing Medical Education* 2: 10-13, 1990.
 8. Grimston, S.K. and Hanley, D.A.: Bone growth and development: the role of calcium. *Nutrition Quarterly* 14: 12-20, 1990.
 9. Grimston, S.K., McKay, H.G., and Hanley, D.A.: Reproductive hormones, bone mass and dietary intakes of red meat and dairy calcium in female runners. in Christiansen, C. and Overgaard, K. (eds): *Osteoporosis 1990 (Proceedings of the 3rd International Symposium on Osteoporosis, Copenhagen, Denmark)*, Osteopres ApS, Copenhagen, pp 1203 - 1205, 1990 (printed for distribution in 1991).
 10. Hanley, D.A., Burgess, E.D., and Andersen M.A.: Renal Osteodystrophy. *Current Opinion in Orthopedics* 2: 126-132, 1991.
 11. Andersen, M.A. and Hanley, D.A. (editors): Section on Metabolic Bone Disease. *Current Opinion in Orthopedics* 2: 75-132, 1991. Editorial, page 75-76.
 12. Hanley, D.A. and Hodsman, A.B.: Investigation of patients with probable osteoporosis. *Osteoporosis Society of Canada Bulletin for Physicians*. Vol. 4, March, 1991.
 13. Andersen, M.A. and Hanley, D.A. (editors): Section on Metabolic Bone Disease. *Current Opinion in Orthopedics* 3: 75-110, 1992. Editorial, pp 75-76.
 14. Andersen, M.A. and Hanley, D.A.: Metabolic Bone Disease: An overview. *Current Opinion in Orthopedics* 4: 1-2, 1993.
 15. Hanley, D.A.: Primary Hyperparathyroidism and Osteoporosis. *Osteoporosis Society of Canada Bulletin for Physicians*. Vol. 2, No. 3, October 1993 (published in 1994).
 16. Hanley, D.A.: Interview with David Hanley, M.D., *Nutrition Quarterly*, 18(2): 33-37, 1994.
 17. Hanley, D.A.: The Investigation of Osteoporosis, *Journal SOGC*, Vol. 17, No. 12, pp. 6-9, 1995.
 18. Dairy Nutrition Council of Alberta, Consumer Mailer (from Nutrition File Television series).
 19. Hanley, D A: Treating Osteoporosis Today: The role of bisphosphonates, *Canadian Journal of Continuing Medical Education*, Vol.8; No 10:pp 58 - 68, 1996
 20. Hanley D.A.: Physician Perspectives , "Viewpoint", Sept 7-11, 1996
 21. Hanley, D. A.: Osteoporosis - Are bisphosphonates (etidronate and alendronate) useful for osteoporosis? *Canadian Journal of Diagnosis*, 13(10):47-50, 1996

22. Hanley, D.A.: Osteoporosis - Why and how are bisphosphonates (etidronate and alendronate) useful for osteoporosis? *Canadian Journal of Diagnosis*, 13(11):44 - 46, 1996
23. Hanley, D A and Josse, R G, Introduction, *Can. Med Assoc. J.* 155 (7):921-3, 1996. (Prevention and Management of Osteoporosis: Consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada.)
24. Sturtridge, W, Lentle, B, and Hanley D A, The use of bone density measurement in the diagnosis and management of osteoporosis, *Can. Med Assoc. J.* 155(7):924-9, 1996. (Prevention and Management of Osteoporosis: Consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada.)
25. Jones, G, Hogan, D B, Yendt, E, and Hanley, D A, Vitamin D metabolites and analogs in the treatment of osteoporosis, *Can Med Assoc J.* 155(7):955-961, 1996. (Prevention and Management of Osteoporosis: Consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada.)
26. Hanley, D. A. Scientific Advisory Board of the Osteoporosis Society of Canada: Clinical Practice Guidelines for the diagnosis and management of Osteoporosis *Can Med Assoc J.* 155(8):1113-33,1996.
27. Hanley, D.A. Options for the Management of Osteoporosis, *J. Rheumatology* 23 (Suppl. 24), August, pp.1-22, 1996.
28. Hanley, D.A.: Old and New Therapies in for Osteoporosis, *Drug Use In the Elderly Quarterly* (13): Jan 1997.
29. Hanley, D.A., Josse, R.G.: Respond to letter to the Editor, *CMAJ: Osteoporosis Guidelines*, *Can. Med. Assoc. J.* 156(11):1530, 1997.
30. Hanley, D.A.: What management is recommended for a 38-year-old woman with borderline low bone density? *The Canadian Journal of DIAGNOSIS*:38-40, Oct 1997.
31. Hanley, D.A., and Carter-Erdman, K.A. The Female Athlete: Increased Risk of Osteoporosis? *The Canadian Journal of CME* 1998; 10;4:51-63. Presented at the Second Annual Stampede Sport Medicine Conference for Family Physicians, The University of Calgary, July 11-13, 1997.
32. Brossard, J-H, Hanley, D.A., and Papaioannou, A.: Highlights from Endo '97 (A review of bone-related papers presented at the Endocrine Society 1997 Annual Meeting. Published by The Medicine Group and distributed to Canadian specialists in Endocrinology, Rheumatology, and Gerontology.
33. Hanley, D.A.: Is calcitonin an effective treatment for osteoporotic fractures in the elderly? Does it reduce the pain from the fracture? What are the indications, contraindications and dosage? *The Canadian Journal of DIAGNOSIS* 1998(Feb): 42-45.
34. Hanley, D.A. and Carter-Erdman, K.A. The Female Athlete: Increased Risk of Osteoporosis? *The Canadian Journal of CME*: 1998;10; 4:51-63.
35. Hanley, D.A.: "Re: Osteoporosis: Breaking Down the Myths". *Impact Magazine* Sept/Oct, 1998 (p. 45).
36. Hanley D.A.: What alternatives to hormone replacement therapy are effective for the prevention of postmenopausal osteoporosis (specifically raloxifene and tibolone)? *The Canadian Journal of DIAGNOSIS* 1999(Oct):58-60.

37. Hanley D.A.: Does the long-term use of furosemide cause osteoporosis or have other adverse effects on calcium metabolism? *The Canadian Journal of DIAGNOSIS* 2000(Jan):32.
38. Hanley D.A.: What are the indications for the use of calcitriol for the treatment of osteoporosis? What are its advantages over other vitamin D products? *The Canadian Journal of DIAGNOSIS* 2000(Mar): 40-41.
39. Tenenhouse A., Kreiger N., Hanley D.A. Canadian Multicentre Osteoporosis Study (CaMos). *Drug Development Research*. Vol. 49, Issue 3, March 2000: 201-205.
40. Triggle C., Hanley D.A.: Osteoporosis Research in Canada. *Drug Development Research*. Vol. 49, Issue 3, March 2000: 119.
41. Hanley D.A.: Effect of thyroid and parathyroid hormones on bone: Feature Article, *Osteoporosis Update: Winter 2000 vol.4 no.1:4-5*.
42. Hanley D.A.: What therapy is recommended for a 40-year-old male with decreased bone density? *The Canadian Journal of DIAGNOSIS* 2000(Jul):32-33.
43. Hanley D.A.: Parathyroid Hormone Plus Alendronate for Osteoporosis. *Endocrinology Update - Faxwatch*, Monday, July 24, 2000.
44. Tenenhouse A., Kreiger N., Hanley D.A. Canadian Multicentre Osteoporosis Study (CaMos). *Drug Development Research*. Vol. 49, Issue 3, March 2000: 201-205.
45. Triggle C., Hanley D.A.: Osteoporosis Research in Canada. *Drug Development Research*. Vol. 49, Issue 3, March 2000: 119.
46. Hanley D.A.: Fracture Cascade. *The Canadian Journal of DIAGNOSIS (Supplement)*. 2001(March):6.
44. Hanley D.A.: The significance of vertebral fractures. *The Canadian Journal of DIAGNOSIS* 2001(May):107-117.
47. Hanley D.A.: What are the indications for the use of calcitriol for the treatment of osteoporosis? What are its advantages over other vitamin D products? *The Canadian Journal of DIAGNOSIS* 2001(May):38-40.
48. Hanley D.A.: Postmenopausal osteoporosis: Prevention is key, but it's never too late to treat. *Parkhurst Exchange* 2002 Sep;10(9):93-97.
49. Rucker D., Hanley D.A., and Zernicke R.F.: Bone adaptation with exercise and aging. In *Proceedings of International Conference on Biomechanics of Man 2002*. Jelen K., Kusova S., Chalupova M., and Otahal J. (eds.) Charles University Press, Prague Czech Republic, pp. 141-146, 2002.
50. Hanley D.A.: Exchanges in Osteoporosis and Bisphosphonates. *Parkhurst Exchange* 2003 Mar, pp. 94-96.
51. Hanley D.A.: Is Ipriflavone useful in combating post-menopausal osteoporosis? *The Canadian Journal of DIAGNOSIS* (2003).
52. Hanley D.A.: Is natural progesterone cream an effective monotherapy for the prevention of post-menopausal osteoporosis? *The Canadian Journal of DIAGNOSIS* (2003).
53. Hanley D.A.: Recombinant full-length parathyroid hormone (1-84). A commentary by David A. Hanley. *Drugs* 2006;66(15): (in press).
54. Hanley D.A.: Vitamin D and Skeletal Health. *The Canadian Journal of DIAGNOSIS* (Sep 2007).
55. Khan OA, Hanley DA. Endocrine Update: Vitamin D and Calcium Supplements for Osteoporosis. *The Canadian Journal of Diagnosis*. Vol 31(10) November 2014.

iii. Books, Chapters:

1. Sherwood, L.M., Hanley, D.A., Takatsuki, K., Birnbaumer, M.E., Schneider, A.B. and Wells Jr., S.A.: Regulation of parathyroid hormone secretion, in *Endocrinology of Calcium Metabolism: Proceedings of the 6th International Parathyroid Conference, June 1977*, Excerpta-Medica, Amsterdam-Oxford: 301-307, 1978.
2. Hanley, D.A.: Clinical physiology of parathyroid hormone & vitamin D. In Najarian, J.S. and J.P. Delaney (eds.), *Endocrine Surgery*, Appleton Century-Crofts, New York: 187-200, 1981.
3. Cole, D.E.C. and Hanley, D.A.: "Osteocalcin". In B.K. Hall (ed.), *Bone: A Treatise. Vol. 3: Bone Matrix and Bone Specific Products*, CRC Press, Inc., Boca Raton, Florida: 239-294, 1991.
4. Hanley, D.A.: "The Canadian Society of Endocrinology and Metabolism". In T.P. Morley (ed.), *Medical Specialty Societies of Canada* Boston Mills Press, Erin, Ontario, Canada: 261-270, 1991.
5. Hanley, D.A., Grimston, S.K., and Andersen, M.A.: Bone: The Role of Dietary Calcium and Exercise in Maintenance of the Skeleton. *Proceedings of the 23rd International Dairy Congress*, Mutual Press, Ottawa, Canada, Volume 2: pp 1180-1186, 1990 (printed for distribution in 1991).
6. Grimston, S.K., K. Morrison, J.A. Harder and Hanley, D.A.: Bone mineral density and calcium intake in children during puberty. In P. Burckhardt and R.P. Heaney (eds.) *Nutritional Aspects of Osteoporosis*. Serono Symposia Publications from Raven Press, vol. 85: pp 77-89, 1991 (printed for distribution in 1992).
7. Hanley, D.A.: Hypercalcemia. In *Metabolic Bone Disorders Classification, Diagnosis and Clinical Management*. Canadian Medical Association Disease Management/Patient Counseling Series, Robert G. Josse (ed.) pp 29-46, 1994.
8. Hanley D.A.: Hypercalcemia. In Gray J (ed) *Therapeutic Choices*, pp. 542-547. Published by Canadian Pharmaceutical Association, 1995.
9. Hanley, D.A., M.A. Andersen and G.F. Pineo: Anticoagulants and Bone in Hull RD and Pineo GF (eds.): *Disorders of Thrombosis*. WB Saunders Co., Chapter 34, pp. 353-358, 1995.
10. Hanley, D.A.: Treatment of Osteoporosis. *Endocrine Society Syllabus of the 46th Post-Graduate Assembly, 1994*; pp. 215-222. A publication of the Endocrine Society, Bethesda, Maryland.
11. Hanley, D.A.: Opening remarks and overview of calcium metabolism in *Symposium on Calcium: Current Controversies and Future Directions, 1995*. Proceedings of a symposium sponsored by The Osteoporosis Society of Canada and The Dairy Farmers of Canada. Published by Langdon Starr, Toronto, 1996, pp. 1-2.
12. Hanley, D.A., Andersen, M.A.: Anticoagulants and Bone. *Venous Thromboembolism: An Evidence-Based Atlas*, edited by Russell, D. Hull, Gary E. Raskob, and Graham F. Pineo, Chapter 40, pp. 331-336, 1996.
13. *Proceedings: Options for the management of osteoporosis*, May 27, 1995, Toronto, Canada. Dr. D. A. Hanley (Guest Editor), *J. Rheumatol* 23 (Suppl. 45), August, pp: 1-22, 1996.

14. Hanley, D.A.: Osteoporosis in Therapeutic Choices; edited by J. Gray et al. 52:406-415, 1998.
15. Hanley, D.A.: Osteoporosis. in Gray J (ed). "Therapeutic Choices". Canadian Pharmaceutical Association 57:476-486, 2000.
16. Hanley, D.A.: Biochemical Markers of Bone Turnover. in Goltzman D. and Henderson J.E. (eds). "The Osteoporosis Primer". Cambridge University Press, Cambridge, UK. 17:239-252, 2000.
17. Hodsman A.B., Hanley D.A., Watson P.H., Fraher L.J.: Pharmacologic Mechanisms of Therapeutics: Parathyroid Hormone. in Principles of Bone Biology, 2nd Edition, Bilezikian J.P., Raisz L.G., and Rodan G.A. (eds.) Academic Press. Vol 2, Chapter 75:1305-1324, 2001.
18. Hanley D.A.: The Diagnosis of Osteoporosis. Published in The Management of Osteoporosis in Canada: Diagnosis, Prevention, Treatment. A publication by Advanced Healthcare Strategies Inc. 2nd Edition, Chapter 2: pp. 9-17, 2002.
19. Hanley, D.A.: Osteoporosis in Gray J, et al (eds.). Therapeutic Choices 4th Edition; Chapter 61, pages 636-646, Canadian Pharmacists Association Press, 2003.
20. Majumdar, S.R. and Hanley, D.A. Bisphosphonate Therapy for Osteoporosis. in Kleerekoper M, (ed), Drug Therapy for Osteoporosis. Taylor and Francis Medicine, London, UK, 2004.
21. Hanley DA. Osteoporosis. in: Gray J (ed.) Therapeutic Choices. Canadian Pharmacists Association, Ottawa, Ontario, Canada. 2007: pages 972-985.
22. Hanley DA, Watson PM, Hodsman AB, Dempster DM. Pharmacologic Mechanisms of Therapeutics: Parathyroid Hormone. in: Bilezikian JP, Raisz LG and Martin TJ (eds.) Principles of Bone Biology, 3rd Edition, Chapter 78, pages 1661-95. Academic Press, Elsevier, Amsterdam, The Netherlands, 2008.
23. Davison KS and Hanley DA. Chapter 4: Fundamentals of Mineral Homeostasis. in: Orwoll ES, Bilezikian JP, Vanderschueren D (eds.) Osteoporosis in Men. Elsevier/Academic Press, San Diego, CA, USA, 2010, pages 41-50
24. Hanley DA. Vitamin D Deficiency in Canada in Holick MF (ed.) Vitamin D: Physiology, Molecular Biology, and Clinical Applications, Second Edition. Humana Press, New York, New York, USA, 2010, pages 425-434
25. Hanley DA. Musculoskeletal disorders: Osteoporosis. In: Repchinsky C, editor. Therapeutic Choices. 6th ed. Ottawa (ON): Canadian Pharmacists Association; 2011. p. 1068-84.
26. Hanley DA. Musculoskeletal disorders: Osteoporosis. In: Jovaisas B, editor. CTC 7: Compendium of Therapeutic Choices Seventh Edition. Publisher: Canadian Pharmacists Association, Ottawa, Canada; 2014. p. 1021-36.

iv. Abstracts - Published:

1. Hanley, D.A., Takatsuki, K., Birnbaumer, M.E., Schneider, A.B., and Sherwood, L.M.: "Perfusion of parathyroid glands: Differences in response to low calcium and catecholamines. Clinical Research 24: 526A, 1976.

2. Takatsuki, K., Hanley, D.A., Schneider, A.B. and Sherwood, L.M.: Effects of magnesium depletion on secretion of parathyroid hormone in vitro. *Clinical Research* 24: 526A, 1976.
3. Takatsuki, K., Hanley, D.A., Schneider, A.B. and Sherwood, L.M.: Studies of the impaired parathyroid hormone secretion in magnesium depletion. *Clinical Research* 25: 401A, 1977.
4. Hanley, D.A., Takatsuki, K., Schneider, A.B. and Sherwood, L.M.: Comparison of low calcium and beta-antagonist stimulation of parathyroid hormone secretion. *Clinical Research* 25: 522A, 1977.
5. Hanley, D.A., Takatsuki, K. and Sherwood, L.M.: Evidence for release of fragments of PTH during "perfusion" of bovine parathyroid glands in vitro. Abstracts of the Endocrine Society 59th Annual Meeting, June 1977, page 184.
6. Hanley, D.A., Takatsuki, K., Sultan, J.M., Schneider, A.B. and Sherwood, L.M.: Secretion of both amino and carboxyl fragments of parathyroid hormone by bovine parathyroid glands. *Clinical Research* 26: 416A, 1978.
7. Hanley, D.A., Takatsuki, K. and Sherwood, L.M.: Regulation of secretion of PTH by beta-agonists and antagonists is modified by extracellular calcium concentration. Abstracts of the Endocrine Society 10th Annual Meeting, June 1978, page 143.
8. Hanley, D.A., Takatsuki, K. and Sherwood, L.M.: Parathyroid hormone (PTH) secretion by parathyroid adenomas in vitro: Lack of response to the beta-agonist isoproterenol (IP). *Clinical Research* 26: 681A, 1978.
9. Hanley, D.A. and Muller, P.J.: Aggressive growth of a prolactinoma after surgery and conventional radiotherapy: Rapid reduction in tumour size by bromocriptine. Selected for presentation at the Annual Meeting of the Royal College of Physicians and Surgeons of Canada, September 14-18, 1981.
10. Hanley, D.A.: In vitro evidence that dopamine and isoproterenol stimulate a release of the same intracellular pool of parathyroid hormone. Abstracts of the Endocrine Society Annual Meeting, 1982, #1180.
11. Hanley, D.A. and Mandin, H.: Increased urinary cyclic AMP in fasting hypercalciuric stone formers. Presented at the meeting of the Royal College of Physicians and Surgeons of Canada, Quebec City, September 13-17, 1982. Published in *Annals RCPSC*, Vol. 15: page 340, 1982.
12. Hanley, D.A.: Release of carboxyl-terminal fragments of parathyroid hormone by human parathyroid adenomas in vitro. Presented at the Annual Meeting of the Canadian Society for Clinical Investigation, Quebec City, 1982. Published in *Clinical and Investigative Medicine* 5: page 36B, 1982.
13. Hanley, D.A.: Familial hypercalcemia: Hypercalciuria and hypocalciuria in a small kindred. Selected for presentation at symposium "Clinical Disorders of Bone and Mineral Metabolism", Detroit, Michigan, May 9-14, 1983.
14. Hanley, D.A.: Comparison of release of fragments of PTH by human parathyroid adenomas and secondary hyperplastic parathyroid tissue in vitro. Selected for presentation at Annual Meeting of American Society for Bone and Mineral Research, San Antonio, Texas, June 5-10, 1983, published in *Calcified Tissue International* 35: 683, 1983.

15. Hanley, D.A., Forsyth, J. and Smith, B.: Episodic secretion of parathyroid hormone by bovine parathyroid tissue in vitro. Presented at 1983 Annual Meeting of the Canadian Society for Clinical Investigation, Calgary, 1983. Published in *Clinical and Investigative Medicine* 6, Suppl. 2; 66, 1983.
16. Forestall, C., Garcia, B. and Hanley, D.A.: Production of PTH by anaplastic lung carcinoma: Demonstration by immunoperoxidase. Presented at the Annual Meeting of the Royal College of Physicians and Surgeons of Canada, 1983. Published in *Annals of RCPSC* 16: 322, 1983.
17. Hanley, D.A., Watanabe, M. and Mandin, H.: Dietary control in assessing hypertension and nephrolithiasis. Presented at the Annual Meeting of the Royal College of Physicians and Surgeons of Canada, 1983. Published in the *Annals of RCPSC* 16: 380, 1983.
18. Andersen, M.A., Penney, C.J. and Hanley, D.A.: Case Report: Regional migratory osteoporosis with evidence for osteomalacia. Presented at the Annual Meeting of the American Society for Bone and Mineral Research, Hartford CT, June, 1984. Published in *Calcif. Tissue Intl.* 36: 488, 1984.
19. Hanley, D.A. and Andersen, M.A.: Familial benign hypercalcemia: Hypercalciuria in two of four affected family members. Presented at Annual Meeting of Royal College of Physicians and Surgeons of Canada, Montreal, 1984. Published in *Annals RCPSC* 17: 331, 1984.
20. Hanley, D.A.: Isoproterenol and dopamine-stimulated parathyroid hormone release: Evidence for a "two-pool" model of parathyroid hormone secretion. Presented at Annual Meeting of Canadian Society for Clinical Investigation, Montreal, 1984. Published in *Clin. Invest. Med.* 7 (Supp 2): p.67, 1984.
21. Cole, D.E.C., Stirk, L.J., Hanley, D.A. and Gundberg, C.M.: Circulating osteocalcin concentrations are decreased during pregnancy: Implications for maternal mineral metabolism. Presented at 7th Annual Meeting of American Society for Bone and Mineral Research, Washington, D.C., June 15-18, 1985.
22. Hanley D.A., Whitmore, B., Watanabe, M. and Mandin, H.: Effects of dietary sodium on calcium metabolism in patients with essential hypertension. Presented at Annual Meeting of the Canadian Society for Clinical Investigation, Vancouver, September 8-10, 1985. Published in *Clin. Invest. Med.* 8: A127, 1985.
23. Hanley, D.A. and Aiken, M.J.: Parathyroid response to an oral calcium load in familial benign hypercalcemia. *Clin. Invest. Med.* 8: A82, 1985.
24. Hanley, D.A., Ayer, L.M. and Szarka, R.J.: Serotonin stimulates parathyroid hormone secretion by isolated bovine parathyroid cells in vitro. *Clin. Invest. Med.* 9: A37, 1986. Presented at Annual Meeting of Canadian Society for Clinical Investigation, September, 1986, Toronto.
25. Hanley, D.A. and Ayer, L.M.: Hyperplastic human parathyroid tissue releases increased amounts of C-terminal fragments of PTH when exposed to high calcium in vitro. Presented at the 9th International Conference on Calcium Regulating Hormones, October, 1986, Nice, France.
26. Hanley, D.A., Ayer, L.M. and Szarka, R.J.: Analysis of parathyroid hormone in bovine parathyroid cysts. *J. Bone Min. Res. (Suppl. 1)*: 298, 1987. Presented at 1987 Annual Meeting of the American Society for Bone and Mineral Research.

27. Hanley, D.A., Ayer, L.M., Burgess, E.D., Schneider, M.P. and Hwang, W.S.: "Tertiary hyperparathyroidism": In vitro evidence for Ca⁺⁺ suppression of parathyroid hormone secretion. *Clin. Invest. Med. (Suppl.)* 10(4): B74, 1987. Presented at 1987 Annual Meeting of Canadian Society for Clinical Investigation.
28. Akai, P.S., Whitelaw, W.A. and Hanley, D.A.: Resectable bronchogenic carcinoma associated with hypercalcemia from tumor-mediated excess 1,25-dihydroxyvitamin D production. *Clin. Invest. Med. (Suppl.)* 10(4): B96, 1987. Presented at 1987 Annual Meeting of Royal College of Physicians and Surgeons of Canada.
29. Hanley, D.A., Ayer, L.M., Burgess, E.D., Schneider, M.P. and Hwang, W.S.: "Tertiary Hyperparathyroidism": Normal Ca⁺⁺ suppression of parathyroid hormone secretion. *J. Bone Min. Res.* 3 (Suppl. 1): 3, 1988. Presented at 1988 annual Meeting of the American Society for Bone and Mineral Research.
30. Hanley, D.A., Ayer, L.M., Gundberg, C.M. and Minuk, G.Y.: Parameters of calcium metabolism during a double-blind randomized control trial of cyclosporin A in primary biliary cirrhosis. *Clin. Invest. Med.* 11(4): R-186, 1988. Presented at 1988 Annual Meeting of Royal College of Physicians and Surgeons of Canada.
31. Hanley, D.A., and Ayer, L.M.: Calcium-induced changes in release of carboxyl-terminal parathyroid hormone fragments by human parathyroid tissue. *Clin. Invest. Med.* 11(4): C-196, 1988. Presented at 1988 Annual Meeting of Canadian Society for Clinical Investigation.
32. Ayer, L.M. and Hanley, D.A.: Calcium induced changes in release of carboxyl-terminal Parathyroid Hormone fragments by human parathyroid tissue occur in parallel with hormone secretion. Presented at the annual meeting of the Endocrine Society, Seattle, 1989. Abst #1796.
33. McLeod, D.R., Hanley, D.A., Molnar, E.M., McArthur, R.G.: Autosomal Dominant Hypoparathyroidism. Presented at the 21st Anniversary Clinical Genetics Conference: Clinical Applications of Molecular Genetics, Sponsored by March of Dimes Birth Defects Foundation and Harvard Medical School, July 9-12, 1989, Boston MA.
34. Tanguay, K. and Hanley, D.A.: Calcium induced secretion of carboxyl terminal fragments of Parathyroid Hormone continues when secretion is stimulated by phorbol ester in vitro. Presented at the joint meeting of the International Conference of Calcium Regulating Hormones and the American Society for Bone and Mineral Research, Montreal, September, 1989. *J Bone Min Res* 4: S145, 1989 (Abst 111).
35. Scappatura, S., Mandin, H., and Hanley, D.A.: Diagnostic assessment of hypercalciuric stone formers. Presented at the joint meeting of the Royal College of Physicians and Surgeons of Canada and the Canadian Society for Clinical Investigation, Edmonton, September, 1989. *Clin Invest Med* 12 (Suppl):B103, 1989 (Abst C-669).
36. Grimston, S.K., Mortimer, S.T. and Hanley, D.A.: Effect of submaximal exercise on PTH and calcium absorption in female runners. *J Bone & Min Res* 5 (Suppl. 2), S125, 1990. Presented at the annual meeting of the American Society for Bone and Mineral Research, Aug. 1990.

37. Grimston, S.K., Engsberg, J.R. and Hanley, D.A.: Hormonal, metabolic, nutritional and biochemical mechanisms for stress fracture. *J Bone & Min Res* 5 (Suppl. 2), S278, 1990. Presented at the annual meeting of the American Society for Bone and Mineral Research, Aug. 1990.
38. Jones, A.R., Hanley, D.A., Blahey, W., and Snodgrass, T.: Hypercalcemia in Hodgkin's Disease (HD): Incidence and etiologies. *Clin Invest Med* 13 (Suppl):B48, 1990. Presented at the Annual Meeting of the Royal College of Physicians and Surgeons and the Canadian Society for Clinical Investigation, September, 1990.
39. Hanley, D.A., Tanguay, K.E., Wood, P.H. and Mortimer, S.T.: Phorbol ester suppresses low calcium stimulated secretion of intact parathyroid hormone by bovine parathyroid cells. *Clin Invest Med* 13 (Suppl):B27, 1990. Presented at the Annual Meeting of the Royal College of Physicians and Surgeons and the Canadian Society for Clinical Investigation, September, 1990. **This paper was selected co-winner of the Antoni Nalecz Prize for the best abstract in Endocrinology and Metabolism submitted to the annual meeting.
40. Wood, P.H., Tanguay, K.E., Mortimer, S.T., and Hanley, D.A.: Protein Kinase C activators affect Ca⁺⁺ regulated PTH secretion in cultured bovine parathyroid cells. Presented at American Society of Cell Biology Annual Meeting, Dec. 9-13,1990. published in *J. Cell Biol.* 111: p. 78a, Abst. 421.
41. Grimston, S.K., Engsberg, J. R., Hanley, D.A. and Patterson, J.L.: Kinetic analysis of female runners with a history of stress fracture. Presented at the 1990 Annual Meeting of the American Society of Biomechanics, and published in *J. Biomechanics* 24: p.245, 1991.
42. Grimston, S.K. and Hanley, D.A.: Increased PTH in osteopenic female runners during exercise: a potential mechanism for osteopenia? Presented at the 1991 meeting of the American College of Sports Medicine, and published in *Med. Sci. Sports Exercise* 23: S121 (abstract 721).
43. Watson (Wood), P.H., K.K.Wang, and D.A. Hanley: In vitro proteolysis of bovine parathyroid hormone by human erythrocyte Calpain I. Presented at American Society for Bone and Mineral Research 1991 Annual Meeting, *J Bone Min Res* 6 (Suppl 1): S179 (Abstr 384), 1991
44. Grimston, S.K., Morrison, K., Harder, J.A., Tamaoki, T., Hanley, D.A.: Bone mineral density and calcium intake during puberty. selected for plenary session presentation at the International Symposium on Nutritional Aspects of Osteoporosis, May 16 - 18, 1991, Lausanne, Switzerland.
45. Hanley, D.A., P.H. Wood, S.T. Mortimer and K.E. Tanguay: Effect of Protein Kinase C activation on parathyroid hormone secretion in vitro. Presented at the annual meeting of the Royal College of Physicians and Surgeons of Canada and Canadian Society of Clinical Investigation Annual Meeting, September, 1991. *Clin Invest Med* 14 (suppl): A35 (Abstr 205), 1991.
46. Walsh, J.M., Hull, R.D., Hanley, D.A. and B.W. Baylis: Heparin-induced osteoporosis in pregnancy. Presented at the annual meeting of the Royal College of Physicians and Surgeons of Canada and Canadian Society of Clinical Investigation Annual Meeting, September, 1991. *Clin Invest Med* 14 (suppl): A78 (Abstr 482), 1991.

47. Mortimer, S.T. and D.A. Hanley: Effect of Calcitonin Gene-Related Peptide on secretion of Parathyroid Hormone by cultured bovine parathyroid cells. Presented at the 11th International Conference on Calcium Regulating Hormones, Florence, Italy, April 24-29,1992.
48. Watson, P.H., Rhyasen, J. and D.A. Hanley: Cell-penetrating Calpain inhibitor, cBz-Val-Phe-H increases Parathyroid Hormone release from cultured bovine parathyroid cells. Presented at the 11th International Conference on Calcium Regulating Hormones, Florence, Italy, April 24-29,1992. ** This paper was selected for a post-doctoral fellow travel award by the program committee of this conference.
49. Watson, P.H. and D.A. Hanley: Increased release of intact Parathyroid Hormone from bovine parathyroid cells cultured in the presence of the cell-penetrating Calpain inhibitor, cBz-Val-Phe-H. ** Selected for oral presentation at the Endocrine Society 74th Annual Meeting 1992, San Antonio, TX, (abstr 835) Program and Abstracts Book, pp. 260.
50. Grimston, S.K. and D.A. Hanley: Bone mineral density in children is related to mechanical loading regime. Oral presentation at annual meeting of the American College of Sports Medicine, and published in *Medicine and Science in Sports and Exercise* 24(5, supplement) p.S45, 1992.
51. Grimston, S.K., M.A. Andersen, and D.A. Hanley: Effect of exercise on ovariectomy-induced osteopenia in the rat. Presented at the Second Workshop on Using the Live Rat in Skeletal Studies, May 11-14,1992, Chicago, Illinois.
52. Hanley, D.A. and P.H. Watson: The cell penetrating Calpain inhibitor, cBz-Val-Phe-H, increases intact parathyroid hormone release from cultured bovine parathyroid cells. Presented at the 1992 annual meeting of the RCPSC and CSCI, Ottawa, Ontario, and published in *Clin Invest Med* 15 (Supp A):p A33 (abstr 192), 1992.
53. Watson, P. H., D.E. Croall, and D.A. Hanley: Localization of calcium activated proteases in the bovine parathyroid gland. Presented at the 1992 annual meeting of the American Society for Bone and Mineral Research and published in *J Bone Min Res* 7: (supp 1) S227 (abstr 540), 1992.
54. Grimston, S.K., M.A. Andersen, and D.A. Hanley: Effect of chronic exercise and flurbiprofen on oophorectomy-induced osteopenia in the rat. Presented at the 1992 annual meeting of the American Society for Bone and Mineral Research and published in *J Bone Min Res* 7: (supp 1) S259 (abstr 666), 1992.
55. Andersen, M.A., S.K. Grimston, and D.A. Hanley: Effect of exercise on oophorectomy-induced osteopenia in the rat. Presented at the 6th International Congress on Bone Morphometry, Lexington, Oct., 1992. Published in *Bone* 13 (5): A1 (abstr #3), 1992.
56. Donovan, L.E., B.D. Toppings, B.A. Corenblum, D.A. Hanley: Skin thickness as an indicator of bone mineral density. Published in *Clin. Invest. Med.* Vol 16, No. 4 (abstr #222), 1993.
57. Grimston, S.K., N.D. Willows, L. Donovan, J.A. Harder, M.R. Hawes, D.A. Hanley: Changes in bone length and bone density during puberty in children. Published in *J. Bone Min. Res.* 8: (supp 1) S257 (abstr 561), 1993.

58. Morrison, K.M., N. Willows, S. Grimston, D.A. Hanley: Influence of puberty, body composition and diet on lipoproteins. Presented at the Tenth International Atherosclerosis Symposium, Montreal, October, 1994. Published in *Atherosclerosis* 109 (No. 1,2): 211 (abstr #117), 1994.
59. Shivji, F., H. Cheng, D.A. Hanley: Differential membrane association of protein kinase C and isoenzymes in response to extracellular calcium levels and phorbol ester treatment in the bovine parathyroid presented at the 1994 annual meeting of the American Society for Bone & Mineral Research and published in *J. Bone Min. Res.* 8: (supp 1) (abstr #A400), 1994.
60. Janicic, N., Z. Pausova, L.E. Donovan, D.A. Hanley, G.N. Hendy: Disease locus segregates with chromosome 3q markers in an unusual kindred with hypocalciuric hypercalcemia presented at the 1994 annual meeting of the American Society for Bone & Mineral Research and published in *J. Bone Min. Res.* 9: (supp 1) (abstr #C488), 1994.
61. Morrison, K., D. Whitfield, S. Brechnin, S. Grimston, D.A. Hanley: Longitudinal study of lipoprotein (a) in children with IDDM: Impact of puberty presented at the 1994 annual meeting of the Royal College of Physicians and Surgeons of Canada/CSCI and published in *Clin Invest Med* Vol. 17, No. 4 (abstr #220), 1994.
62. Shivji, F., D.A. Hanley: Identification of two protein kinase C isoenzymes in bovine parathyroid cells. Presented and published in the abstracts of the Endocrine Society 76th Annual Meeting, June 15-18 (abstr #1328), 1994.
63. Burgess, E., Hanley, D., Krause, G.: Bone density and parameters of calcium metabolism in predialysis renal patients vs. renal transplant patients. Presented at the 1995 meeting of the International Bone & Mineral Society and published in *Bone* 16: (supp 1) (abstr #185), 1995.
64. D.A. Hanley, H. Cheng: Inhibition of Calpain in bovine parathyroid cells exposed to high calcium causes stimulation of parathyroid hormone secretion and reduced secretion of fragments of parathyroid hormone. Presented at the 1995 annual meeting of the Canadian Society for Clinical Investigation/Royal College of Physicians & Surgeons of Canada, and published in the abstracts of *Clin. Invest. Med.: supp.* Vol 18, No. 4 (abstr #234), 1995.
65. G. Krause, E. Burgess, D. Hanley: Bone density and parameters of calcium metabolism in predialysis renal patients vs renal transplant patients. Presented at the 1995 annual meeting of the Canadian Society for Clinical Investigation/Royal College of Physicians & Surgeons of Canada, and published in the abstracts of *Clin. Invest. Med.: Supp.* Vol 18, No. 4 (abstr #629), 1995.
66. I. Auer, H. Mandin and D.A. Hanley: Correlation between drinking water aluminum and serum aluminum levels in patients on chronic hemodialysis. Presented at the 1995 annual meeting of the Canadian Society for Clinical Investigation/Royal College of Physicians & Surgeons of Canada, and published in the abstracts of *Clin. and Invest. Med.: Supp.* Vol. 18, No. 4 (abstr #641), 1995.
67. F. Shivji, H. Cheng, D.A. Hanley: Immunological detection of novel and atypical protein kinase C isoforms in bovine parathyroid cell fractions. Presented at the 1995 annual meeting of the American Society for Bone & Mineral Research, and published in *J. Bone Min. Res.* 10 (Suppl.1) abstract S516 (page S279), 1995.

68. E. Burgess, G. Krause, D. Hanley: Bone density and parameters of calcium in predialysis renal patients vs. renal transplant patients. *J. Am. Soc. Nephrol* Vol. 6, pp. 957, 1995.
69. D. Hanley, S. Grimston, N. Willows, R. Kloiber, C. Gundberg: Dietary variables and bone density in children advancing through puberty. *Osteoporosis Int.* 6 (Supp 1): p. 127, 1996. Presented at the World Congress on Osteoporosis, Amsterdam May 18-23, 1996.
70. F. Shivji, H. Zwiers, D. Hanley: Phosphorylation of human parathyroid hormone by protein kinase C. Program of the International Congress of Endocrinology, p. 363 (abstract P1-915), 1996. Presented at the International Congress of Endocrinology.
71. D. Hanley, S. Matus, H. Cheng: Effects of 1,25-dihydroxyvitamin D and dopamine on secretion of parathyroid hormone fragments in cultured bovine parathyroid cells. Program of the American Society for Bone and Mineral Research, 1996. Printed in Journal of Bone and Mineral Research.
72. D. Hanley, S. Matus, H. Cheng: Effects of 1,25-dihydroxyvitamin D on secretion of parathyroid hormone fragments in cultured bovine parathyroid cells. Accepted for oral presentation, annual meeting of the Canadian Society for Clinical Investigation, 1996.
73. D. Hanley, H. Cheng, E.F. Nemeth: Effect of the calcimimetic NPS R-467 on extracellular calcium mediated secretion of parathyroid cells. *The Endocrine Society*, p.484 (abstract P3-191), 1997.
74. R. Crilly, R.J. Sebaldt, J.D. Adachi, J.P. Brown, D.A. Hanley, W.P. Olszynski, A. Petrie, L.G. Ste-Marie, A.B. Hodsmann: Comparison of BMD measurements at 6 and 12 months in assessing response to etidronate in osteoporosis. Presented at the Nineteenth Annual Meeting of the American Society for Bone and Mineral Research, and published in the 1997 Program & Abstracts of the *Journal of Bone and Mineral Research*: Vol. 12, Supp. 1, (abstr. #S486), 1997.
75. D. Hanley, N.A. Sacco-Gibson, J.D. Adachi, A.B. Hodsmann, J.P. Brown, S. Pack, and A.A. Chines for the Canadian CIO Research Group: Etidronate therapy in patients on high dose corticosteroids: Differences in bone resorption marker responses. Presented at the Nineteenth Annual Meeting of the American Society for Bone and Mineral Research, and published in the 1997 Program & Abstracts of the *Journal of Bone and Mineral Research*: Vol. 12, Supp. 1, (abstr. #S626), 1997.
76. G.M. Hargrove, J.L. Pasiaka, D.A. Hanley, and M.B. Murphy: Short and long-term outcome of total parathyroidectomy with immediate autografting versus subtotal parathyroidectomy in patients with end-stage renal disease. Presented at the annual meeting of the Canadian Society for Clinical Investigation/Royal College of Physicians and Surgeons of Canada, and published in the abstracts of *Clin. Invest.Med.:* Supp. Vol 20, No. 4 (abstr #675), 1997.
77. L.G. Ste-Marie, J.D. Adachi, J.P. Brown, A.A. Chines, D. Hanley, A.B. Hodsmann, S. Pack, N.A. Sacco-Gibson, G.F. Stephenson for the Canadian CIO Research Group. The Effect of Etidronate Therapy on Markers of Bone Turnover in Patients on High Dose Corticosteroids. *Bone* Vol. 22, No.3. Supplement March 1998:(Abstract# B74).

78. Roger S. Rittmaster, M. Bolognese, M. Ettinger, D.A. Hanley, A. Hodsmann, D.L. Kendler, C.J. Rosen. Treatment of Osteoporosis with Parathyroid Hormone Followed by Alendronate. *J. Bone & Min. Res.*: Vol. 23, Supp. 5 (abstr. #F451), 1998. Presented at the Second Joint Meeting of The American Society for Bone and Mineral Research and The International Bone and Mineral Society, Dec 1-6, 1998.
79. Roger S. Rittmaster, M. Bolognese, M. Ettinger, D.A. Hanley, A. Hodsmann, D.L. Kendler, C.J. Rosen. Treatment of Osteoporosis with Parathyroid Hormone Followed by Alendronate. Bone Density Results. *J. Bone & Min. Res.*: Vol 23, Supp. 5 (abstr. #F452), 1998. Presented at the Second Joint Meeting of The American Society for Bone and Mineral Research and The International Bone and Mineral Society, Dec 1-6, 1998.
80. D.A. Hanley, J.D. Adachi, T.P. Anastassiades, J.P. Brown, A.A. Chines, A.B. Hodsmann, R. Josse, D. Kendler, W. Olszynski, S.Pack, L.G. Ste-Marie, G.F. Stephenson, A. Tenenhouse, for the Canadian CIO Research Group. Prevention of Corticosteroid-Induced Osteoporosis with Etidronate: One Year Follow-up With Calcium Only. *J. Bone & Min. Res.*: Vol 23, Supp. 5 (abstr. #T460), 1998. Presented at the Second Joint Meeting of The American Society for Bone and Mineral Research and The International Bone and Mineral Society, Dec 1-6, 1998.
81. L. D'Souza-Li, D.E.C. Cole, D.A. Hanley, S.-W. Kooh, S. Salisbury, H. Juppner, G.N. Hendy. Four Novel Calcium-Sensing Receptor Mutations in Familial Hypocalciuric Hypercalcemia and Autosomal Dominant Hypocalcemia. *J. Bone & Min. Res.*: Vol 23, Supp. 5 (abstr. #W350), 1998. Presented at the Second Joint Meeting of The American Society for Bone and Mineral Research and The International Bone and Mineral Society, Dec 1-6, 1998.
82. J.M. Chandler, A.R. Martin, A. Tenenhouse, S. Poliquin, D. Hanley, A. Adachi, T. Anastassiades, W. Olszynski, C. Joyce. Merck Research Laboratories, Blue Bell, PA. The CaMos Research Group, Canada. The Impact of Osteoporosis on Quality of Life of Canadian women: CaMos. Presented at the Second Joint Meeting of The American Society for Bone and Mineral Research and The International Bone and Mineral Society, Dec 1-6, 1998.
83. Kieren J. Mather, R. Brent Scott, John B. Meddings, David A. Hanley: Prevalence of Positive Anti-Endomysial Antibody Tests for Celiac Disease Among Patients with Idiopathic osteoporosis. Presented and published in the abstracts of the Endocrine Society's 81st Annual Meeting, June 12-15 (abstr# P3-3), 1999.
84. S. Poliquin, G. Ioannidis, C. Berger, M. Papadimitropoulos, A. Papaioannou, L. Pickard, T. Murray, D. Hanley, W. Hopman, J. Brown, T. Anastassiades, L. Joseph, J. Adachi, A. Tenenhouse, and the CaMos Research Group. The Influence of Fractures on Health Related Quality of Life (HRQL) in Community Dwelling Men and Women Across Canada. Presented at the 28th Annual Scientific and Educational Meeting of the Canadian Association on Gerontology, November 4-7, 1999 and the American Society of Bone and Mineral Research Meeting, September 30 - October 4, 1999.
85. R. Rittmaster, M. Bolognese, M. Ettinger, D. Hanley, A. Hodsmann, D. Kendler, C. Rosen. Treatment of osteoporosis with PTH followed by alendronate. Presented at the

Ottawa 99 CDA/CSEM Professional Conference and Annual Meetings October 13-16 (abstr# 53), 1999.

86. F. Shivji, G. Fick, D. Kendler, W. Olszynski, W. Sturtridge, L.-G. Ste-Marie, A. Tenenhouse, D. Hanley. Markers of bone turnover and bone density response to alendronate in Canadian participants in Fosamax International Trial (FOSIT). Presented at the Ottawa 99 CDA/CSEM Professional Conference and Annual Meetings October 13-16 (abstr# 114), 1999.
87. D. Hanley, R. Josse, L.-G. Ste-Marie, D. Kendler, A. Tenenhouse, A. Chines, N. Watts. Prevention of vertebral and non-vertebral fractures in women with postmenopausal osteoporosis treated with risedronate. Presented at the Ottawa 99 CDA/CSEM Professional Conference and Annual Meetings October 13-16 (abstr# 53), 1999.
88. D. Rucker, D.A. Hanley, M.S. Rose, J.A. Allan. Age and BMI influences the prediction of hip and spine DXA BMD from phalangeal CDA BMD. *J. Bone & Min. Res.:* Vol. 15, Suppl 1 (abstr. #SA275), 2000. Presented at the Twenty-Second Annual Meeting of the American Society for Bone and Mineral Research, Toronto, September 2000.
89. R.J. Sebaldt, J.D. Adachi, W. Olszynski, J. Brown, D.A. Hanley, A. Tenenhouse, J. Caminis, A. Petrie, C. Yuen, G. Stephenson, C.H. Goldsmith. Patient compliance with bisphosphonate therapy. Presented at the World Congress on Osteoporosis, Chicago, Illinois, June 2000.
90. M. Hooper, D.A. Hanley, R. Eastell, E. Boling, C. Ribot, G. Woodson, I. Barton. Sustained effect of risedronate in the prevention of the first vertebral fracture in women. *J. Bone & Min. Res.:* Vol. 15, Suppl 1 (abstr. #SU400), 2000. Presented at the Twenty-Second Annual Meeting of the American Society for Bone and Mineral Research, Toronto, September 2000.
91. R.J. Sebaldt, J.D. Adachi, W. Olszynski, J. Brown, D.A. Hanley, A. Tenenhouse, J. Caminis, A. Petrie, C. Yuen, G. Ioannidis, C. H. Goldsmith. Vertebral fractures and Quality of Life. *J. Bone & Min. Res.:* Vol. 15, Suppl 1 (abstr. #M446), 2000. Presented at the Twenty-Second Annual Meeting of the American Society for Bone and Mineral Research, Toronto, September 2000 and the World Congress on Osteoporosis, Chicago, Illinois, June 2000.
92. R.J. Sebaldt, J.D. Adachi, W. Olszynski, J. Brown, D.A. Hanley, A. Tenenhouse, J. Caminis, A. Petrie, G. Ioannidis, C. H. Goldsmith. Non-Vertebral Fractures and Quality of Life. *J. Bone & Min. Res.:* Vol. 15, Suppl 1 (abstr. #M447), 2000. Presented at the Twenty-Second Annual Meeting of the American Society for Bone and Mineral Research, Toronto, September 2000 and the World Congress on Osteoporosis, Chicago, Illinois, June 2000.
93. D. Kendler, D.A. Hanley, A. Liu, K.S. Davison. Clinical Impact of Osteoporosis Risk Assessment. *J. Bone & Min. Res.:* Vol. 15, Suppl 1 (abstr. #SU354), 2000. Presented at the Twenty-Second Annual Meeting of the American Society for Bone and Mineral Research, Toronto, September 2000.
94. R.J. Sebaldt, J.D. Adachi, W. Olszynski, J. Brown, D.A. Hanley, A. Tenenhouse, J. Caminis, A. Petrie, A. Papaioannou, G. Stephenson, C.H. Goldsmith. Patient Adherence to Bisphosphonate Therapy. *J. Bone & Min. Res.:* Vol. 15, Suppl 1

- (abstr. #SU417), 2000. Presented at the Twenty-Second Annual Meeting of the American Society for Bone and Mineral Research, Toronto, September 2000.
95. A. Tenenhouse, L. Joseph, D. Hanley, N. Kreiger, CaMos Research Group. Prevalence of Low Bone Mineral Density of the Femoral Neck in Canadian Women: The Canadian Multicentre Osteoporosis Study (CaMos). *J. Bone & Min. Res.*: Vol. 15, Suppl 1 (abstr. #M315), 2000. Presented at the Twenty-Second Annual Meeting of the American Society for Bone and Mineral Research, Toronto, September 2000.
 96. Farzana Shivji, David A. Hanley, Gordon Fick, David L. Kendler, Wojciech P. Olyszynski, William C. Sturtridge, Markers of Bone Turnover and Bone Density Response to Alendronate in Canadian Participants in the Fosamax International Trial (FOSIT). Presented at the Endocrine Society's 82nd Annual Meeting, June 21-24, 2000.
 97. D. Hanley, L.G. Ste-Marie, D. Kendler, R. Josse. Osteoporotic Women with Incident Vertebral Fracture Have a High Risk of Subsequent Vertebral Fracture Within One Year. Presented at the Annual Meeting of the Canadian Society of Endocrinology and Metabolism/Canadian Diabetes Association, Halifax, 2000. Published in the Abstracts of 2000 CDA/CSEM Professional Conference, Supplement to the Canadian Journal of Diabetes Care
 98. D. Kendler, D. Hanley, L.G. Ste-Marie, R. Josse. Risedronate is Well-Tolerated in Women with Postmenopausal Osteoporosis Using NSAIDs or with Underlying Gastro-Intestinal Disorder. Presented at the Annual Meeting of the Canadian Society of Endocrinology and Metabolism/Canadian Diabetes Association, Halifax, 2000. Published in the Abstracts of 2000 CDA/CSEM Professional Conference, Supplement to the Canadian Journal of Diabetes Care.
 99. D. Hanley. Prevalence of Low Bone Mineral Density of the Femoral Neck and Trochanter in Canadian Women: The Canadian Multicentre Osteoporosis Study (CaMos). Presented at the Annual Meeting of the Canadian Society of Endocrinology and Metabolism/Canadian Diabetes Association, Halifax, 2000. Published in the Abstracts of 2000 CDA/CSEM Professional Conference, Supplement to the Canadian Journal of Diabetes Care.
 100. G. Ioannidis, J.D. Adachi, A. Petrie, R.J. Sebaldt, A. Papaioannou, W.P. Olszynski, D.A. Hanley, C.H. Goldsmith. The effects of treatment interventions on health related quality of life (HRQL) in post-menopausal women registered in the Canadian database of osteoporosis and osteopenia (CANDOO) patients. Presented at the 1st Joint Meeting of the International Bone and Mineral Society and the European Calcified Tissue Society, June 2001.
 101. M. Bolognese, I. Fogelman, P. Geusens, D.A. Hanley, I. Barton, P. Bettica. Risedronate significantly reduces the risk of non-vertebral fractures in postmenopausal osteoporotic women in just one year. Presented at the American Society for Bone and Mineral Research, October 9-16, 2001.
 102. J.D. Adachi, G. Ioannidis, C. Berger, L. Pickard, J. Prior, D.A. Hanley, W.P. Olszynski, T. Murray, T. Anastassiades, J.P. Brown, S. Kirkland, C. Joyce, L. Joseph, A. Papaioannou, S. Poliquin, A. Tenenhouse. The Impact of Co-morbid Conditions on Bone Mineral Density and Vertebral Deformities in Community Dwelling Men

- and Women Across Canada. Presented at the American Society for Bone and Mineral Research, October 2001.
103. D.A. Hanley, R.J. Sebalt, G. Ioannidis, A. Petrie, W.P. Olszynski, J.P. Brown, R.G. Josse, C.H. Goldsmith, A. Papaioannou, J.D. Adachi. The Impact of Treatment Interventions on Health Related Quality of Life (HRQL) in Post-menopausal Women Registered in the Canadian Database of Osteoporosis and Osteopenia (CANDOO) Patients. Presented at the American College of Rheumatology and the American Society for Bone and Mineral Research, October 2001.
 104. E.A. Papadimitropoulos, J.D. Adachi, G. Ioannidis, C. Berger, L. Pickard, J. Prior, D.A. Hanley, W.J. Olszynski, T. Murray, T. Anastassiades, J.P. Brown, S. Kirland, C. Joyce, L. Joseph, A. Papaioannou, S. Poliquin, A. Tenenhouse. The Impact of Osteoporotic Fractures on Health Related Quality of Life (HRQL) as Measured by the Health Utilities Index. Presented at the American College of Rheumatology, October 2001.
 105. D. Rucker, J. Allan, G.H. Fick, D.A. Hanley. Vitamin D Insufficiency in Western Canadians. Published in the Abstracts of 2001 CDA/CSEM Professional Conference, Supplement to the Canadian Journal of Diabetes Care.
 106. D. Rucker, J.A. Allan, G.H. Fick, D.A. Hanley. Effect of Season on 25-Hydroxy Vitamin D and Parathyroid Hormone in a Healthy Population of Western Canadians. BONE: Vol. 28, Suppl 5 (abstr. #P464 T) May, 2001. Presented at the 1st Joint Meeting of the International Bone and Mineral Society and the European Calcified Tissue Society, June 5-10 2001, Madrid, Spain.
 107. D. Rucker, J.A. Allan, G.H. Fick, D.A. Hanley. Seasonal Variations in 25-Hydroxy Vitamin D, Parathyroid Hormone and 1,25 Dihydroxy Vitamin D in a Healthy Population of Western Canadians. J. Bone & Min. Res.: Vol. 16, Suppl 1 (abstr. #SU318), 2001. Presented at the Annual Meeting of the American Society for Bone and Mineral Research, October 2001, Phoenix, Arizona.
 108. D.A. Hanley, D. Rucker, T.S. Fung, S. Ezzat, A. Diamandi, J. Khosravi. Positive Association Between Circulating Insulin-Like Growth Factor I and Bone Mineral Density in Healthy Adult Males. Presented at the Endocrine Society's 83rd Annual Meeting (abstr #P3-136) June, 2001.
 109. Papaioannou A., Sebaldt R.J., Olszynski W.P., Ioannidis G., Hanley D.A., Petrie A., Brown J.P., Josse R.G., Murray T., Goldsmith C.H., Adachi J.D.: Patient adherence to etidronate (ETD), alendronate (ALD) and hormone replacement therapy (HRT). Presented at the National Osteoporosis Foundation's 5th International Symposium Clinical Advances of Osteoporosis, Hawaii, March 2002.
 110. Adachi J.D., Sebaldt R.J., Olszynski W.P., Brown J.P., Hanley D.A., Josse R.G., Murray T., Petrie A., Ioannidis G., Goldsmith C.H.: CANDOO: A longitudinal Canadian multi-centre tertiary-care network for observational research in osteoporosis (OP) and osteopenia using standardized clinical practice data: 11 years of follow-up. Presented at the World Congress on Osteoporosis (Abstr. #P79MO), Lisbon, Portugal, May 2002.
 111. Hanley D.A., Siminoski K., Adachi J.D., Kline G.: The accuracy of height loss during prospective monitoring for detection of incident vertebral fractures. Presented at

- the World Congress on Osteoporosis (Abstr. #P225SA), Lisbon, Portugal, May 2002.
112. Adachi J.D., Olszynski W.P., Sebaldt R.J., Ioannidis G., Hanley D.A., Brown J.P., Josse R.G., Murray T., Petrie A., Goldsmith C.H.: Iliacostal distance (ILCD) is associated with prevalent vertebral (VERT) and non-vertebral (NV) fractures in patients registered in the Canadian database of osteoporosis and osteopenia (CANDOO). Presented at the World Congress on Osteoporosis (Abstr. #P251MO), Lisbon, Portugal, May 2002.
 113. Hanley D.A., Brown J.P., Olszynski W.P., Ioannidis G., Sebaldt R.J., Petrie A., Goldsmith C.H., Papaioannou A., Adachi J.D., Josse R.G., Murray T.M.: A prospective study of the impact of thyroid hormone therapy (THT) on bone density (BMD) in patients registered in the Canadian database of osteoporosis and osteopenia (CANDOO). Presented and published in the abstracts of the Endocrine Society's 84th Annual Meeting (Abstr #P3-352), June 2002.
 114. Felsenberg D., Hanley D.A., Johnson T.D., Manhart M.D., Genant H.K.: Risedronate significantly reduces moderate and severe vertebral fractures by 70% in one year. Presented at the 2002 ASBMR, from the Journal of Bone and Mineral Research. Vol 17 (Abstr. #F343/SA343), September 2002.
 115. Papaioannou A., Ioannidis G., Sebaldt R.J., Olszynski W.P., Hanley D.A., Petrie A., Brown J.P., Josse R., Murray T., Goldsmith C.H., Adachi J.D. Adherence Profile of Etidronate (ETD), Alendronate (ALD) and Hormone Replacement Therapy (HRT) in Patients Registered in the Canadian Database of Osteoporosis and Osteopenia (CANDOO). Presented at the 2002 ASBMR, from the Journal of Bone and Mineral Research. Vol. 17 (Abstr. #SA340), September 2002.
 116. Majumdar S.R., Rowe B.H., Folk D., Johnson J.A., Holroyd B.H., Morrish D.W., Harley C.H., Maksymowych W.P., Steiner I., Wirzba B., Hanley D.A., Russell A.S.: An interview that educates wrist fracture patients and their physicians can increase the detection and treatment of osteoporosis – interim results of a controlled trial. Presented at the 2002 ASBMR, from the Journal of Bone and Mineral Research. Vol. 17 (Abstr. #SU366), September 2002.
 117. Sebaldt R.J., Adachi J.D., Olszynski W.P., Brown J.P., Hanley D.A., Josse R.G., Murray T., Stephenson G.F., Petrie A., Mark A., Goldsmith C.H.: CANDOO: A longitudinal Canadian multi-centre tertiary-care network for observational research in osteoporosis and osteopenia using standardized clinical practice data: 11 years of follow-up. Presented at the 2002 ASBMR, from the Journal of Bone and Mineral Research. Vol. 17 (Abstr. #SU296), September 2002.
 118. Adachi J.D., Siminoski K.G., Kline G., Brown J.P., Cranney A.B., Goltzman D., Hanley D.A., Hodsman A.B., Josse R.G., Kendler D.L., Ste-Marie L., Olszynski W.P., Tenenhouse A., Li Z.: The impact of dropouts on the efficacy of 5 mg risedronate: An assessment based on an imputation analysis. Presented at the 2002 ASBMR, from the Journal of Bone and Mineral Research. Vol. 17 (Abstr. #SU343), September 2002.
 119. Doschak M.R., Wohl G.R., Hanley D.A., Bray R.C., Zernicke R.F.: Risedronate conserves periarticular bone and ligament mechanical properties in early

- osteoarthritis. Presented at the 2002 ASBMR, from the Journal of Bone and Mineral Research. Vol. 17 (Abstr. #M428), September 2002.
120. Watts N.B, Hanley D.A., Ste-Marie L-G., Kendler D., Josse B.: Once a week Risedronate is effective in reducing vertebral fracture risk. Published in the Abstracts of 2002 CDA/CSEM Professional Conference (Abstr. #236), Supplement to the Canadian Journal of Diabetes.
 121. Ste-Marie, L-G., Hanley D.A., Kendler D., Josse B.: Once-a-week (35 mg) Risedronate is therapeutically equivalent to daily (5 mg). Published in the Abstracts of 2002 CDA/CSEM Professional Conference (Abstr. #241), Supplement to the Canadian Journal of Diabetes.
 122. Josse B., Hanley D., Ste-Marie L-G., Kendler D.: Nonvertebral fracture risk is significantly reduced with Risedronate treatment in just one year. Presented at the Annual Meeting of the Canadian Society of Endocrinology and Metabolism/Canadian Diabetes Association, Vancouver, 2002. Published in the Abstracts of 2002 CDA/CSEM Professional Conference (Abstr. #58), Supplement to the Canadian Journal of Diabetes.
 123. Majumdar S.R., Rowe B.H., Folk D., Johnson J.A., Holroyd B.H., Morrish D.W., Harley C.H., Maksymowych W.P., Steiner I., Wirzba B., Hanley D.A., Russell A.S.: An intervention that educates wrist fracture patients and their physicians can increase the detection and treatment of osteoporosis – results of a controlled trial. *J Gen Intern Med.* 2003;18:(in press). Podium presentation at the 26th Annual Meeting of the Society for General Internal Medicine, Vancouver BC, May 1-4, 2003.
 124. Josse R.G., Sawka A.M., Ioannidis G., Murray T.M., Sebaldt R.J., Hanley D.A., Brown J.P., Goldsmith C.H., Papaioannou A., Olszynski W.P., Petrie A., Adachi J.D.: Predictors of early failure of bisphosphonate therapy in patients registered in the Canadian database of osteoporosis and osteopenia (CANDOO). *Calcif Tissue Int* (2003) 72(4): abstr.# P-256.
 125. Papaioannou A., Ioannidis G., Sebaldt R.J., Brown J.P., Goldsmith C.H., Hanley D.A., Petrie A., Josse R.G., Murray T.M., Boulos P., Ferko N., Adachi J.D.: Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the Canadian database of osteoporosis and osteopenia (CANDOO). *Calcif Tissue Int* (2003) 72(4): abstr.# P-258.
 126. Olszynski W.P., Ioannidis G., Sebaldt R.J., Hanley D.A., Petrie A., Brown J.P., Josse R.G., Murray T.M., Goldsmith C.H., Papaioannou A., Adachi J.D.: Effectiveness of etidronate and alendronate in the treatment of osteoporosis in men registered in the Canadian database of osteoporosis and osteopenia (CANDOO). *Calcif Tissue Int* (2003) 72(4): abstr.# P-262.
 127. Olszynski W.P., Ioannidis G., Berger C., Papaioannou A., Prior J.C., Joseph L., Hanley D.A., Pickard L., Murray T.M., Brown J.P., Tenenhouse A., Anastassiades T., Hopman W., Kirkland S., Joyce C., Poliquin S., Kreiger N., Adachi J.D., and the CaMos Research Group: Participant characteristics that predict 3-year incident clinically recognized vertebral deformity in menopausal women enrolled the Canadian Multicentre Osteoporosis study (CAMOS). *Calcif Tissue Int* (2003) 72(4): abstr.# P-263.

128. Brown J.P., Ioannidis G., Berger C., Hanley D.A., Prior J.C., Joseph L., Olszynski W.P., Papaioannou A., Pickard L., Murray T.M., Tenenhouse A., Anastassiades T., Hopman W., Kirkland S., Joyce C., Poliquin S., Kreiger N., Adachi J.D., and the CaMos Research Group: Risk factors that predict three year incident non-vertebral fragility fracture in menopausal women in the Canadian Multicentre Osteoporosis Study. *Calcif Tissue Int* (2003) 72(4): abstr.# P-264.
129. Ioannidis G., Papadimitropoulos E.A., Berger C., Papaioannou A., Brown J.P., Joseph L., Hanley D.A., Olszynski W.P., Prior J.C., Pickard L., Murray T.M., Tenenhouse A., Anastassiades T., Hopman W., Kirkland S., Joyce C., Poliquin S., Kreiger N., Adachi J.D., and the CaMos Research Group: The relationship among osteoporotic fractures and health related quality of life (HRQL) as measured by the Health Utilities Index Mark II and Mark III systems. *Calcif Tissue Int* (2003) 72(4): abstr.# P-267.
130. Hanley D.A., Ioannidis G., Josse R.G., Murray T.M., Brown J.P., Sebaldt R.J., Goldsmith C.H., Papaioannou A., Olszynski W.P., Petrie A., Adachi J.D.: Risk factors associated with health related quality of life (HRQL) in postmenopausal women with vertebral fractures registered in the Canadian database of osteoporosis and osteopenia (CANDOO). *Calcif Tissue Int* (2003) 72(4): abstr.# P-352.
131. Adachi J.D., Ioannidis G., Papaioannou A., Tenenhouse A., Prior J.C., Joseph L., Hanley D.A., Olszynski W.P., Brown J.P., The CaMos Research Group: Patient characteristics that predict the time to first clinically recognized vertebral deformity in postmenopausal women enrolled in the Canadian Multicentre Osteoporosis Study (CAMOS). *BONE* (2003) 32(5) (Supplement): abstr.# P396.
132. Brown J.P., Ioannidis G., Papaioannou A., Tenenhouse A., Prior J.C., Joseph L., Hanley D.A., Olszynski W.P., Adachi J.D., The CaMos Research Group: Risk factors that predict the time to first non-vertebral fracture in postmenopausal women recruited from the Canadian Multicentre Osteoporosis Study (CAMOS). *BONE* (2003) 32(5) (Supplement): abstr.# P397.
133. Olszynski W.P., Ioannidis G., Sebaldt R.J., Hanley D.A., Petrie A., Brown J.P., Josse R.G., Murray T.M., Goldsmith C.H., Adachi J.D.: Effectiveness of etidronate and alendronate in the treatment of osteoporosis in men registered in the Canadian database of osteoporosis and osteopenia (CANDOO). *BONE* (2003) 32(5) (Supplement): abstr.# P469.
134. Sawka A.M., Papaioannou A., Adachi J.D., Ioannidis G., Olszynski W., Brown J.P., Hanley D.A., Murray T., Josse R., Sebaldt R.J., Petrie A., Tenenhouse A., Goldsmith C.H.: Men present with a higher rate of prevalent fractures than women when started on bisphosphonate therapy in Canadian specialty osteoporosis practices. Presented at the 2003 ASBMR, from the *Journal of Bone and Mineral Research*. Vol. 18 (Abstr. #M291), September 2003.
135. Papaioannou A., Ioannidis G., Brown J.P., Berger C., Hanley D.A., Prior J.C., Joseph L., Olszynski W.P., Murray T.M., Tenenhouse A., Anastassiades T., Kirkland S., Joyce C., Poliquin S., Kreiger N., Siminoski K., Adachi J.D.: Risk factors that predict new non-vertebral fracture in postmenopausal women: The Canadian Multicentre Osteoporosis Study (CaMos). Presented at the 2003 ASBMR, from

the Journal of Bone and Mineral Research. Vol. 18 (Abstr. #SU276), September 2003.

136. Olszynski W.P., Ioannidis G., Berger C., Papaioannou A., Prior J.C., Joseph L., Hanley D.A., Murray T.M., Brown J.P., Tenenhouse A., Anastassiades T., Kirkland S., Joyce C., Poliquin S., Kreiger N., Siminoski K., Adachi J.D.: Participant characteristics that predict new clinically recognized vertebral fracture in postmenopausal women: The Canadian Multicentre Osteoporosis Study (CaMos). Presented at the 2003 ASBMR, from the Journal of Bone and Mineral Research. Vol. 18 (Abstr. #SU277), September 2003.
137. Hanley D.A., Ioannidis G., Josse R.J., Murray T.M., Brown J.P., Sebaldt R.J., Goldsmith C.H., Papaioannou A., Olszynski W.P., Petrie A., Davison K.S., Adachi J.D.: Risk factors related with Quality of Life (QOL) in postmenopausal women with prevalent vertebral fractures: The Canadian Database of Osteoporosis and Osteopenia (CANDOO). Presented at the 2003 ASBMR, from the Journal of Bone and Mineral Research. Vol. 18 (Abstr. #SU282), September 2003.
138. Ioannidis G., Brown J.P., Berger C., Hanley D.A., Prior J.C., Joseph L., Olszynski W.P., Pickard L., Murray T.M., Tenenhouse A., Anastassiades T., Hopman W., Kirkland S., Joyce C., Papaioannou A., Cranney A., Johnell O., Papadimitropoulos E.A., Adachi J.D.: Predicting previous fracture with the Health Utilities Index (HUI) Mark II and III Systems in both women and men: The Canadian Multicentre Osteoporosis Study (CaMos). Presented at the 2003 ASBMR, from the Journal of Bone and Mineral Research. Vol. 18 (Abstr. #SU288), September 2003.
139. Khan A., Hanley, D.A., O'Brien C., Pasiaka J., Ste-Marie L., Rotstein L., Rosen I., Young J., Josse R., Bilezikian J.: Asymptomatic primary hyperparathyroidism: Standards and guidelines for diagnosis and management in Canada. *Endocr Pract.* 2003;9(No.5) 400-405. Presented at the Canadian Society of Endocrinology and Metabolism/Canadian Diabetes Association (CDA/CSEM) Professional Conference, Ottawa, October 15-18, 2003.
140. Sebaldt RJ, Shane LG, Pham B, Cook R, Thabane L, Petrie A, Olszynski WP, Hanley DA, Brown J, Adachi JD, Murray TM, Josse R, Papaioannou A. Longer-Term Effectiveness Outcomes of Non-Compliance and Non-Persisitence With Daily-Regimen Bisphosphonate Therapy in Patients with Osteoporosis Treated in Tertiary Specialist Care. Poster Abstract P391 SA presented at IOF World Congress on Osteoporosis, Rio de Janeiro, Brazil, May 14-18, 2004.
141. Kline G, Hanley DA. Wider Limits of Acceptable Change in Projected Vertebral Areas Between Serial Scans Still Renders Many Serial DXA Interpretations Invalid. Abstract [M095] presented at the American Society for Bone and Mineral Research; published in *J Bone Miner Res* 2004;19 (suppl 1): S365.
142. Bensen R, Papaioannou A, Adachi JD, Ioannidis G, Olszynski W, Sebaldt R, Murray T, Josse R, Brown J, Hanley D, Petrie A, Goldsmith C. Evaluation of Easily Measured Risk Factors in the Prediction of Osteoporotic Fractures. Abstract [F371] presented at the American Society for Bone and Mineral Research; published in *J Bone Miner Res* 2004;19 (suppl 1): S90.

143. Sawka AM, Thabane L, Papaioannou A, Gafni A, Ioannidis G, Hanley DA, Papadimitropoulos E, Pickard L, Adachi JD, and the CaMOS Investigators. The Number of Canadian Men and Women Needed to be Screened to Detect a Case of Osteoporosis: A Population-Based Study from the Canadian Multicentre Osteoporosis Study (CaMos). Abstract [M109] presented at the American Society for Bone and Mineral Research; published in *J Bone Miner Res* 2004;19 (suppl 1): S368.
144. Sebaldt RJ, Shane LG, Pham BZ, Cook RJ, Thabane L, Petrie A, Olszynski WP, Hanley DA, Brown J, Adachi JD, Murray T, Josse R, Papaioannou A. Impact of Non-Compliance and Non-Persistence With Daily Bisphosphonates on Longer-Term Effectiveness Outcomes In Patients With Osteoporosis. Abstract [M423] presented at the American Society for Bone and Mineral Research; published in *J Bone Miner Res* 2004;19 (suppl 1): S445.
145. Sawka AM, Thabane L, Papaioannou A, Gafni A, Ioannidis G, Papadimitropoulos E, Hopman W, Cranney A, Hanley DA, Pickard L, Adachi JD, and the CaMOS Investigators. Health Utilities Index 3 Scores in Osteoporosis Compared to other Chronic Medical Conditions: A Population-Based Study from the Canadian Multicentre Osteoporosis Study (CaMos). Abstract [SA455] presented at the American Society for Bone and Mineral Research; published in *J Bone Miner Res* 2004;19 (suppl 1): S180.
146. Anna M. Sawka, Lehana Thabane, Alexandra Papaioannou, Amiram Gafni, George Ioannidis, David A. Hanley, E. Papadimitropoulos, Laura Pickard, Jonathan D. Adachi, CaMos Investigators. Prevalence of Undiagnosed Osteoporosis in Canadians Age 65 Years and Older: the Canadian Multicentre Osteoporosis Study (CaMos). Chosen for Oral Presentation, presented at the American College of Rheumatology Annual Meeting, San Antonio, Texas, October 16-21, 2004.
147. Robert Bensen, Jonathan D. Adachi, George Ioannidis, Alexandra Papaioannou, Timothy Murray, Wojciech Olszynski, Jacques Brown, Robert Josse, Rolf Sebaldt, Charlie Goldsmith, David Hanley, Annie Petrie. The Usefulness of Seven Easily Measureable Risk Factors for Early Recognition of Future Osteoporotic Fracture. Poster Presentation, presented at the American College of Rheumatology Annual Meeting, San Antonio, Texas, October 16-21, 2004.
148. Greenspan SL, Marriott TB, Hanley DA, Zanchetta JR, Bone HG, Ettinger MP, Lindsay R. Full-length PTH prevents first vertebral fracture in postmenopausal women with osteoporosis: results from the T.O.P. study. Oral presentation given by Dr. Hanley at 5th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, Rome Italy, March 16-19, 2005. Abstract OC34, published in *Osteoporos Int* 2005; 16 (Suppl 3): S11.
149. Adachi JD, Hanley DA, Lorraine JK, Boudreau T. Compliance, acceptance and safety of teriparatide injection over 6 months in a severely osteoporotic population who has failed prior therapy. Poster Presentation at 5th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, Rome Italy, March 16-19, 2005. Abstract P364, published in *Osteoporos Int* 2005; 16 (Suppl 3): S99.
150. Maxwell CJ, Roberts M, Poss J, Hirdes JP, Hanley D, Vik SA, Hogan DB. "Continued evidence for the suboptimal treatment of osteoporosis among older adults", (oral

presentation) presented at the Annual Conference of the Canadian Association for Population Therapeutics and the 2nd Canadian Therapeutics Congress, Vancouver BC, April 13-19, 2005. Abstract published in *The Canadian Journal of Clinical Pharmacology* 2005;12 (1):e43.

151. Majumdar SR, Johnson JA, Lier DA, Russell AS, Hanley DA, Blitz S, Steiner IP, Maksymowych WP, Morrish DW, Holroyd BR, Rowe BH. Persistence, generalizability, and cost-effectiveness of an intervention to improve quality of osteoporosis care after a fracture of the wrist: results of a controlled trial. *Osteoporos Int.* 2006;17 (suppl2):19. IOF World Congress on Osteoporosis, Toronto ON, June 2-6, 2006.
152. Sawka AM, Papaioannou A, Josse RG, Murray TM, Thabane L, Hanley DA, Ioannidis G, Olszynski WP, Brown JP, Sebaldt RJ, Petrie A, Tenenhouse A, Goldsmith CH, Boulos P, Adachi JD. Low rates of vitamin D supplementation in Canadians with low bone mass or fractures. *International Osteoporosis Foundation World Congress on Osteoporosis.* Toronto, Canada, June 2-6, 2006. *Osteoporosis Int.* 2006; (Suppl 2):17:P366. S105.
153. Greenspan SL, Hanley DA, Morris S, T. B. Marriott TB. Bone Turnover Markers and BMD Remain Elevated in Postmenopausal Osteoporotic Women through a Full 24 Months of Treatment with Human Parathyroid Hormone 1-84 (PTH). (Abstract F389) Chosen for Plenary Poster Session at the 28th Annual Meeting of the American Society for Bone and Mineral Research, Philadelphia, September, 2006.
154. Juby AG, Plaquin R, Hanley DA. The value, if any, of grip strength measurements in the frail elderly. Presented at the Canadian Geriatrics Society Annual Scientific Meeting in Vancouver, Canada, April 20-22, 2006. *Canadian Journal of Geriatrics* 2006; Vol. 9 (Issue 2):P70. Abstract # 20.
155. Juby AG, Plaquin R, Hanley DA. Evaluation of the association between serum 25(OH)D levels and calcaneal bone mineral density in long term care residents. Presented at the Canadian Geriatrics Society Annual Scientific Meeting in Banff, Alberta, Canada, April 19-21, 2007. *Canadian Journal of Geriatrics* 2006; Vol. 10 (Issue 1):P24.
156. Juby AG, Davis P, Hanley D, Prior J, Abu-Hakima M. Evaluating the impact of the location of an osteoporosis awareness poster. Presented at the African League Against Rheumatism 5th Congress, Nairobi, Kenya, February 2007. *Clinical Rheumatology* 2007;P31. Abstract AFPL-65.
157. Juby AG, Davis P, Hanley D, Prior J, Abu-Hakima M. An Osteoporosis awareness poster: where should it be located? Presented at the Seventh European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis meeting in Porto, Portugal, March 28-31, 2007. *Osteoporosis Int.* 2007;(Suppl 1):18:P174.
158. Hanley DA, Morrish DW, Majumdar SR, Beaupre LA, Harley C, Lier D, Juby A, Maksymowych W, Bell NR. A case-manager improves osteoporosis investigation and treatment after hip fracture: results of a randomized controlled trial. Presented at the 2007 Annual Meeting of the International Society for Clinical Densitometry, Tampa, Florida, March 14-17, 2007.
159. Qureshi A, Adachi JD, Papaioannou A, Sebaldt R, Brown J, Tenenhouse A, Olszynski WP, Hanley D, Josse R, Murray TM, Petrie A, Ioannidis G. Amibisphosphonates

- reduce incident fractures compared to etidronate in postmenopausal women with osteoporosis. *Can J Clin Pharmacol* 2007; 14(2).
160. Kaiser SM, Ioannidis G, Lorraine J, Olszynski WP, Prior JC, Hanley DA, Brown JP, Papaioannou A, Josse RG, Anastassiades T, Siminoski K, Kirkland S, Joyce C, Goltzman D, Adachi JD. 5-Year Incidence of Fractures in Patients with Severe Osteoporosis: The Canadian Multicentre Osteoporosis Study (CaMOS). Chosen for Plenary Poster Session at the 29th Annual Meeting of the American Society for Bone and Mineral Research, Honolulu, Hawaii, September, 2007.
 161. Morrish DW, Majumdar SR, Beaupre LA, Bell NR, Cinats JG, Hanley DA, Harley CH, Juby AG, Lier DA, Maksymowych WP. Using a case-manager to improve osteoporosis treatment after hip fracture: Results of a randomized controlled trial. Chosen for Plenary Poster Session at the 29th Annual Meeting of the American Society for Bone and Mineral Research, Honolulu, Hawaii, September, 2007.
 162. Davison KS, Adachi R, Hanley DA, Brown JP, Olszynski WP. Associations between Bone Mineral Density and Speed of Sound: Canadian Multicentre Osteoporosis Study (CaMOS). Chosen for Plenary Poster Session at the 29th Annual Meeting of the American Society for Bone and Mineral Research, Honolulu, Hawaii, September, 2007.
 163. Jamal SA, Goltzman D, Hanley DA, Papaioannou A, Prior JC, Josse RG. Nitrates and BMD among Canadian Men and Women. Chosen for Oral Presentation at the 29th Annual Meeting of the American Society for Bone and Mineral Research, Honolulu, Hawaii, September, 2007.
 164. Olszynski WP, Brown JP, Adachi JD, Hanley DA, Davison KS. Canadian Normative Data for Sunlight Omnisense Quantitative Ultrasound: Canadian Multicentre Osteoporosis Study (CaMOS). Chosen for Plenary Poster Session at the 29th Annual Meeting of the American Society for Bone and Mineral Research, Honolulu, Hawaii, September, 2007.
 165. Juby AG, Davis P, Hanley D, Prior J, Abu-Hakima M. An osteoporosis awareness poster: where should it be located? Chosen for Plenary Poster Session at the 7th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, Porto, Portugal, March 28-31, 2007.
 166. Majumdar S, Boutroy S, Boyd SK, Bogado C, Delmas PD, Hanley DA, Sellmeyer D, Cheung AM, Seeman E, Thomas T. Dissection of radial DXA BMD measurements using high resolution peripheral quantitative computed tomography (HR-pQCT) parameters. Presented at the International Society for Clinical Densitometry Annual Meeting, San Francisco, March 12-15, 2008
 167. Leslie W, O'Donnell S, Claudia Lagacé C, Peter Walsh P, Bancej C, Jean S, Morin S, Hanley D, Cranney A, Papaioannou A. Secular Decrease in Hip Fracture Rates in Canada 1985-2005. *J Bone Miner Res* 2009; 24 (Suppl 1): Abstract SU0314 (available at www.asbmr.org/Meetings/PastAnnualMeetings.aspx). Poster Presentation at American Society for Bone and Mineral Research Annual Meeting, Denver Colorado September 11-15, 2009.
 168. Ioannidis G, Papaioannou A, Prior JC, Kennedy CC, Pickard L, Davison KS, Anastassiades T, Jacques P, Brown JP, Olszynski WP, David A, Hanley DA,

Robert G. Josse RG, David Goltzman D, Adachi JD. The Prevalence of Participants at High Risk for Fracture based on the Recommendation for Bone Mineral Density (BMD) Reporting in Canada. *J Bone Miner Res* 2009; 24 (Suppl 1): Abstract MO0275 (available at www.asbmr.org/Meetings/PastAnnualMeetings.aspx). Poster Presentation at American Society for Bone and Mineral Research Annual Meeting, Denver Colorado September 11-15, 2009.

169. Berger C, Leslie W, Langsetmo L, Tsang J, Papaioannou A, Kovacs C, Hanley D, Goltzman D. Exclusion of vertebral artifacts from spine DXA does not alter fracture prediction. *J Bone Miner Res* 2009; 24 (Suppl 1): Abstract SU0280 (available at www.asbmr.org/Meetings/PastAnnualMeetings.aspx). Poster Presentation at American Society for Bone and Mineral Research Annual Meeting, Denver Colorado September 11-15, 2009.
170. Pauchard Y, Ayres F, Szabo E, Macdonald H, Hanley D, Boyd S. A Comparison of Manual and Automated Methods for the Standardization of Subject Motion Artifact in HR-pQCT. *J Bone Miner Res* 2009; 24 (Suppl 1): Abstract SA0018 (available at www.asbmr.org/Meetings/PastAnnualMeetings.aspx). Poster Presentation at American Society for Bone and Mineral Research Annual Meeting, Denver Colorado September 11-15, 2009.
171. Macdonald H, Nishiyama K, Buie H, Hanley D, Boyd S. High Parity Is Associated with Increased Cortical Porosity of the Distal Radius as Measured with High-resolution pQCT. *J Bone Miner Res* 2009; 24 (Suppl 1): Abstract SA0027 (available at www.asbmr.org/Meetings/PastAnnualMeetings.aspx). Poster Presentation at American Society for Bone and Mineral Research Annual Meeting, Denver Colorado September 11-15, 2009.
172. Nishiyama K, Macdonald H, Buie H, Hanley D, Boyd S. Age-related Changes in Human Radius Cortical Porosity are More Strongly Associated with Increased Pore Size than Pore Number as Assessed In vivo by HR-pQCT. *J Bone Miner Res* 2009; 24 (Suppl 1): Abstract SU0019 (available at www.asbmr.org/Meetings/PastAnnualMeetings.aspx). Poster Presentation at American Society for Bone and Mineral Research Annual Meeting, Denver Colorado September 11-15, 2009.
173. Brown RA, Schnackenburg K, Macdonald H, Hanley D, Frayne R, Boyd S. Texture Analysis for Fracture Prediction in Osteoporosis based on HRpQCT and the Fast S-Transform. *J Bone Miner Res* 2009; 24 (Suppl 1): Abstract SU0038 (available at www.asbmr.org/Meetings/PastAnnualMeetings.aspx). Poster Presentation at American Society for Bone and Mineral Research Annual Meeting, Denver Colorado September 11-15, 2009.
174. Langsetmo L, Hanley DA, Josse R, Kovacs CS, Kreiger N, Morin S, Papaioannou A,

Adachi JD, Olszynski WP, Goltzman D, Jamal J. Assessment of Fracture Risk in Osteopenic Women Is Improved by Consideration of Prior Fracture, Physical Health, and Height Loss. *J Bone Miner Res* 2009; 24 (Suppl 1): Abstract SU0275 (available at www.asbmr.org/Meetings/PastAnnualMeetings.aspx). Poster Presentation at American Society for Bone and Mineral Research Annual Meeting, Denver Colorado September 11-15, 2009.

175. Beattie K, Larche M, Ioannidis G, Papaioannou A, Shawn Davison S, Hanley D, Robert Josse R, Stephanie Kaiser S, Kovacs C, Kreiger N, Olszynski W, Prior J, Towheed T, Adachi JD, Bensen W. Bone DESTINY™ Predicts 10-year Clinical Fracture Risk in Women in the CaMos Cohort. *J Bone Miner Res* 2009; 24 (Suppl 1): Abstract SU0276 (available at www.asbmr.org/Meetings/PastAnnualMeetings.aspx). Poster Presentation at American Society for Bone and Mineral Research Annual Meeting, Denver Colorado September 11-15, 2009.
176. Seeman E, Cheung AM, Shane E, Thomas T, Boyd B, Boutroy B, Hanley DA, Bogado B, Sellmeyer D, Majumdar S, Kearns A, Fan M, Zanchetta JM, Libanati C. Baseline Remodeling Intensity and Greater Suppression by Denosumab Than Alendronate: Effects on HR-pQCT Parameters at the Radius. *J Bone Miner Res* 2009; 24 (Suppl 1): Abstract 1244 (available at www.asbmr.org/Meetings/PastAnnualMeetings.aspx). Oral Presentation at American Society for Bone and Mineral Research Annual Meeting, Denver Colorado September 11-15, 2009.
177. Beattie K, Larche M, Ioannidis G, Papaioannou A, Shawn Davison S, Hanley D, Robert Josse R, Stephanie Kaiser S, Kovacs C, Kreiger N, Olszynski W, Prior J, Towheed T, Adachi JD, Bensen W. Bone DESTINY™ Predicts 10-year Clinical Fracture Risk in Men in the CaMos Cohort. *J Bone Miner Res* 2009; 24 (Suppl 1): Abstract FR0280 (available at www.asbmr.org/Meetings/PastAnnualMeetings.aspx). Poster Presentation at American Society for Bone and Mineral Research Annual Meeting, Denver Colorado September 11-15, 2009.
178. Langsetmo L, Nguyen TV, Hanley DA, Kovacs CS, Nguyen N, Eisman J, Center J, Adachi JD, Prior JC, Josse RG. External Validation of Nomograms Predicting Fracture Risk and Hip Fracture Risk: Canadian Men and Women. *J Bone Miner Res* 2009; 24 (Suppl 1): Abstract FR0287 (available at www.asbmr.org/Meetings/PastAnnualMeetings.aspx). Poster Presentation at American Society for Bone and Mineral Research Annual Meeting, Denver Colorado September 11-15, 2009.
179. Berger C, Goltzman D, Langsetmo L, Kreiger K, Tenenhouse A, Joseph L, Josse R, Prior J, Hanley D. Use of longitudinal data to derive peak bone mass discloses sex and skeletal site heterogeneity and differences in osteoporosis prevalence. *J Bone*

Miner Res 2009; 24 (Suppl 1): Abstract FR0290 (available at www.asbmr.org/Meetings/PastAnnualMeetings.aspx). Poster Presentation at American Society for Bone and Mineral Research Annual Meeting, Denver Colorado September 11-15, 2009.

180. Leslie W, Zhou W, Langsetmo L, David Goltzman D, Josse R, Kovacs CS, Olszynski WP, Davison KS, Prior J, Anastassiades T, Towheed T, Hanley D, Kaiser S, Kreiger N. Fracture Risk Thresholds in Men and Women: Misleading Effects of Sex- Specific Reference Data. J Bone Miner Res 2009; 24 (Suppl 1): Abstract FR0300 (available at www.asbmr.org/Meetings/PastAnnualMeetings.aspx). Poster Presentation at American Society for Bone and Mineral Research Annual Meeting, Denver Colorado September 11-15, 2009.
181. Macdonald HM, Nishiyama KK, Kang J, **Hanley DA**, Boyd SK. Predicted Age-Related Declines In Distal Radius Bone Strength Are Similar In Women And Men Despite Differences In Age-Related Changes In Bone Microarchitecture. Accepted for oral (podium) presentation by Dr. Hanley European Calcified Tissue Society, Glasgow June 26-30, 2010
182. Papaioannou A, Kennedy CC, Ioannidis G, Adachi JD, **Hanley D**, Giangregorio L, Nixon M, Pritchard J, DeBeer J, Letcher K, Farrauto L. High Versus Low Dose Vitamin D In Acute Hip Fracture Patients: A Randomised, Controlled Trial. Abstract P490. Presented at the International Osteoporosis Foundation World Congress on Osteoporosis & Tenth European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, Florence, Italy May 5-8, 2010. Osteoporos Int 2010; 21[Suppl1]: S201
183. Nishiyama KK, Macdonald HM, **Hanley DA**, Boyd SK. Trabecular Bone Density And Microarchitecture At The Distal Radius Are Predictors Of Fragility Fractures In Postmenopausal Women As Measured By HR-pQCT. Abstract P541. Presented at the International Osteoporosis Foundation World Congress on Osteoporosis & Tenth European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, Florence, Italy May 5-8, 2010. Osteoporos Int 2010; 21[Suppl1]: S223
184. Ioannidis G, Papaioannou A, Kennedy CC, Pickard L, Davison KS, Brown JP, Olszynski WP, **Hanley DA**, Josse RG, Anastassiades T, Prior JC, Goltzman D, Adachi JD and CaMos Research Group. Defining Fracture Risk In Women Using The Recommendations For Bone Mineral Density (BMD) Reporting In Canada. Abstract P595. Presented at the International Osteoporosis Foundation World Congress on Osteoporosis & Tenth European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, Florence, Italy May 5-8, 2010. Osteoporos Int 2010; 21[Suppl1]: S247
185. Beaupre LA, Morrish D, **Hanley DA**, Juby AG, Maksymowych WP, Bell NR,

Majumdar SR. Oral Bisphosphonate Use After Hip Fracture Is Associated With Reduced Mortality. Abstract P796. Presented at the International Osteoporosis Foundation World Congress on Osteoporosis & Tenth European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, Florence, Italy May 5-8, 2010. *Osteoporos Int* 2010; 21[Suppl1]: S337

186. Seeman E, Cheung A, Shane E, Thomas T, Boyd S, Boutroy S, **Hanley D**, Bogado C, Sellmeyer D, Majumdar S, Kearns A, Fan M, Zanchetta J, Libanati C. Relationship Between Baseline Remodelling Intensity And Changes In HR-pQCT Parameters At The Radius In Postmenopausal Women Treated With Denosumab Or Alendronate. Abstract P850. Presented at the International Osteoporosis Foundation World Congress on Osteoporosis & Tenth European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, Florence, Italy May 5-8, 2010. *Osteoporos Int* 2010; 21[Suppl1]: S362
187. Langsetmo L, **Hanley D**, Berger C, Kreiger N, Kovacs C, Papaioannou A, Davison KS, Prior J, Josse R, Goltzman D. 50 Year Predicted Changes in BMD Distribution and Hip Fracture Incidence in Canada. *J Bone Miner Res* 25 (Suppl 1) 2010. Poster Sessions, Presentation Number: SA0331
188. Macdonald H, Nishiyama K, Kang J, **Hanley D**, Boyd S. Age-Related Changes in Bone Microarchitecture and Strength of the Distal Radius May Explain Sex Differences in Forearm Fracture Risk. *J Bone Miner Res* 25 (Suppl 1) 2010. Oral Presentations, Presentation Number: 1237
189. Leslie W, Berger C, Langsetmo L, Adachi J, **Hanley D**, Ioannidis G, Josse R, Kovacs C, Towheed T, Kaiser S, Olszynski WP, Prior J, Jamal S, Kreiger N, Goltzman D. Construction and Validation of a Simplified Fracture Risk Assessment Tool for Canadian Women and Men: Results from the CaMos and Manitoba BMD Cohorts. *J Bone Miner Res* 25 (Suppl 1) 2010. Plenary Poster Session, Presentation Number: FR0299 Poster Sessions, Presentation Number: SA0299
190. Fraser L-A, Langsetmo L, Berger C, Ioannidis G, Goltzman D, Adachi J, Papaioannou A, Josse R, Kovacs C, Olszynski WP, Towheed T, **Hanley D**, Kaiser S, Prior J, Jamal S, Kreiger N, Brown J, Johansson H, Kanis J, Leslie W. Fracture Prediction and Calibration of a Canadian FRAX[®] Tool: A Population-Based Report From CaMos. *J Bone Miner Res* 25 (Suppl 1) 2010. Plenary Poster Session: FR0301 Poster Sessions, Presentation Number: SA0301
191. Fraser L-A, Ioannidis G, Adachi J, Pickard L, Kaiser S, Prior J, Brown J, **Hanley D**, Olszynski WP, Anastassiades T, Jamal S, Josse R, Goltzman D, Papaioannou A. Fragility Fractures and the Osteoporosis Care Gap in Women: the Canadian Multicentre Osteoporosis Study. *J Bone Miner Res* 25 (Suppl 1) 2010. Poster Sessions, Presentation Number: SU0333
192. Berger C, Langsetmo L, Kreiger N, Greene-Finestone L, Kovacs C, Richards B, Hidioglou N, Sarafin K, Davison KS, Adachi J, Brown J, **Hanley D**, Goltzman

D. Temporal Trends and Determinants of Longitudinal Change in 25-Hydroxyvitamin D Levels in a Population-based Study. *J Bone Miner Res* 25 (Suppl 1) 2010. Poster Sessions, Presentation Number: SA0330

193. Boyd SK, Nishiyama KK, Zebaze RM, **Hanley DA**, Zanchetta JR, Thomas T, Boutroy S⁵, C. Bogado C, Austin M, Libanati C, Seeman E. Denosumab Decreases Cortical Porosity In Postmenopausal Women With Low BMD. Plenary and Poster presentation. 3rd Meeting of European Calcified Tissue Society and International Bone and Mineral Society, Athens, May 7-11, 2011. Published in *Bone*, Volume 48, Supplement 2, 7 May 2011, Page S182
194. Berger C, Greene-Finestone L, Langsetmo L, Joseph L, Kreiger N, Richards B, Kovacs C, Sarafin K, Davison KS, Adachi JD, Brown J, **Hanley D**, Goltzman D. Temporal Trends in 25-Hydroxyvitamin D Levels and Parathyroid Hormone in a Population-Based Study. Plenary Poster Session: Abstr# FR0384 *J Bone Miner Res.* 2011; 26 (Suppl 1) Page S139. Available at [<http://www.asbmr.org/Meetings/AnnualMeeting/Abstract2011.aspx>]
195. Seeman E, Libanati C, Chapurlat R, Boyd S, Zebaze R, **Hanley DA**, Zanchetta JR, Grauer A, Bilezikian JP. The Transitory Increase in PTH Following Denosumab Administration Is Associated With Reduced Intracortical Porosity: A Distinctive Attribute of Denosumab Therapy. Oral Presentation: Abstr# 1064 *J Bone Miner Res.* 2011; 26 (Suppl 1) Page S22. Available at [<http://www.asbmr.org/Meetings/AnnualMeeting/Abstract2011.aspx>]
196. Nishiyama K, Macdonald H, **Hanley D**, Boyd S. Bone Microarchitecture and Finite Element Analysis Measured with HR-pQCT Can Identify Postmenopausal Women with and Without Forearm Fragility Fracture. Poster Session II & Poster Tours: Abstr# SU0037 *J Bone Miner Res.* 2011; 26 (Suppl 1) Page S253. Available at [<http://www.asbmr.org/Meetings/AnnualMeeting/Abstract2011.aspx>]
197. Berger C, Langsetmo L, **Hanley D**, Adachi J, Kovacs C, Brown J, Josse R, David Goltzman D. Relative Prevalence of Normocalcemic and Hypercalcemic Hyperparathyroidism in a Community-Dwelling Cohort. Poster Session II & Poster Tour: Abstr# SU0173 *J Bone Miner Res.* 2011; 26 (Suppl 1) Page S292. Available at [<http://www.asbmr.org/Meetings/AnnualMeeting/Abstract2011.aspx>]
198. Majumdar S, McAlister FA, Johnson JA, Bellerose D, Siminoski K, **Hanley DA**, Ibrahim Q, Lier DA, Lambert RG, Russell AS, Rowe BH. Controlled Trial of Two Interventions To Increase Osteoporosis Treatment in Patients with "Incidentally" Detected Vertebral Fractures on Chest Radiographs (NCT00388908). Oral Presentation Abstr# 1136. *J Bone Miner Res.* 2011; 26 (Suppl 1) Page S47. Available at [<http://www.asbmr.org/Meetings/AnnualMeeting/Abstract2011.aspx>]
199. Morin SM, Papaioannou A, Belanger A, Brown J, Cheung A, **Hanley D**, Kendler D, Ngui D. Variability in Screening for Post-Menopausal Osteoporosis by Canadian

Family Physicians. Poster Session III & Poster Tour, Abstr# MO0331. J Bone Miner Res. 2011; 26 (Suppl 1) Page S476. Available at [http://www.asbmr.org/Meetings/AnnualMeeting/Abstract2011.aspx]

200. Dempster DW, Zhou H, Recker RR, Brown JP, Bolognese MA, Recknor C, Kendler DL, Lewiecki EM, **Hanley DA**, Rao DS, Miller PD, Woodson III GC, Lindsay R, Binkley N, Wan X, Ruff VA, Janos B, Taylor KA. Skeletal Histomorphometry in Patients On Teriparatide or Zoledronic Acid Therapy (SHOTZ) Study: 6-Month Results of a Randomized Clinical Trial. Oral Presentation Abstr# 1203. J Bone Miner Res. 2011; 26 (Suppl 1) Page S66. Available at [http://www.asbmr.org/Meetings/AnnualMeeting/Abstract2011.aspx]
201. Boyd SK, Nishiyama KK, Zebaze RM, **Hanley DA**, Zanchetta JR, Thomas T, Boutroy S, Bogado C, Austin M, Libanati C, Seeman E. Denosumab Decreases Cortical Porosity in Postmenopausal Women with Low BMD. Oral Presentation: Abstr# OR29-4. Endocrine Reviews **2011; 32 (3):Available on line at http://edrv.endojournals.org/content/vol32/03_MeetingAbstracts**
202. Burt L.A., Macdonald H.M., Hanley, D.A., Boyd, S.K. 2012 Changes in Bone Mineral Density and Bone Strength from 16 to 34 Years of Age, As Assessed by High Resolution Peripheral Quantitative Computed Tomography. J Bone Miner Res 27 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=21000f9f-d73b-4ca4-8eb5-f3a91bf771bd>.
203. Morin S, Berger C, Brown JP, Leslie WD, Wall M, Langsetmo L, Kaiser S, Jerilynn Prior J, Robert Josse RG, David Hanley DA, Alexandra Papaioannou A, Jonathan Adachi JD, Kovacs C, Shawn Davison KS, Olszynski WP, Toweed T, Goltzman D. 2012 Clinical Characteristics Among Patients with Different Femur Fracture Subtypes. J Bone Miner Res 27 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/Abstracts12.aspx> Oral Presentations, Presentation Number: 1093 Session: Concurrent Oral Session 16: Osteoporosis Epidemiology
204. JPrior J, Macdonald H, Zhou W, Berger C, Kovacs C, Hanley DA, Anastassiades T, Kaiser S, and CaMOS Research Group. 2012 Combined Hormonal Oral Contraceptive Use and Bone Mineral Density Change in the Premenopausal Population: 10-year data from the Canadian Multicentre Osteoporosis Study. J Bone Miner Res 27 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/Abstracts12.aspx> Plenary Sessions, Presentation Number: FR0319
205. Langsetmo L, Berger C, Prior J, Hanley DA, Brown JP, Adachi JD, Jamal SA, Josse RG, Kovacs C, Morin S, Barr S, Davison KS, Goltzman D, Kreiger N. 2012 Dietary Patterns in Men and Women Aged 25 Years and Older: Relationship with Body Mass Index, 25-hydroxyvitamin D Levels, Fasting Glucose, and Risk of Diabetes Mellitus. J Bone Miner Res 27 (Suppl 1). Available at

<http://www.asbmr.org/Meetings/AnnualMeeting/Abstracts12.aspx> Poster Sessions, Presentation Number: SA0325

206. Dempster D, Zhou H, Recker R, Brown J, Bolognese M, Recknor C, Kendler D, Lewiecki EM, Hanley DA, Rao DS, Miller PD, Woodson G, Lindsay R, Binkley N, Wan X, Ruff V, Janos B, Taylor K. 2012 Differential Effects of Teriparatide and Zoledronic Acid on the Outer and Inner Surfaces of Cortical Bone in Postmenopausal Women with Osteoporosis: Results from the SHOTZ Trial. *J Bone Miner Res* 27 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/Abstracts12.aspx> Oral Presentations, Presentation Number: 1170
207. Papaioannou A, Adachi JD, Colizza C, Hanley DA, Kaiser S, Kendler DL, Lin P, Shapiro M, Morin S. 2012 How Primary Care Physicians Assess Postmenopausal Women Following Education on the 2010 Osteoporosis Canada Guidelines (OC CPG). *J Bone Miner Res* 27 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/Abstracts12.aspx> Poster Sessions, Presentation Number: SU0303
208. Berger C, Almohareb O, Langsetmo L, David Hanley DA, Kovacs C, Josse RG, Adachi JD, Prior J, Towheed T, Davison KS, Kaiser S, Jacques Brown JP, Goltzman D. 2012 Predictors of PTH and Association of PTH with Skeletal Outcomes in a Population-based Study. *J Bone Miner Res* 27 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/Abstracts12.aspx> Poster Sessions, Presentation Number: SA0140
209. Langsetmo L, Lentle B, Jamal SA, Kovacs C, David Hanley DA, Whiting S, Berger C, Kaiser S, Josse RG, Prior J, Adachi JD, Hodsmann AB, Davison KS, Morin S, Genest J, Kreiger N, Goltzman D. 2012 Serum 25-hydroxy-vitamin D is an Independent Risk Factor for Abdominal Aortic Calcification. *J Bone Miner Res* 27 (Suppl 1). Available at <http://www.asbmr.org/Meetings/AnnualMeeting/Abstracts12.aspx> Poster Sessions, Presentation Number: SU0146
210. Burt L.A., Macdonald H.M., Hanley, D.A., Boyd, S.K. Establishment of T-scores for HR-pQCT using a normative Canadian population. *J Clin Densitometry* 2013; 16(3): 264-265. Presented at the 19th Annual ISCD Meeting, Florida, USA

v. Miscellaneous Publications and Unpublished Communications:

1. Book Review: Hanley, David A. "The Osteoporotic Syndrome" ed. by L. V. Avioli, Grune & Stratton, Toronto, 1987; reviewed in *THE MEDICAL POST*, March 8, 1988.

2. David A. Hanley. "Medications used in the treatment of osteoporosis". Kerby News, Page 9, February 2000.
3. Numerous radio and television interviews on calcium metabolism and osteoporosis.